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Anthocyanins, the subclass of polyphenol flavonoids responsible for the red-blue-
purple pigmentation of fruit and vegetables, have gained much research focus 
recently due to their propensity to preserve or even improve vascular function. 
There is some evidence that higher-intake of foods rich in these compounds can 
positively impact risk factors associated with (CVD) cardiovascular disease such 
as blood pressure, endothelial function and arterial stiffness; albeit ambiguity 
remains as to whether this translates to a reduced risk of CVD. One of the most 
studied anthocyanin-rich foods in recent years has been tart Montmorency 
cherries (Prunus Cerasus, cv Montmorency; MC), particularly in exercise and to 
a lesser extent in health paradigms. Indeed, cherries can contribute to a 
considerable dietary intake of anthocyanins, but they are also a rich source of 
other polyphenols, which might confer health benefits due to the synergistic and 
additive properties on antioxidant or anti-inflammatory actions.  
Certainly, there is some promising evidence from in vitro and animal models that 
MC can influence pathways that might improve cardiovascular and metabolic 
health. Moreover, accumulating evidence has shown that acute postprandial 
exposure to MC, potentially due to its anthocyanin content, effects vascular and 
metabolic function in humans. Despite this there is a paucity of original research 
relating to the longer-term influence on cardiovascular function, and health in 
general. Moreover, existing studies are difficult to interpret due to limitations and 
the paradoxical findings, highlighting the need for well-designed clinical trials 
investigating MC on cardiovascular risk factors. Taken all together, the 
overarching aim of this thesis, was to further investigate the potential role of 
dietary anthocyanins in cardiovascular health. The reliability of a test battery of 
cardiovascular risk factors was also assessed, leading to three experimental 
studies (Chapter 3-5).  
Firstly, a systematic literature review evaluated the current evidence for the 
association between dietary anthocyanin intake and risk of CVD. In the largest 
and most comprehensive meta-analysis of existing prospective cohort studies, it 
was found that a higher intake of anthocyanins reduced risk of both coronary 
heart disease (CHD) and CVD mortality. These data further support the notion 
that exposure to anthocyanins could have a putative role in cardiovascular health, 




prelude to a randomised controlled trial, Chapter 4 investigated the repeatability 
of a battery of vascular function test measures.  The repeatability of blood 
pressure, arterial stiffness and macro-vascular endothelial function was found to 
be adequate and this was used to inform the final study. Chapter 5 reports the 
influence of anthocyanin-rich MC on physiological or cognitive function in middle-
aged adults. This randomised, double-blind, placebo-controlled trial had several 
strengths such that it was successfully blinded, relatively large sample size, 
longer-term supplementation period and well controlled compared to other 
studies of a similar nature. However, the results suggested no influence of MC 
juice on vascular function, metabolic health, cognitive function, or exercise 
capacity after three months in middle-aged adults. There was an effect on mental 
fatigue and alertness visual analogue scales (VAS) during the cognitive function 
test battery, suggesting an anti-fatiguing effect of MC. Moreover, Chapter 6 
outlines important limitations and future research directions, that will help 
strengthen the evidence base regarding the intake of anthocyanin-rich foods and 
CVD. Collectively, these studies have contributed to knowledge on longer-term 
exposure to dietary anthocyanins and how they can impact on indices associated 
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Cardiovascular disease (CVD) and type II diabetes combined are the primary 
cause of global mortality (Danaei et al., 2014). Advancing age is the strongest 
risk factor for these diseases, with ~90% of CVD occurring in adults aged 40-80 
years or older (Ekoé, Punthakee, Ransom, Prebtani, & Goldenberg, 2013; 
Yazdanyar & Newman, 2009) and the number of middle-aged and older adults is 
rapidly increasing (ONS, 2017). However, amongst modifiable lifestyle factors of 
age-related diseases, diet can play an integral part (Afshin et al., 2019). For 
example, increased intake of fruit and vegetables (F&V) have also been shown 
to reduce risk of type II diabetes, premature death and CVD mortality (Aune et 
al., 2017; Forouzanfar et al., 2016). Fruit and vegetables are an important source 
of dietary phytochemicals, in particular polyphenols, that are thought to contribute 
to the observed inverse relationship between intake of F&V and chronic disease 
(Adriouch et al., 2018a; Kesse-Guyot et al., 2011). In recent years there has been 
an enormous research focus into anthocyanins, a specific subclass of 
polyphenols, and how foods which contain these compounds can be exploited to 
improve human health (Cassidy, 2017; Keane et al., 2016b; Rodriguez-Mateos 
et al., 2019a). Accumulating data suggests that these compounds might protect 
against diseases due to their antioxidant and anti-inflammatory actions and their 
ability to interact with cell signalling pathways involved in cell adhesion, cell 
migration, and cell differentiation (Krga, Milenkovic, Morand, & Monfoulet, 2016; 
Reis et al., 2016; Rodriguez-Mateos et al., 2019a). 
One of the most studied anthocyanin-rich foods in recent years has been tart 
Montmorency cherries (Prunus Cerasus, cv Montmorency; MC) in health and 
exercise. Indeed, the physiological and biochemical effects that MC (and its 
constituents) might afford in both clinical and exercise domains has garnered 
much attention (Bell, McHugh, Stevenson, & Howatson, 2014c; Kelley, Adkins, & 
Laugero, 2018; McCune, Kubota, Stendell-Hollis, & Thomson, 2011). There is 
now emerging evidence that MC can positively influence risk factors for 
cardiometabolic and neurodegenerative diseases, effects that have been largely 
attributed to its anthocyanin content (Chai, Davis, Wright, Kuczmarski, & Zhang, 
2018; Desai, Roberts, & Bottoms, 2019; Keane et al., 2016b). Given the global 
health issues associated with poor cardiovascular and cognitive function, foods 
rich in naturally occurring compounds such as anthocyanins that could be 




diseases would not only have economic implications, but would also improve 
health and wellbeing. However, epidemiological studies (Ponzo et al., 2015; 
Tresserra-Rimbau et al., 2014a) supporting the putative role of anthocyanins in 
cardiovascular health, and indeed recent findings from longer-term MC 
supplementation on CVD risk factors, are inconsistent and equivocal (Chai et al., 
2018; Desai, Roberts, & Bottoms, 2020; Johnson et al., 2020; Lynn et al., 2014). 
Moreover, due to the heterogeneity amongst those existing studies the current 
understanding of the potential application anthocyanin-rich foods in human health 
is limited. This area requires more attention due to the existing challenge for the 
primary prevention and management of non-communicable diseases in the 
globally aging population.  
The overarching aim of this thesis is to provide novel insight into potential role of 
dietary anthocyanins in cardiovascular health.  
This aim is broken down into the following specific aims which will be addressed 
in the subsequent experimental chapters: 
1) To synthesize and evaluate the relationship between dietary intake of 
anthocyanins and the risk of CVD and related mortality from prospective 
cohort studies (Chapter 3) 
2) As a prelude to investigating the influence of anthocyanins on 
cardiovascular risk factors – to determine the reliability of a battery of 
commonly used non-invasive measures of vascular function in vivo 
(Chapter 4) 
3) To investigate the influence of longer-term (3 month) tart cherry (Prunus 
Cerasus, cv Montmorency) supplementation on vascular function, 































Given the diverse nature of this thesis which focuses on the application of dietary 
anthocyanins in the form of tart cherries in health and exercise paradigms, this 
review will examine the literature pertaining to the following areas:  
• Phytochemical uses, structure and function with particular emphasis on 
those present in tart cherries.  
• The pharmacokinetics and the factors that affect the bioavailability of 
phenolic compounds in tart cherries.  
• The potential mechanisms of action of tart cherry polyphenols. 
• The current research pertaining to effects of tart cherry supplementation 
on various aspects of health and exercise.  
Many fruits grown in the Rosaceae plant family have significant economic 
importance, including; apples, apricots, blackberries, cherries, peaches, pears, 
plums, raspberries, and strawberries (Farinati, Rasori, Varotto, & Bonghi, 2017; 
Yue et al., 2017). Cherries (genera Prunus) ripen first among the stone fruits and 
are grown in two main species; sweet (Prunus avium L.) and tart (Prunus cerasus 
L.), also known as sour (Quero-García, Iezzoni, Pulawska, & Lang, 2017). In 
recent years, there has been an increased demand for tart cherry production, with 
the USA reportedly producing more than 140 thousand tonnes in 2016 alone 
(FAO, 2018; Thornsbury & Martinez, 2012). Unlike sweet cherries, which are 
normally consumed as fresh fruit, tart cherries are mostly processed, for example; 
powdered, frozen, dried, made into juice or juice concentrate (Chaovanalikit & 
Wrolstad, 2004). The sale of these and other fruit and vegetable derived products 
has burgeoned, as consumers have gained interest into their purported health 
and exercise related benefits (Lee, 2016; Wootton-Beard & Ryan, 2011). There 
is now a growing body of evidence to support that tart cherries, specifically from 
the Montmorency cultivar, elicit cardio- and neuro-protective properties (Keane 
et al., 2016b; Thangthaeng et al., 2016). Montmorency tart cherries (MC) have 
also been demonstrated to be effective in enhancing exercise performance and 
recovery (Bell, Stevenson, Davison, & Howatson, 2016; Howatson et al., 2010; 
Levers et al., 2016). Such benefits are thought to be attributable to the 
phytochemical, specifically anthocyanin, content of cherries that compare 




phytochemicals and findings from recent studies suggested MC to be a salient 
functional food in both clinical and exercise domains; these will be discussed in 
the forthcoming sections (Keane, Haskell-Ramsay, Veasey, & Howatson, 2016c; 
Kirakosyan, Gutierrez, Ramos Solano, Seymour, & Bolling, 2018; Levers et al., 
2016).    
2.1.1 Historic and medicinal uses of phytochemicals 
Phytochemical-rich plants have formed the basis of sophisticated traditional 
medicine systems that have been in existence for thousands of years. 
Ethnobotany has described a variety of medicinal plant and derivatives such as 
regional herbs, spices, teas, wines, fruits, barks, roots and leaves used to treat 
and cure a number of ailments. In the ancient Western world, the Greeks 
contributed significantly to the rational development of the use of medicinal 
plants, said to have originated with Hippocrates (460–377 BC) and Aristotle (384–
322 BC), who were inspired by ancient beliefs from India and Egypt, some of the 
primary users of herbal medicines (Gurib-Fakim, 2006). As early as 668 BC the 
ancient Greeks were utilizing mushrooms, dried figs and various wine 
concoctions to enhance their sporting performance in the Olympics (Moffat, 
2006). With regards to traditional herbal medicines; Indian Ayurveda, Islamic 
Unani and Chinese medicine represent good examples of philosophical systems 
that remain prominent despite the intellectual imperialism of Western medicine 
(Hoffmann, 2003). Two previous analyses of the phytochemistry of medicinal 
Chinese herbs demonstrated that some were particularly rich sources of 
melatonin and polyphenols, up to 3000 ng·g-1 dry mass and 280.46 mg gallic acid 
equivalents (GAE)·g-1, respectively (Chen et al., 2003; Liu, Qiu, Ding, & Yao, 
2008). Interestingly, those herbs containing the higher levels of melatonin; 
yinyanghuo (1105 ng·g-1) and sangbaipi (1110 ng·g-1) were typically used to slow 
the aging process (Chen et al., 2003). On the other hand, the highest levels of 
total polyphenol content was observed in the Chinese white olive, which were 
predominantly used to cure pain and swelling in the throat, an action which might 
be related to their antioxidant capacity (Liu et al., 2008).  
Historically, berries such as blackberries and raspberries, with more comparable 
phytochemical composition to cherries than the aforementioned herbals, have 
also been described as medicinal sources. These plants, from the Rubus genera, 




fluids and for treating droopy eyes, mouth sores, haemorrhoids, and snakebites 
(Hummer, 2010). Whereas, cherries were purportedly utilized in Unani medicine 
to treat various ancient diseases such as ‘Usr al-Bawl (Dysuria), Qarha-e-Alate 
Baol, Hasah-al-kulya (Nephrolithiasis), and (Cystolithiasis) Hasah-al-Mathana 
(Shamsi, 2017). Similarly, in Africa, their native cherries (Prunus Africana) were 
also widely exploited. The bark and leaves used to target illnesses (e.g. 
gonorrhoea) and symptoms such as fevers and pains (Stewart, 2003). More 
recently, there is accumulating evidence that tart cherries, particularly MC, could 
be a valuable medicinal plant in many age-related diseases, which is likely due 
to the unique phytochemical composition, including both melatonin and 
polyphenols (Bell et al., 2014c; Kelley et al., 2018; McCune et al., 2011).   
2.1.2 Tart cherry phytochemical synthesis and classification 
Tart cherries contain an array of bioactive phytochemicals; these include 
polyphenols, carotenoids and indolamine compounds (Ferretti, Bacchetti, 
Belleggia, & Neri, 2010). Notably, MC do not have the highest phytochemical 
content of any fruit, however, they contain more than sweet cherries and other 
tart cherry cultivars (Chaovanalikit & Wrolstad, 2004; Kirakosyan et al., 2010). 
Moreover, amongst the 20 most commonly consumed fruits, cherries appear to 
have the fifth highest total polyphenol content (Vinson et al., 2001).  In addition 
their phytochemicals have previously been demonstrated to have synergistic and 
additive effects, thus any health effects associated with their intake could be 
enhanced by such interactions (Kirakosyan et al., 2010). The following section 
aims to summarise the phytochemicals specifically found in tart cherries an 












2.1.2.1 Tart cherry polyphenols 
Polyphenols are naturally occurring compounds found largely in the fruits, 
vegetables, cereals and beverages. Used as an umbrella term, polyphenols 
describe phenolic compounds which are characterized by having at least one 
aromatic ring with one or more hydroxyl group attached. These can be further 
classified into four categories: phenolic acids, flavonoids, stilbenes and lignans 
(Pandey & Rizvi, 2009). These phenolics are not related to the plants primary 
metabolism of compounds which are vital for its immediate survival (e.g. in the 
same way as photosynthesis) but represent a secondary pathway that 
nonetheless, indirectly increases the survivability of the plant. As such, the term 
‘secondary metabolite’ has been applied to polyphenolic compounds and the 
survivability-enhancing actions they confer are associated with three main areas. 
Firstly, they can act as deterrents to potentially damaging herbivores and 
competitors; secondly, they can attract potentially beneficial symbiotes; and 
finally they provide phytoalexin-mediated protection against potentially damaging 
stressors (Quideau, Deffieux, Douat‐Casassus, & Pouysegu, 2011). Although 
long ignored, the function of these compounds is now attracting widespread 
attention because of their diverse range of bio-physicochemical properties 
(Crozier, Jaganath, & Clifford, 2006).  
With regards to tart cherries, the total phenolic content (TPC) has previously been 
reported anywhere between 74-754 mg per 100 g of fresh weight (Quero-García 
et al., 2017). They have also been identified to be rich sources of phenolic acids, 
mainly hydroxybenzoic and hydroxycinnamic acids, and flavonoids. Flavonoids 
can be further sub-categorised, with MC and related products reportedly 
containing varying concentrations of flavonols (quercetin and kaempferol), 
flavanols (also known as flavon-3-ols; catechin and epicatechin)  and 
anthocyanidins (cyanidin, malvidin, pelargonidin, peonidin, delphinidin and 
petunidin)  the skeleton for which are shown in Figure 1 (Bell et al., 2014a; 
Kirakosyan, Seymour, Llanes, Kaufman, & Bolling, 2009; Quero-García et al., 
2017). Both flavonoids and phenolic acids are derived from the phenylpropanoid 
pathway and anthocyanins synthesized when the enzyme chalcone synthase 
produces tetrahydroxychalcone from 4-coumaroyl-CoA and malonyl-CoA 




Due to their distinct red colour, cherries are usually associated with high levels of 
anthocyanins, which are glycosides generated from anthocyanidins and are the 
pigments often responsible for the orange, red, and blue colours in fruits, 
vegetables, flowers, and other storage tissues in plants (Blando, Gerardi, & 
Nicoletti, 2004). As such, the highest proportion of anthocyanins in MC are found 
in the skin, with minimal amounts reported in the flesh and pits (Chaovanalikit & 
Wrolstad, 2004). The most abundant anthocyanins in tart cherry fruits are 
cyanidins and peonidins with glucose and rutinose sugar moieties; e.g. cyanidin 
3-O-glucoside; C3G, cyanidin 3-O-glucosyl-rutinoside, cyanidin 3-O-rutinoside, 
peonidin 3-O-rutinoside and peonidin 3-O-glucoside (Rothwell et al., 2013). To 
date, interest in polyphenols, particularly anthocyanins (Rodriguez-Mateos et al., 
2019a), has intensified because of their possible health-promoting properties 
(Blando et al., 2004; Pandey & Rizvi, 2009). 
2.1.2.2 Tart cherry carotenoids 
Carotenoids, a class of terpenoids (also known as isoprenoids), are another 
example of pigments and are responsible for red, orange, and yellow colours of 
fruits, vegetables and flowers. Carotenoids are classified by their chemical 
structure as: (1) carotenes that are constituted by carbon and hydrogen; (2) 
oxycarotenoids or xanthophylls that have carbon, hydrogen, and, additionally, 
oxygen. In plants, carotenoids primarily function as essential components 
required for photosynthesis (e.g. beta-carotene), photoprotection (e.g. 
zeaxanthin) and the production of phytohormones, hence can be either primary 
or secondary metabolites. These compounds are  produced  in  fruit chromoplasts  
during  the  maturation  process and are synthesized by the isoprenoid pathway, 
where isopentenyl  pyrophosphate is  the  most common  precursor (Delgado-
Vargas, Jiménez, & Paredes-López, 2000).Tart cherries contain carotenoids, 
mainly beta-carotene (770 µg per 100 g fresh weight) and to a lesser extent lutein 
and zeaxanthin (85 µg per 100 g fresh weight) (Ferretti et al., 2010). Dietary 
sources of carotenoids, because of their potential role as antioxidants, have been 
suggested to be protective against chronic diseases (Tapiero, Townsend, & Tew, 
2004). However, because of the limited evidence to support this concept (Krinsky 




2.1.2.3 Tart cherry indolamines 
Indolamines, for example melatonin, are neurotransmitters, now widely accepted 
as important plant metabolites participating in diverse processes such as 
spanning reproduction, germination, vegetative growth, perception and 
morphogenesis (Erland, Shukla, Singh, Murch, & Saxena, 2017). Although the 
biosynthetic pathways in humans and mammals have been well established, the 
synthesis of indolamines in plants is less well understood. As with humans, the 
aromatic amino acid tryptophan is the metabolic precursor, which is converted to 
either serotonin (5-hydroxy-tryptamine) or normelatonin (N-acetyl-serotonin), and 
finally (N-acetyl-5-methoxy-tryptamine) melatonin (Arnao & Hernández‐Ruiz, 
2015). The melatonin content of MC has previously been reported as 
approximately 13 ng·g-1, more than that of sweet cherries (Burkhardt, Tan, 
Manchester, Hardeland, & Reiter, 2001; Kirakosyan et al., 2010). Exogenous 
intake of melatonin has been associated with improved regulation of circadian 
rhythms as well as reduced risk of various cancers, cardiovascular diseases, 
improved sleep quality, mood and cognitive function (Posadzki et al., 2018). 
Improved sleep in particular might reduce cardiovascular risk factors in older 
individuals (Carroll et al., 2015), and the dose of dietary melatonin currently 
recommended for dietary supplementation in this cohort is 0.3 to 2mg (Vural, Van 
Munster, & De Rooij, 2014). Although the levels of melatonin in tart cherries are 
much lower than those of melatonin given as a nutritional supplement, 
consumption (~85.2 ϻg per day) has been shown to significantly increases 
circulating melatonin levels and improve sleep efficiency (Howatson et al., 2012). 
Enhanced sleep following the consumption of tart cherries has been reported 
elsewhere (Losso et al., 2017; Pigeon, Carr, Gorman, & Perlis, 2010). While this 
has been speculated to be due to the melatonin content of tart cherries, it might 
also be due to the stimulation endogenous melatonin production due to the 
tryptophan content of tart cherries (Jiki, Lecour, & Nduhirabandi, 2018). However, 
another potential mechanism for these benefits has been attributed to the anti-
inflammatory effects of tart cherry polyphenols (Losso et al., 2017), in that a 
number of inflammatory cytokines are intricately related to the modulation of 
sleep (Opp, 2004). Nonetheless, while the mechanisms are still impossible to 
discern, they are likely due to more than just melatonin content. Furthermore, 
previous studies have shown strong synergistic and additive activities for 




focus of this thesis remains dietary anthocyanins it is important to take in to 
consideration that tart cherries contain other phytochemicals as summarised in 
Figure 1. 
2.1.3 Bioavailability of tart cherry phytochemicals 
The efficacy of any nutraceutical is reliant on the bioavailability in vivo, that is, 
following ingestion, the active compounds are absorbed through the gastro-
intestinal tract and made available in the circulation, in sufficient quantities, to be 
utilized by cells (Rein et al., 2013). Consequently, it is not only important for tart 
cherries to contain sufficient quantities of phytochemicals, but it is also critical 
that those phytochemicals are absorbed and distributed in biologically effective 
doses. The former of which is influenced heavily by the cultivar and subject to a 
number of pre- and post-harvest factors.  
Environmental factors such as rainfall, temperature, sun exposure and light 
intensity could all affect the synthesis and subsequently quantity of 
phytochemicals in tart cherries (Quero-García et al., 2017). Moreover, pre-
harvest treatments is another important factor, as demonstrated in tart cherries 
harvested from ethephon-sprayed trees which had reduced anthocyanin content 
and antioxidant activity than non-sprayed controls (Khorshidi & Davarynejad, 
2010). Furthermore, the degree of ripeness can also affect both the concentration 
and proportion of various phytochemicals, for example phenolic acid 
concentrations potentially decrease during ripening, whereas anthocyanin 
content increase (Gonçalves et al., 2007). Other post-harvest factors include, but 
are not limited to; food processing, transport, storage and cooking of tart cherries 
and related-products, all of which can impact the phytochemical, including 
polyphenol, content (Ferretti et al., 2010).  
Bioavailability of tart cherry phytochemicals is further complicated by systemic 
and intestinal factors relating to the individual. Systemic factors include sex, age, 
and genetic variation. Notably, genetic variation in pathways affecting absorption, 
metabolism, and distribution of phytochemicals is likely to influence exposure at 
the tissue level. Likewise, genetic variation in cell signalling pathways, within 
which these compounds interact can alter biological response. Intestinal factors 
include variations in enzyme activity and colonic microflora (D’Archivio, Filesi, 
Varì, Scazzocchio, & Masella, 2010; Lampe & Chang, 2007). In recent years, an 




phytochemicals (mainly anthocyanins;Table 1), the ensuing section will provide 
an overview of the disposition, through absorption, distribution, metabolism and 





Table 1. Acute pharmacokinetics of tart cherry polyphenols 





























0.05 ± 0.05 μg·L-1 
 
60 
Bell et al. (2014a) 
 
Healthy 12 60 ml MC concentrate 
0-8 hours 
 
- 547.0 C3G 
 
1.28 ± 2.40 μg·L-1 60 




13.0 - a.C3GR 
b. C3R 
a. 117,743 raw MS peak* 
b. 103,226 raw MS peak* 
a. 120 
b. 120 
Seymour et al., (2014) Healthy 12 90 IQF cherries (~367 g) 
-0.5-12 hours 
 
25.8 - a.C3GR 
b. C3R 
a. 183,873 raw MS peak* 
b. 122,582 raw MS peak* 
a. 240 
b. 120 
Keane et al. (2016a) Healthy 
males 
12 30 ml MC concentrate 
0-8 hours 
 
71.4 31.2 a. PCA 
b. CHL 
       c. VA 
 
a. 2760 ± 100 μg·L-1 
b. nd 
c. 300 ± 10 μg·L-1 
a. 60 
b. nd 
 c. 120 
Keane et al. (2016a) Healthy 
males 
12 60 ml MC concentrate 
0-8 hours 
 
142.7 62.5 a. PCA 
b. CHL 
        c. VA 
a. 2750 ± 130 μg·L-1 
b. nd 




Keane et al. (2016b) Healthy 
males 
16 60 ml MC concentrate 
0-8 hours 
 
178.8 73.5 a. PCA 
        b. VA 
a. 2350 ± 80 μg·L-1 




Abbreviations; chlorogenic acid, CHL; cyanidin 3 glucoside, C3G; cyanidin-3-glucosylrutinoside, C3GR; cyanidin-3-rutinoside, C3R; individually quick frozen, 
IQF; mass spectrometry, MS; maximum concentration, Cmax; Montmorency tart cherries, MC; Not detected, nd;  protocatechuic acid, PCA; time to Cmax, Tmax; 
total anthocyanin content, TAC; total polyphenol content, TPC; vanillic acid, VA.  




2.1.3.1 Absorption and distribution 
The study of phytochemical absorption and distribution in the human body is 
crucial to determine those bioactive metabolites which might be responsible for 
any health benefits, however because polyphenols undergo extensive 
metabolism before they can be absorbed this remains poorly understood 
(Williamson, Kay, & Crozier, 2018). On the one hand, melatonin appears to be 
easily absorbed reaching relatively large concentrations in the serum, as per 
human bioavailability studies of melatonin-rich foods (Maldonado, Moreno, & 
Calvo, 2009; Sae‐Teaw, Johns, Johns, & Subongkot, 2013). Whereas, although 
some MC anthocyanins are quickly absorbed from the stomach and small 
intestine, circulating in the plasma without undergoing metabolic changes and 
reaching maximum blood levels within one to two hours, these appear in small 
amounts which would suggest that tart cherry polyphenols exhibit poor 
bioavailability (Table 1). However, there are extensive differences between the 
absorption of polyphenols mainly because most are in the form of esters, 
glycosides, or polymers that cannot be absorbed in their intrinsic form. In fact, 
many compounds must be either deglycosylated in the mouth, hydrolysed in the 
stomach or enzymatically modified by intestinal enzymes (glycosidases, 
esterases, oxidases, and hydrolases; Phase I metabolism) before they can be 
absorbed into systemic circulation (Karaś, Jakubczyk, Szymanowska, Złotek, & 
Zielińska, 2017). Polyphenol aglycones may then enter the epithelial cells by 
passive diffusion as a result of its increased lipophilicity or alternatively polar 
glucosides are transported into the epithelial cells, possibly with the involvement 
of the active Na-dependent transporters, e.g. SGLT1 and GLUT2 (Teng & Chen, 
2019). 
A large proportion of dietary polyphenols, particularly those of large molecular 
mass,  pass to the large intestine, where they are transformed by the gut 
microbes where they undergo microbial catabolism (Bohn et al., 2015). The level 
of biotransformations that polyphenols will undergo is dependent on the structure 
of: (a) the polyphenol and (b) intestinal microbial community. Subsequently, the 
gut microbiome (determined by the physiology of the host, host genotype and 
environmental factors) can potentially affect the metabolism of polyphenols and 
ultimately the distribution of any bioactive compounds (Zoetendal, Akkermans, 




predominately reach the large intestine, where they are catabolized by the 
microbiota, yielding an array of phenolic constituents that are absorbed, with 
some being metabolized to phase II conjugates as described in section 2.1.3.1 
(Kay, Pereira-Caro, Ludwig, Clifford, & Crozier, 2017). In vitro studies have 
reported phenolic acids, such as protocatechuic (PCA), syringic, vanillic (VA), and 
p-hydroxybenzoic acids, to be main metabolites of anthocyanins after faecal 
fermentation (Aura et al., 2005; Keppler & Humpf, 2005). Both PCA and VA have 
been shown in the blood in larger concentrations than parent anthocyanins 
following ingestion of tart cherry concentrate (Table 1). However, only a limited 
number of metabolites have been studied to date, given the diverse nature of the 
phytochemicals previously described (Figure 1), larger more comprehensive 
studies of the absorption and distribution of tart cherry compounds are warranted, 
i.e. through the use of metabolomics.  
Interestingly, because of their poor absorption in the upper gastrointestinal tract 
and anti-microbial actions, there is some evidence to suggest that some 
polyphenols, specifically anthocyanins, can act as prebiotics, modulating the 
microbiota (Coman et al., 2017). To what extent modulation of the gut microbial 
community is important in context of health benefits has yet to be fully elucidated. 
However, because microbiome dysbiosis has been associated with chronic 
diseases, such as cardiovascular disease, the importance of determining the 
relationship between diet and the gut bacteria is becoming more apparent (Moco, 
Martin, & Rezzi, 2012). Thus far, the interactions between human gut microbiome 
and tart cherry phytochemicals, likely important determinants of clinical efficacy, 
remains under-researched and human trials are equivocal with some evidence 
that modulation of microbiota may be specific to certain bacteria and is dependent 
on initial enterotype (Lear et al., 2019; Mayta-Apaza, Marasini, & Carbonero, 
2017; Mayta-Apaza et al., 2018).  
With regards to distribution, those studies summarised in Table 1 demonstrate 
that a number of MC parent anthocyanins and their metabolites are absorbed and 
distributed, at least in the intravascular space. In rats, tissue bioavailability of 
certain cherry anthocyanin compounds (C3G, cyaniding-3-rutinoside, cyaniding-
3-glucosylrutinoside, cyaniding-3-sophoroside, peonidin-3-glucoside and 
pelargonidin) has been investigated following 3 weeks of supplementation with 




The authors demonstrated anthocyanin bioavailability in the bladder, kidney, 
liver, heart and brain, but not retroperitoneal fat. Moreover, there was a dose-
response for the 1% and 10% group in the brain, 152.6 ± 9.7 vs. 337.8 ± 17.4 pg 
total anthocyanin content (TAC)∙g-1 of tissue. Perhaps the most interesting finding 
of this study was that these compounds could cross the blood brain barrier and 
the preferential storage of certain phenolic compounds in these tissues. 
Collectively, there is some, but limited evidence that MC phytochemicals are 
absorbed and distributed into circulation and tissues, suggesting the ability of tart 
cherries to have biological effects. However, existing pharmacokinetic data is 
restricted to acute plasma studies, thus a gap in our understanding of the overall 
metabolism in these compounds following MC intake including excretion, and 
indeed the chronic exposure to these completely unexplored. 
2.1.4.2 Metabolism and excretion  
Other potential bioactive metabolites are those deriving from phase II metabolism 
of polyphenols in the liver. Compounds that are absorbed into the blood stream 
can undergo biotransformations such as sulphation, glucuronidation, methylation 
and glycine-conjugation, so that the resulting metabolites are nontoxic and 
become easier to excrete in urine or bile (Moco et al., 2012). Accordingly, 
previous human studies have demonstrated increases in urine anthocyanin 
metabolites, C3G equivalents and peonidin 3-glucoside equivalents following an 
acute dose of individually quick frozen (IQF) MC powder in 12 healthy humans 
(Seymour et al., 2014). Howatson and colleagues (2012) also demonstrated a 
significant increase in total urinary 6-sulphatoxymelatonin (a major melatonin 
metabolite) following a 7 day supplementation with MC concentrate (~85.2 
μg·day-1 melatonin) compared with placebo. In addition, some compounds that 
are absorbed intact, without enzymatic modification, might still undergo 
metabolism in the liver, and those metabolites, can be recycled back into the 
intestine through the enterohepatic cycle, where further modifications may occur 
(Van Duynhoven et al., 2011). Therefore because of this potential enterohepatic 
as well as enteric recycling (in the small intestine) many polyphenols (Borges, 
Ottaviani, van der Hooft, Schroeter, & Crozier, 2018), including anthocyanins and 
their metabolites (Ferrars et al., 2014), exhibit a biphasic pharmacokinetic 
response (e.g. Figure 2). For example, serum and urine concentrations of 




isotopically labelled cyanidin-3-glucoside (13C5-C3G) in 8 healthy males (Czank 
et al., 2013). The same authors reported large concentrations of some phase II 
conjugates in the serum and urine, up to 24 hours after supplementation, whereas 
previously described MC studies were limited to 8-12 hours.  
Figure 2. Serum (left) and urine (right) pharmacokinetics of cyanidin-3-glucoside 
(C3G) and phase II conjugates, after the consumption of a 500-mg bolus dose of 
isotopically labelled 13C5-C3G by 8 healthy male participants over 48 h and 
expanded views of the first 6 h (Czank et al., 2013). 
 
As of yet, there has been no attempt to determine the biliary excretion of 
phytochemical metabolites derived from the intake of tart cherries in humans, but 
based on previously described isotope studies, urinary excretion (of anthocyanins 
in particular) appears to be the primary route. Nonetheless, in a recent addition 
to the literature Mayta-Apaza and colleagues (2018) also established 
fermentation and degradation of other native tart cherry polyphenols through in 
vitro digestion. Bacterial degradation of tart cherry polyphenols resulted in high 
quantities of 4-hydroxyphenylpropionic and 3,4 and 4-hydroxybenzoic acids, 
which they speculated were derived from 5-caffeoylquinic acid and quercetin, 
respectively. However, these compounds have yet to be identified following 
ingestion of tart cherries in humans.  Albeit,  Mosele and colleagues (2015) 
demonstrated that a 4 week supplementation with 200 ml of polyphenol-rich 




resulted in significant increases in faecal concentrations of phenolic metabolites; 
dihydroxy-urolithin, phenylpropionic acid, catechol, hydroxytyrosol and  total 
phenolic metabolites (mg·g-1 dry faeces; P < 0.05). A limitation of this study is 
that no control group was used. In a more recent, randomized and controlled (33 
case, 8 control) study of red wine, TPC: 1758 mg  GAE·L-1, nontargeted 
metabolomics analysis after the 4-week intervention established microbial-
derived red wine-metabolites in the faeces, but also high intra- and inter- 
individual variability of faecal metabolite content (Jiménez-Girón et al., 2014). 
Similar to tart cherries, both pomegranates and red wine are good sources of 
anthocyanins (Cassidy, 2017), suggesting that the intake of MC may result in 
faecal polyphenol catabolites, but human studies are needed to verify this.  
The research summarised above demonstrates that phytochemicals are 
intensively modified and metabolised (Figure 3) and could be present in the body 
longer than 12 hours. To further illustrate this point the known metabolites from 
one anthocyanin (C3G) found in tart cherries are shown in Table 2 below. 
subsequently, it is likely that the bioavailability of tart cherry phytochemicals has 
likely been underestimated in previous research.  Similarly, another main 
limitation of the existing data regarding the bioavailability of tart cherry 
phytochemicals is they have often been restricted to single phytochemicals of 
interest, mainly anthocyanins (Keane et al., 2016a; Seymour et al., 2014). 
Although anthocyanins may be at least partly be having an effect there is need 
for a better understanding of a global perspective of exposure to MC. Since 
sustained exposure to anthocyanins and other phenolics may alter gene 
expression (Rodriguez-Mateos et al., 2019b) and metabolites represent 
endpoints of gene expression, the metabolome might better characterise global 
physiological effects following nutritional interventions. The use of metabolomics 
for example has become increasingly popular in nutritional research and showed 
that anthocyanin-rich foods increase circulating polyphenol metabolites that 
might be responsible for acute and chronic changes in health indices (Istas et al., 
2019a; Jacobs et al., 2012). Once again highlighting the value of metabolomics 





Figure 3. (Created with BioRender) Schematic representation of the fate of tart 
cherry phytochemicals: (1) ingested phytochemicals are liberated from food 
matrixes to become bioaccessible for absorption; (2) absorption, the movement 
of a compound from the site of administration through the gastrointestinal tract to 
the blood circulation, some compounds may undergo enzymatic modification in 
the mouth, stomach and small intestine (e.g. hydrolysis) or large intestine (host 
microbiome co-metabolism); (3) distribution, some compounds diffuse or are 
transferred from the intravascular (blood) to the extra-vascular space (body 
tissues) where they may elicit biological effect; (4) metabolism, the biochemical 
conversion or transformation of  compounds into a form that is easier to eliminate 
(e.g. sulphation, glucuronidation, and methylation); and (5) excretion, unchanged 
compounds or metabolites are eliminated from the body, mainly via renal and to 




Table 2. Known metabolites from cyanidin 3-O-glucoside precursor 
Based on Phytohub database (Giacomoni et al., 2017)  





Metabolite  Biofluid identified in 
3-Hydroxybenzoic acid  faeces, urine 
4-Hydroxybenzoic acid  faeces, urine 
Protocatechuic acid  faeces, serum, urine 
Vanillic acid  faeces, serum, urine 
3',4'-Dihydroxyphenylacetic acid  faeces, urine 
4-Hydroxybenzaldehyde  faeces, urine 
4'-Hydroxyphenylacetic acid  faeces, urine 
Caffeic acid  Faeces 
Ferulic acid  faeces, serum, urine 
Hippuric acid  faeces, serum, urine 
Peonidin 3-glucoside  liver, urine 
2-Hydroxy-4-methoxybenzoic acid  faeces, urine 
Protocatechualdehyde  faeces, urine 
4-Methoxybenzaldehyde  Faeces 
Cyanidin 3-glucoside glucuronide*  Urine 
Cyanidin glucuronide  plasma, urine 
Isopeonidin 3-glucoside*  Urine 
Isopeonidin glucuronide*  Urine 
Isovanillic acid  faeces, serum, urine 
Isovanillic acid-3-O-glucuronide  faeces, serum, urine 
Isovanillic acid-3-O-sulfate  faeces, serum, urine 




Methylcyanidin glucuronide  Urine 
Methylvanillate  Faeces 
Peonidin 3-glucoside glucuronide*  Urine 
Peonidin glucuronide*  Urine 
Phloroglucinaldehyde  faeces, serum, urine 
Protocatechuic acid-3-O-glucuronide  faeces, serum, urine 
Protocatechuic acid-3-O-sulfate  faeces, serum, urine 
Protocatechuic acid-4-O-glucuronide  faeces, serum, urine 
Protocatechuic acid-4-O-sulfate  faeces, serum, urine 
Vanillic acid 4-O-glucuronide  faeces, serum, urine 




2.2 The role of tart cherries in human health and aging 
Recent advances in technology and medicine have resulted in a universal aging 
population. For example, in the UK in the next 20 years it is estimated that almost 
a quarter of the population will be aged 65 or over (ONS, 2017). Although aging 
is an inevitable process, there are extensive inter-individual variability in health 
status and quality of life as humans grow older. This has originated the 
multidimensional concept of ‘healthy aging’, defined as not only longevity devoid 
of major chronic diseases, but also maintaining good cognitive, physical, and 
mental health (Rowe & Kahn, 1997). As the number of older adults is rapidly 
increasing, establishing strategies to facilitate healthy aging in these populations 
has become a research priority, with nutrition playing an integral role (Kiefte-de 
Jong, Mathers, & Franco, 2014). 
One important challenge faced with aging is impaired vascular function (Thijssen, 
Carter, & Green, 2016). Poor vascular function is implicated in cognitive decline 
(Knopman et al., 2001), mood disorders (Paranthaman et al., 2010) and reduced 
physical and functional capacity that typically occur with advancing age (Poole, 
Behnke, & Musch, 2020). Moreover, endothelial dysfunction and arterial stiffening 
are independent risk factors of atherosclerosis and cardiovascular disease; CVD 
(Mudau, Genis, Lochner, & Strijdom, 2012; Niiranen et al., 2016), but are also 
associated with vascular aging. Additionally, vascular dysfunction might 
contribute to the genesis and progression of other age-related diseases such as 
type II diabetes and dementia (Dickstein et al., 2010; Wang et al., 2014a). 
However, the degree of deterioration in vascular function varies within older 
populations. Vascular aging is accelerated by other cardiovascular risk factors 
such as hyperglycaemia, hyperinsulinemia, hypertension, and dyslipidaemia 
(Rubin et al., 2012; Sowers et al., 1993; Terentes-Printzios et al., 2017) but is 
now considered a modifiable risk factor in itself (El Assar, Angulo, & Rodríguez-
Mañas, 2013). Given, that vascular function appears to be a key mediator in 
human health and wellbeing, interventions that could improve these risk factors 
and help preserve vascular health, physical and cognitive function and reduce 
disease trajectory are of great interest.  
Epidemiological data suggests that a greater anthocyanin intake is associated 
with reduced risk of type II diabetes (Rienks, Barbaresko, Oluwagbemigun, 




likelihood of better health and wellbeing in individuals surviving to older ages 
(Samieri, Sun, Townsend, Rimm, & Grodstein, 2014). As highlighted in the 
previous sections, MC are relatively rich in anthocyanins, which become 
bioavailable in the blood (see Table 1). More recently there has been emerging 
evidence that MC (possibly due to their anthocyanin content) can improve 
cardiovascular risk factors (Chai et al., 2018; Desai et al., 2019) and modulate 
vascular function (Desai et al., 2020; Keane et al., 2016b). This makes the 
expectation tenable that MC could have a putative role in cardiovascular, and 
subsequently overall health. Therefore, the ensuing sections will outline the 
current evidence pertaining to the influence of MC on human health, physical and 
cognitive performance, and disease. 
2.2.1. Cardiovascular-protective properties of tart cherries 
Cardiovascular diseases are comprised of a class of diseases that involve heart 
and systemic blood vessels. In coronary heart disease, cerebrovascular disease 
or peripheral arterial disease, impaired blood vessel function leads to an 
inadequate blood supply to organs (Mangge, Becker, Fuchs, & Gostner, 2014). 
Atherosclerosis is also the most common cause of these diseases and is 
preceded by endothelial dysfunction (Bonetti, Lerman, & Lerman, 2003). Under 
physiological conditions endothelial cells regulate vascular tone and structure, as 
well as vascular inflammation and thrombosis (Gonzalez & Selwyn, 2003). 
However, the aforementioned cardiovascular risk factors, as well as age, can 
alter endothelial function as a result of increased exposure and impaired ability 
for defence mechanisms to resist oxidative stress and inflammation (Thijssen et 
al., 2016). Initially reactive oxygen species (ROS) activate the endothelial cells 
stimulating expression of adhesion molecules, such as vascular cell adhesion 
molecule-1 (VCAM-1), allowing mononuclear leukocytes, such as monocytes, to 
attach to the endothelium and infiltrate into the intima (Giannotti & Landmesser, 
2007). Moreover, ROS can oxidise low-density lipoproteins (LDL) that have 
permeated the damaged endothelium. The monocytes differentiate into 
macrophages and internalize modified oxidised LDL (oxLDL) to become foam 
cells. These lipid-containing foam cells in the arterial wall can accumulate into 
atherosclerotic plaques or atheromas, which can cause hardening and narrowing 
of the vessels or rupture to cause adverse cardiovascular events such as 




Cardiovascular disease remains the most common cause of morbidity and 
mortality, increasing in prevalence with age (Townsend et al., 2016). Thus, 
improving cardiovascular health and delaying or preventing CVD would not only 
have important economic implications but would serve to promote healthy aging 
as described in the preceding section (Mooney & Mc Auley, 2016). 
Although the exact biological mechanisms by which tart cherries might elicit 
cardiovascular-protection has yet to be fully elucidated it might relate to their 
antioxidant and anti-inflammatory actions, as well as the ability to interact with 
important cell-signalling pathways which will be summarised below (Kelley et al., 
2018). 
2.2.1.1 Tart cherry antioxidant and anti-inflammatory potential 
Oxidative stress and inflammation, key mechanisms of endothelial dysfunction 
and arterial damage, link these risk factors to vascular aging and CVD (Guzik & 
Touyz, 2017). Moreover, there is inherent interplay between the two, as oxidative 
stress might be induced by inflammation, inflammation is also one of the most 
common outcomes of oxidative stress (Mukhopadhyay, Eid, Abdelmegeed, & 
Sen, 2018). As highlighted in section 2.2.1 vascular aging could be exacerbated 
by reduced resistance to ROS and inflammation, therefore natural antioxidant 
and anti-inflammatory agents might elicit cardiovascular protection. This section 
will outline the evidence for the antioxidant and anti-inflammatory potential of tart 
cherries. 
Tart cherry phytochemicals, particularly flavonoids and melatonin, are potent 
antioxidants, due to their ability to scavenge oxygen free radicals and other 
reactive species. In particular, anthocyanins have been shown to act as more 
potent antioxidants compared to some other polyphenols (Pojer, Mattivi, 
Johnson, & Stockley, 2013). Subsequently, some but not all, species of tart 
cherry, including MC have been demonstrated to have high antioxidant activity 
(Wang, Nair, Strasburg, Booren, & Gray, 1999b; Wojdyło, Nowicka, Laskowski, 
& Oszmiański, 2014). Moreover, MC phytochemicals with the highest antioxidant 
capacity (e.g. kaempferol and melatonin) have been shown to have strong 
synergistic types of interactions (Kirakosyan et al., 2010) and importantly MC 
products; frozen and dried cherries, powders from individually quick frozen 




despite industrial processing (Kirakosyan et al., 2009; Ou, Bosak, Brickner, 
Iezzoni, & Seymour, 2012a).  
In murine models, intake of tart cherry juice was demonstrated to increase 
antioxidant enzymes, superoxide dismutase and glutathione peroxidase (GPx) 
compared to the controls (Sarić et al., 2009). In endothelial cells C3G has been  
shown to activate mitogen‐activated protein kinase (MAPK), inducing Nuclear 
factor erythroid 2-related factor 2 (Nrf2), which in turn regulates a number of 
detoxification enzymes such as those described above (Speciale et al., 2013).     
Whereas, in humans longer-term supplementation with tart cherry juice 
compared to a control (with negligible phytochemicals) has been reported to 
increases in plasma antioxidant capacity in healthy middle-aged (Lynn et al., 
2014) and older adults  (Chai, Davis, Zhang, Zha, & Kirschner, 2019a). Moreover, 
these findings may be more pronounced in individuals exposed to increased 
oxidative stress, such as following; a high fat meal (Polley, Oswell, Pegg, & 
Cooper, 2019), ischemia-reperfusion (Traustadóttir et al., 2009) or exercise-
induced muscle damage (Bell, Walshe, Davison, Stevenson, & Howatson, 2014b; 
Howatson et al., 2010), suggesting enhanced antioxidant capacity in vivo. As an 
aside, it should be acknowledged that there are extensive limitations with 
antioxidant assays because of the short half-life, low sensitivity, protein 
interference and that they are not inclusive of all antioxidant defence systems 
(Hollman et al., 2011). Therefore, the biological relevance of any direct 
antioxidant effects of tart cherry phytochemicals for human health based on the 
studies described above should be interpreted with a certain degree of caution. 
It should also be emphasised that phytochemicals are versatile bioactives rather 
than just mere antioxidants as will be described in the forthcoming sections.  
Subclinical chronic low‐grade inflammation has emerged as a cardiovascular risk 
factor and elevated pro‐inflammatory biomarkers (such as interleukin‐6 [IL‐6], 
tumour necrosis factor‐α[TNF‐α] and C‐reactive protein [CRP]) are associated 
with atherosclerosis and future cardiovascular events (Blake, Rifai, Buring, & 
Ridker, 2003; Haddy et al., 2003). Inflammatory cytokines, such as TNF-α and 
IL-6, promote adhesion of leukocytes to endothelial cells and cause an increase 
in vascular permeability (Maruo, Morita, Shirao, & Murota, 1992). Whereas CRP, 
secreted in response to IL-6, enhances clot formation, lipid oxidation and 




in atherogenesis through all stages of its development, from initiation, through 
progression to its thrombotic complication (Libby, 2012).  Chronic inflammation is 
interrelated to vascular dysfunction as endothelial dysfunction stimulates 
inflammation and vice versa, chronic inflammation can promote endothelial 
dysfunction (Giannotti & Landmesser, 2007). However, chronic inflammation is a 
pervasive feature of aging (inflammaging) but is also aggravated by poor diet and 
other cardiovascular risk factors (Sanada et al., 2018). Moreover, inflammaging 
plays a critical role in the pathogenesis of age-related deterioration and diseases 
(Franceschi & Campisi, 2014). Hence anthocyanin-rich foods have become a 
focus of research due to their potential anti-inflammatory/immunomodulatory 
actions (Mena et al., 2014). 
Tart cherries, potentially due to their anthocyanin content (Wang et al., 1999a), 
might elicit anti-inflammatory properties at both an enzymatic and transcriptional 
level. For example, MC powder has recently been shown to inhibit inflammatory 
enzymes, cyclooxygenase (COX)-1, COX-2 and lipoxygenase (LOX), in vitro 
(Kirakosyan et al., 2018). Interestingly, LOX inhibition was significantly higher 
than red raspberry, blueberry and grape extracts, despite reports that these fruits 
are richer in anthocyanins (Cassidy, 2017), once again suggesting possible 
synergy between MC phytochemicals. A dose-response inhibition of COX-2 has 
also been reported in mice fed with 10% and 50% tart cherry juice when 
compared with commercial pellet (Sarić et al., 2009). Moreover, MC derivatives 
have been shown to inhibit COX-1 activity in vitro with the MC concentrate 
exhibiting the greatest inhibitory effect, compared to frozen dried and dried 
cherries and our laboratory has previously reported higher anthocyanin content 
of the concentrate than the other analogues (Keane et al., 2016a; Ou, Bosak, 
Brickner, Iezzoni, & Seymour, 2012b). In addition to COX inhibitory activities, 
C3G and its metabolites have been shown to inhibit inducible nitric oxide 
synthase (iNOS) in macrophages, with PCA demonstrating the most potent 
inhibition compared to C3G and its aglycon (Min, Ryu, & Kim, 2010). These 
enzymes play a role in the pathophysiology of atherosclerosis by propagating the 
inflammatory process (Bishop-Bailey, Mitchell, & Warner, 2006; Poeckel & Funk, 
2010). On a transcriptional level, Balstad and colleagues (2010) found significant 
suppression of the transcriptional factor, nuclear factor-kappa beta (NF-κβ), 




fed tart cherry powder compared to those fed an isocaloric control. In male Zucker 
rats, 90 day supplementation with 1% tart cherry powder was also demonstrated 
to significantly reduce NF-κβ activity and plasma inflammatory markers, 
interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α), compared to a 
calorie- and macronutrient-matched control diet (Seymour et al., 2009). In the 
pathophysiology of atherosclerosis, NF-κB is involved in the crosstalk between 
cytokines, adhesion molecules and growth factors, leading to atherosclerotic 
plaque formation, growth and eventual rupture and it has been identified as a 
potential therapeutic target for CVD (Dąbek, Kułach, & Gąsior, 2010). 
Nonetheless, despite some promising pre-clinical indications for the beneficial 
anti-inflammatory effects of tart cherries, the effects of this on humans, from a 
health perspective, has not received much attention until quite recently. 
Collectively there is some evidence that MC influence inflammation in humans. 
This has predominantly been studied in the context of exercise recovery in which 
MC concentrate has repeatedly been demonstrated to reduce circulating IL-6 and 
CRP in response to strenuous exercise (Hill, Keane, Quinlan, & Howatson, 2020). 
Whereas, in health domains there have been limited studies investigating the 
effect of MC on inflammation, with the majority being published in the last few 
years. Moreover, despite the pre-clinical evidence for an anti-inflammatory effect 
the data from clinical trials remains inconsistent. For example, Lynn et al. (2014) 
reported no influence of 6-week supplementation with 30 ml MC (273.5 mg 
anthocyanins) on hs-CRP in healthy middle-aged adults. Similarly, 4-week 
supplementation with MC concentrate (296 mg anthocyanins) or MC powder (226 
mg anthocyanins) consumed bi-daily had no influence on IL-6 or CRP in inactive 
middle-aged adults (Aboo-Bakkar et al., 2018; Lear et al., 2019). However, tart 
cherry juice was demonstrated to reduce TNF-α, but not IL-6 or CRP, in 
overweight and obese individuals in a 4 week randomised, placebo-controlled 
crossover study (Martin, Burrell, & Bopp, 2018). Furthermore, MC concentrate 
has been shown to reduce plasma CRP after 12 weeks in older adults (Chai et 
al., 2019a). In addition, a randomised double-blind crossover study, also reported 
significant reductions in serum high sensitivity CRP (hs-CRP) in osteoarthritic 
participants, following 6-week supplementation with MC juice (containing at least 
30 mg of anthocyanins) compared to a placebo (Schumacher et al., 2013). 




it appears the most promising data comes from those in a pro-inflammatory state. 
Given the role of oxidative stress and inflammation in vascular aging and CVD, 
tart cherries through their antioxidant and/or anti-inflammatory actions could elicit 
cardioprotection.  
 2.2.1.2 Other tart cherry cardiovascular bioactivities  
While earlier studies have focused on the antioxidant activities of purified 
anthocyanins it has become increasingly apparent in recent years that the 
cardiovascular activities associated with their intake are likely the result of 
circulating metabolites formed by chemical and microbial metabolism (see 
Section 2.1.3). For example, previous work from our research group has 
demonstrated that 60 ml of MC concentrate resulted in increases in simple 
anthocyanin metabolites, VA and PCA (Keane et al., 2016a). Moreover, when 
these two phenolic acids were administered to vascular smooth muscle cells 
(VSMC) in concert in physiologically relevant concentrations found in the blood, 
they increased cell migration, but not proliferation. This was speculated to be 
beneficial in blood vessel remodelling, however this was not specifically 
investigated. In addition, other studies have shown that C3G (a major tart cherry 
anthocyanin) increased endothelial nitric oxide synthase (eNOS) in human 
umbilical vein endothelial cells in vitro (Edwards, Czank, Woodward, Cassidy, & 
Kay, 2015). The same authors also demonstrated that physiologically relevant 
amounts of C3G phenolic metabolites; VA, PCA and syringic acid significantly 
reduced superoxide production, which might be attributable to modulation of 
nicotinamide adenine dinucleotide phosphate-oxidase (NOX-2). Upregulation of 
eNOS and reduced NOX-2 activity would favour increased nitric oxide (NO) 
bioavailability, by increasing production and reducing degradation by superoxide 
species. This is important because vascular NO released by eNOS is one of the 
major determinants of vascular tone and thus vasodilation. Additionally, NO 
released towards the vascular wall can protect against thrombosis by inhibiting 
platelet aggregation and adhesion to the blood vessels which is an early phase 
of atherogenesis (Jin & Loscalzo, 2010). Furthermore, decreased NO 
bioavailability has been associated with aging and pathological conditions 
including type II diabetes (Tessari et al., 2010), hypertension and CVD 
(Desjardins & Balligand, 2006). Conversely, increasing NO bioavailability has 




mitigate age-related cardiometabolic and neurodegenerative diseases (Shannon, 
Stephan, Minihane, Mathers, & Siervo, 2018). Thus, the potential for MC 
anthocyanins to potentiate NO production and decrease NO degradation through 
their antioxidant potential is another potential mechanism by which they could 
elicit cardiovascular protective properties. Additionally, in a recent addition to the 
literature Rodriguez-Mateos and colleagues (2019b) reported that 4-week 
supplementation of blueberries resulted in an increase in 63 plasma metabolites 
and that 21 of them correlated with improved endothelial function and NO 
bioavailability following supplementation (as measured by flow mediated dilation; 
FMD). After nutrigenomic analysis it was shown that some of these anthocyanin 
metabolites influenced genes involved in regulation of cell adhesion, cell 
migration, inflammation, and cell differentiation processes (Rodriguez-Mateos et 
al., 2019a). Thus, it would appear that any cardiovascular activities associated 
with the intake of tart cherries are likely to involve multiple cell-signalling 
pathways such as those summarised above. 
2.2.2. Modulation of vascular function in vivo after intake of tart cherries in 
humans 
In line with evidence that tart cherry phytochemicals might have vasculo-
protective properties, supplementation with MC has also been shown to improve 
vascular function in vivo, such as acute blood pressure (BP) modulation (Desai 
et al., 2019; Keane, Bailey, Vanhatalo, Jones, & Howatson, 2018; Keane et al., 
2016b; Keane et al., 2016c). The most promising data comes from acute studies 
which suggests that 30-60 ml of MC concentrate can reduce systolic blood 
pressure (SBP) by ~7 mmHg approximately 2 hours after consumption as 
summarised in Figure 4. More recent evidence suggests a similar time frame 
may see the same transient improvements in augmentation index (AIx), a proxy 
measure of arterial stiffness (Desai et al., 2019). These measurements seemingly 
coincide with peak plasma levels of anthocyanins and their metabolites which 
suggest these compounds could be, at least partly, responsible (Table 1). 
However, the aforementioned studies have only shown transient reductions in 
SBP which return to baseline within 3-4 hours (Desai et al., 2019; Keane et al., 






Figure 4. Random effects meta-analysis of peaks systolic blood pressure 
reductions following acute ingestion of Montmorency tart cherry concentrate or 
an isocaloric placebo. Studies included healthy participants (Keane et al., 2018; 
Keane et al., 2016c), males with early hypertension (Keane et al., 2016b) and 
participants with metabolic syndrome (Desai et al., 2019).   
 
Whereas those studies above suggest an acute effect of MC on vascular function, 
mainly SBP, the research pertaining to the longer-term effects is inconsistent. 
The findings from existing studies are somewhat equivocal, as summarised in 
Table 3. There is tantamount evidence that tart cherries reduce SBP with longer-
term (6-12 weeks) supplementation (Ataie-Jafari, Hosseini, Karimi, & Pajouhi, 
2008; Chai et al., 2018), with other studies suggesting no effect (Johnson et al., 
2020; Lynn et al., 2014). There are several factors that could influence the 
efficacy of tart cherry supplementation. For example, the baseline characteristics 
of the cohort as it is likely that those with higher SBP are more likely to be more 
amenable to anthocyanin interventions such as MC (Vendrame & Klimis-Zacas, 
2019). In a recent addition to the literature Desai and colleagues (2020) found no 
effect of 6-day supplementation with 30 ml MC concentrate (270 mg 
anthocyanins) on SBP. However, the same authors reported that following 7 days 
ambulatory 24-hour readings of SBP, diastolic BP (DBP) and mean arterial 
pressure (MAP) were lower when compared to a placebo. These data could also 
call in to question the sensitivity of conventional BP measurements to detect 
changes that would undoubtably be small, particularly in individuals with 
measurements within the normal ranges. Alternatively, the findings could be 
conflicted by the shorter-duration and lower dose of MC concentrate used (30 
ml). Similarly, there have only been few studies to investigate the influence of 
longer-term MC exposure on other markers of vascular function, such as arterial 
stiffness and endothelial function (Johnson et al., 2020; Lynn et al., 2014). As 
opposed to possible influences on AIx as previously mentioned, there have been 




inconclusive as to whether MC could influence endothelial function or arterial 
stiffness as previous studies have either been short of duration (Aboo-Bakkar et 
al., 2018; Desai et al., 2020) or used lower dosing strategies (Johnson et al., 
2020; Lynn et al., 2014) than our research group have previously shown to be 
physiologically relevant. Certainly, there is some evidence that longer study 
periods (12 weeks) have shown an effect of foods abundant in anthocyanins on 
these markers (Istas et al., 2019b; Jeong et al., 2016; Zhu et al., 2011). Thus, 
further research is warranted given the major role of preserving vascular function 














Table 3. Summary of studies investigating the effects of longer-term tart cherry supplementation on vascular function 








Type II diabetes 
F 
20 Quasi-experimental 40 g/day x 6 weeks 720 SBP: 129 ± 16 









47 Parallel open-labelled 
controlled 
 
30ml/day x 6 weeks 274 bkPWV: 8.2 ± 1.7 
SBP: 111 ± 14 
DBP: 70 ± 10 
bkPWV: 8.0 ± 1.2 
SBP: 110 ± 12 











60ml/day x 20 days 540 SBP: 118 ±12 
DBP: 74 ±10 
HR: 65 ±11 
SBP: 117 ±16 
DBP: 73 ±10 









34 Parallel, double-blind, 
placebo-controlled 
480ml/day x 12 weeks NR SBP: 141 ± 27 
DBP:80 ± 17 
SBP: 133 ± 15 











1.7g/day x 4 weeks 226 FMD: 5.8 ± 1.0 FMD: 6.2 ± 0.8 
↔FMD* 
 






240 ml/day x 4weeks 15.6 SBP: 123 ± 10 
DBP: 77 ± 7 
SBP: 128 ± 11 









19 Parallel, single-blind, 
placebo-controlled 
480ml/day x 6 weeks 176 SBP: 124 ± 12 
DBP: 77± 9 
MAP: 94 ± 12 
Hr: 63 ± 9 
C-AP: 7 ± 3 
C-SBP: 113 ± 12 
C-DBP: 78 ± 9 
C-MAP: 94 ± 12 
AIx: 20 ± 6 
AIx@75: 15 ± 9 
cfPWC: 10.2 ± 1.5 
baPWV: 12.8 ± 1.2 
SBP: 128 ± 13 
DBP: 78 ± 13 
MAP: 96 ± 13 
Hr: 65 ± 9 
C-AP: 10 ± 6 
C-SBP 118 ± 16 
C-DBP: 79 ± 13 
C-MAP: 96 ± 13 
AIx: 24 ± 13 
AIx@75: 19 ± 13 
cfPWC: 11.0 ± 3 
















faPWV: 9.97 ± 0.9 faPWV: 9.3 ± 1.3 ↔faPWV 
 





19 Parallel, single-blind, 
placebo-controlled 
480ml/day x 12 weeks 176 SBP: 124 ± 12 
DBP: 77± 9 
MAP: 94± 12 
Hr: 63 ± 9 
C-AP: 7 ± 3 
C-SBP: 113 ± 12 
C-DBP: 78 ± 9 
C-MAP: 94 ± 12 
AIx: 20 ± 6 
AIx@75: 15 ± 9 
cfPWC: 10.2 ± 1.5 
baPWV: 12.8 ± 1.2 
faPWV: 9.97 ± 0.9 
SBP: 128 ± 13 
DBP: 78 ± 13 
MAP: 96 ± 13 
Hr: 65 ± 9 
C-AP: 10 ± 6 
C-SBP 118 ± 16 
C-DBP: 79 ± 13 
C-MAP: 96 ± 13 
AIx: 24 ± 13 
AIx@75: 19 ± 13 
cfPWC: 11.0 ± 3 
baPWV: 12.9 ± 1.9 






















30ml/day x 6 days 270 SBP: 134 ± 17 
DBP: 75 ± 10 
MAP: 98 ± 12 
A-SBP: 124 ± 15 
A-DBP: 81 ± 9 
AP: 12 ± 7 
AIx: 25 ± 14 
AIx@75: 21 ± 12 
SBP: 127 ± 16 
DBP: 75 ± 10 
MAP: 98 ± 12 
A-SBP: 124 ± 12 
A-DBP: 80 ± 7 
AP: 11 ± 6 
AIx:26 ± 11 

















30ml/day x 7 days 270 24h-SBP: 128 ± 10 
24h-DBP: 76 ± 7 
24h-MAP: 93 ± 9 
24h-SBP: 128 ± 9 
24h-DBP: 77 ± 8 




Data is mean ± SD; *45 min after prolonged (20 min) occlusion, the FMD response was better preserved after MC vs. placebo 
Abbreviations: 24 hour ambulatory, 24h-; AIx normalised for Hr of 75 beats, AIx@75; aortic, A-; arterial pressure, AP; central, C-; 
augmentation index, AIx;  brachial knee, bk; brachial-ankle, ba; carotid-femoral, cf; diastolic blood pressure, DBP;  females, F; femoral-
ankle, fa; flow mediated dilation, FMD; heart rate, Hr; males, M; mean arterial pressure, MAP; not reported, NR; pulse wave velocity, PWV;  




2.2.3 Effects of Montmorency tart cherries on metabolic health 
Metabolic dysfunctions such as obesity, dyslipidaemia, insulin resistance, and 
hyperglycaemia are well established risk factors for both type II diabetes and CVD 
(Taube, Schlich, Sell, Eckardt, & Eckel, 2012). Moreover, aging per se is 
associated with significant metabolic changes, resulting in age-dependent 
increases in body weight, reduced insulin sensitivity, glucose tolerance and 
altered lipid metabolism (Liu & Li, 2015; Ryan, 2000). Thus, targeting metabolic 
health with respect to preventing or reversing CVD progression is an important 
aspect of a healthy aging phenotype. 
Adverse lifestyle factors such as excess calorie intake and insufficient physical 
activity can accelerate these metabolic perturbations, whereas anthocyanin-rich 
foods might improve metabolic function (Yang et al., 2017). Moreover, 
epidemiological evidence suggests higher intakes of polyphenols, including 
anthocyanins, has been associated with lower risk of type II diabetes (Reis et al., 
2016). This is paradoxical given the high sugar content of many anthocyanin-rich 
foods, e.g. 60 g per 100 ml and 50 g per 100 g for MC concentrate and freeze-
dried blueberries, respectively. There is some pre-clinical evidence that MC 
polyphenols might influence metabolic health and body composition (Lachin, 
2014; Seymour et al., 2009; Seymour et al., 2008). Most recently MC have been 
shown to increase the lifespan in Caenorhabditis elegans by altering metabolic 
pathways (Jayarathne, Ramalingam, Edwards, Vanapalli, & Moustaid-Moussa, 
2020; van de Klashorst et al., 2020). These studies have suggested that tart 
cherries act as a calorie restriction mimetic and enhance mitochondrial function 
and reduce oxidative stress. Furthermore, tart cherries were shown to interact 
with the Peroxisome Proliferator-Activated Receptor (PPAR) signalling pathways 
(van de Klashorst et al., 2020). This has been shown in rodent models, for 
example Seymour et al. (2008) reported an increase in both PPAR -alpha (α) and 
-gamma (γ) mRNA in male Dahl rats supplemented with tart cherry extract for 90 
days compared to the control. Upregulation of PPARs might indirectly provide 
cardioprotection because of their reported anti-inflammatory, anti-atherosclerotic 
and antidiabetic properties (Duan, Usher, & Mortensen, 2008). Thus, tart cherries 
and other anthocyanin rich foods might protect against and ameliorate the 




Figure 5. Potential anti-atherogenic properties of tart cherries in relation to other 
metabolic risk factors; taken from (Aboonabi & Aboonabi, 2020). Abbreviations: 
HO-1, heme oxygenase-1; NQO1, NAD(P)H, quinone oxidoreductase 1; SOD, 
superoxide dismutase; ROS, reactive oxygen species; NF-κB, nuclear factor 
kappa-light-chain-enhancer of activated B cells; IκBα, NF-κB inhibitor – alpha; 
IKK, IκB kinase; Nrf2, nuclear factor erythroid 2-related factor 2; ARE, antioxidant 
response element; Keep, Kelch-like ECH protein; ICAM-1, intercellular adhesion 
molecule-1; VCAM-1, vascular cell adhesion molecule 1; COX-2, 
cyclooxygenase-2. 
Furthermore, through their potential prebiotic actions as demonstrated with in 
vitro and mouse models (Garcia-Mazcorro et al., 2018; Mayta-Apaza et al., 2018), 
tart cherry phytochemicals could also improve metabolic parameters. The 
observed changes in gut bacteria could be important because the microbiome in 
itself is a metabolic organ, but also through a myriad of poorly understood 
mechanisms might also influence insulin sensitivity, glucose tolerance and lipid 
profiles (Hansen, Gøbel, Hansen, & Pedersen, 2015). As described in earlier 
section, tart cherry phytochemicals could modulate the gut microbiota. For 
instance, in a recent meta-analysis, anthocyanins were shown to increase the 




spp. demonstrating their prebiotic actions (Igwe, Charlton, Probst, Kent, & Netzel, 
2018). Lactobacillus strains of bacteria have been reported to alleviate aging-
induced metabolic disorders in aged rats (Hor et al., 2019). Nonetheless, whether 
changes in microbial communities as a result of MC supplementation could 
translate to improved metabolic health remains unknown. 
There have been few human trials determining the effects of MC on metabolic 
health. Desai et al. (2019) previously reported that a 30 ml of MC juice or capsules 
containing the same amount of anthocyanins (270 mg) acutely reduced serum 
insulin levels compared to an isocaloric placebo in individuals with metabolic 
syndrome. Interestingly, after consumption of the juice insulin was significantly 
lowered up to 3 hours post-prandially compared to a placebo. Moreover, the 
difference between the capsule and the juice was not significantly different 
refuting any superiority of capsules despite the limited sugar content (17.9 g vs. 
0.1 g) and suggestions that inducing a glycaemic stress might outweigh any 
benefits (Desai et al., 2019). Nonetheless, as with the effects on vascular function 
the influence of longer-term tart cherry supplementation on indices of metabolic 
health are limited. The same authors reported no effects of 20 day 
supplementation with MC juice on glucose, triglycerides, total cholesterol in 
healthy individuals (Desai, Bottoms, & Roberts, 2018). Whereas in individuals 
with metabolic syndrome both short-term and long-term supplementation seem 
to improve some parameters of metabolic health (Desai et al., 2020; Johnson et 
al., 2020). For example, glucose, total cholesterol, LDL concentrations, total 
cholesterol:HDL ratio were reduced and there was a tendency for lower insulin 
levels following 6-day consumption of 30 ml MC concentrate (Desai et al., 2020). 
Following 12-week supplementation with 480 ml of MC juice participants had less 
oxidised LDL and a tendency for lower total cholesterol (Johnson et al., 2020). 
Moreover, Chai and colleagues (2018) reported reduced LDL cholesterol in older 
individuals using a similar dosing strategy. However, Martin and Coles (2019) 
reported no effect of 4 week MC supplementation (240 ml; 15.6 mg anthocyanins) 
on lipid profiles, glucose or insulin in overweight or obese individuals. Again, the 
limitations described in the previous section make it difficult to make any firm 
conclusions. However, because there is some evidence that tart cherries could 
improve indices of metabolic health, and because of the interplay between these 




2.2.4 The role of tart cherries on cardiovascular risk factors and cognitive function 
As previously described maintaining good cognitive function and mental health is 
a key concept in healthy aging. However, gradual diminishment of cognitive 
functions commences in early adulthood and starts progressing more rapidly 
during mid-life (Harada, Love, & Triebel, 2013). Moreover, declining cognitive 
function and neurodegenerative diseases associated with aging has been linked 
to those previously mentioned cardiovascular risk factors (Dickstein et al., 2010; 
Grodstein, 2007). In particular, metabolic and vascular function dysfunction are 
well implicated in the pathophysiology of dementia and mood disorders (Ogle, 
Speisman, & Ormerod, 2013). Thus, interventions that could improve these 
factors, such as MC, could also have the propensity to improve cognition and 
mood and area of research that is now gaining research traction (Travica et al., 
2020). 
2.2.4.1 The influence of tart cherries on cerebral haemodynamics and 
cognitive function 
Cerebral blood flow (CBF) and velocity regulates delivery of blood borne neural 
fuels, oxygen and glucose to the brain and thus is an important factor in optimal 
cerebral functioning (Ajmani et al., 2000). As such, compromised CBF due to 
vascular dysfunction and the resultant hypoperfusion to the brain has been 
suggested as a key contributor to cognitive function decline and a 
neurodegenerative diseases observed with advancing age (de la Torre, 2012). 
Thus, it is likely that dietary components such as polyphenols which have the 
potential to modulate of cerebral heamodynamics might influence cognition. As 
previously described in the preceding sections, MC polyphenols might elicit 
vasomodulatory effects, demonstrated by reduced SBP following consumption 
(Chai et al., 2018; Keane et al., 2016b) and this may translate into increased CBF. 
In accordance, previous work from this laboratory demonstrated that acute 
supplementation with the same dose of MC concentrate modulated CBF, 
measured indirectly by (NIRS) near-infrared spectroscopy (Keane et al., 2016c). 
This study found that a single bolus of MC concentrate resulted in increased 
blood volume (i.e. CBF; represented by total haemoglobin) and oxygen delivery 
(represented by oxygenated haemoglobin) in the prefrontal cortex toward the end 
of the 60-min resting/absorption period and during the cognitive assessment 1 




increase in cognitive function. However, our research group speculate that the 
population could have conflicted these results, as the participants were healthy 
with no apparent issues pertaining to cerebral blood flow or cognitive ability, 
therefore might not have benefited because CBF is already sufficient. This is 
further supported by the fact as opposed to the other parameters there was no 
observed difference deoxygenated haemoglobin, which essentially represents 
oxygen utilisation. To date this is the only study in tart cherries to try and match 
the CBF mechanism to cognitive outcomes.  
This is surprising given that Kent and colleagues (2017a) who reported significant 
increase in verbal fluency, short term memory and long term memory, following 
12 week supplementation with Bing sweet cherry juice, in participants with 
moderate dementia. Moreover, in a recent addition to the literature reported MC 
juice improved some aspects of cognitive performance, specifically visual 
sustained attention and spatial working memory, in healthy older adults without 
cognitive impairment after the same supplementation duration (Chai, Jerusik, 
Davis, Wright, & Zhang, 2019b). Importantly, both aforementioned studies found 
that post-supplementation SBP was reduced once again suggesting that the 
vaso-relaxatory properties might be at least partly driving this response, but the 
effects on cerebral haemodynamics were not measured making this only 
speculative. In contrast, has previously been demonstrated that regardless of 
dosing strategy cherry juice (presumably sweet; 55.8 mg anthocyanins) had no 
acute impact on cognitive function in young people or older people or dementia 
patients, despite influencing BP (Caldwell, Charlton, Roodenrys, & Jenner, 2016). 
Importantly, although to date there has been only one investigation following 
longer-term supplementation of MC on cognitive outcomes, the reported 
improvements in both vascular and cognitive function following longer-term 
anthocyanin supplementation are not in isolation (Ahles et al., 2020; Bowtell, 
Aboo-Bakkar, Conway, Adlam, & Fulford, 2017). In a recent addition to the 
literature Krikorian and colleagues (2020) reported improvements in semantic 
access and non-verbal memory cognitive performance following consumption of 
blueberries and this was correlated with urinary levels of blueberry anthocyanins 
suggesting these benefits are as a result of recurrent exposure to anthocyanins. 
It would therefore seem that the cerebrovascular response required to elicit 




anthocyanin dosing strategies that have the potential to induce sustained 
modifications in cognition but there is still ambiguity to whether these chronic 
changes are a result of enhanced CBF or some of the mechanisms as will be 
described in the ensuing section. 
2.2.4.2 Other potential neuroprotective properties of tart cherries 
Limited pre-clinical studies have shown tart cherry phytochemicals exert anti-
neuro-inflammatory properties and to suppress neuronal apoptosis and stimulate 
pro-survival signalling cascades - mechanisms that might protect against 
cognitive aging  (Kim, Heo, Kim, Yang, & Lee, 2005; Shukitt-Hale, Kelly, Bielinski, 
& Fisher, 2016; Thangthaeng et al., 2016). Recently, Thangthaeng and 
colleagues (2016) reported improvements in working memory, markers of 
inflammation (GFAP, NOX-2, and COX-2) and autophagy (phosphorylated 
mTOR, Beclin 1, and p62/SQSTM) in aged Fischer rats following 6 week 
supplementation with MC powder compared to the control. Moreover, pre-
treatment with MC powder has recently been shown to reduce 
lipopolysaccharide-induced inflammation in HAPI rat microglial cells, as 
demonstrated by suppression of TNF-α and COX-2 in vitro (Shukitt-Hale et al., 
2016). As previously described, tart cherry anthocyanins have also been 
demonstrated to cross the blood-brain-barrier where they might elicit protection 
on neuronal cells (Kirakosyan et al., 2015).  
Besides their potential antioxidant and anti-inflammatory actions, tart cherries 
could stimulate cell signalling pathways involved in neuronal plasticity, and 
survival brain regions susceptible to degeneration. Notably, blueberries have also 
been reported to upregulate the MAPK-CREB-brain derived neurotrophic factor 
(BDNF) pathway in aged Lister-hooded rats (Williams et al., 2008). Williams et al. 
(2008) reported improved special working memory in the blueberry-
supplemented rats following 12 weeks. The same authors speculated that 
anthocyanin stimulation of this cell signalling pathway in the brain was 
responsible for observed improvements in memory. Moreover, in rats fed 
blueberry powder or purified anthocyanins both resulted in improvements in 
spatial working memory to a similar extent (Rendeiro et al., 2013). These 
behavioural changes were paralleled by increases in hippocampal BDNF, 
suggesting a common mechanism for the enhancement of memory in 




BDNF, the regional enhancement of BDNF mRNA expression in the 
hippocampus appeared to be predominantly enhanced by anthocyanins, 
suggesting a causal link between dietary anthocyanin intake and improved 
cognition. Although the polyphenol composition of blueberries and cherries differ, 
blueberries utilised in both studies contained both cyanidins and peonidins the 
major tart cherry anthocyanins (Rendeiro et al., 2013; Williams et al., 2008). This 
section is a brief synopsis of how tart cherries and their isolated components 
could influence cognitive function from existing in vitro and animal studies. These 
studies once again suggest interactions between dietary anthocyanins and 
multiple cell-signalling pathways might account for their potential neuroprotection, 
however, research involving humans is not as straight-forward. Given the role of 
good cognitive functioning in healthy aging future studies are needed. 
2.2.5 The effects of tart cherries on exercise  
Exercise capacity declines progressively with advancing age even in the absence 
of disease (Houghton et al., 2016). Moreover, risk of CVD is reduced by relatively 
small increases in exercise capacity (Kokkinos et al., 2009).  Importantly, vascular 
function is a major determinant of exercise capacity in healthy individuals and 
vascular dysfunction predicates exercise intolerance and disease (Poole et al., 
2020). Accordingly, foods rich in anthocyanins that could improve exercise 
capacity through improved vascular function have recently become a topic of 
interest (Cook, Sandu, & Joyce, 2020; Cook & Willems, 2019). Notably, 
increasing the capacity to exercise is an important issue, because the ability to 
perform physical activity to reduce co-morbidities and maintain health, as humans 
grow older, could help manage some of the multifaceted aspects associated with 
aging. Thus far, tart cherry research in the exercise domain has accumulated 
evidence for their application in recovery (Bell, Walshe, Davison, Stevenson, & 
Howatson, 2015; Howatson et al., 2010), however, only recently has focus turned 
to their effects on physical performance (Keane et al., 2018; Morgan, Barton, & 
Bowtell, 2019). Because of the possible interplay between tart cherries, exercise 
and health, the following section will outline the existing literature surrounding the 
use of tart cherries in exercise domains. 
2.2.5.1 Tart cherries in Recovery 
Exercise results in oxidative stress, inflammation and decreased muscle force 




The high content of phytochemicals in tart cherries, via their antioxidant and anti-
inflammatory effects, have been proposed to lessen muscle damage, reduce 
levels of pain, and ultimately improve recovery (Vitale, Hueglin, & Broad, 2017). 
For example, a series of investigations have demonstrated MC elicit recovery-
promoting effects following endurance running (Dimitriou et al., 2015; Howatson 
et al., 2010; Kuehl, Perrier, Elliot, & Chesnutt, 2010b). Howatson et al. (2010) 
demonstrated faster recovery of isometric strength, measured as maximum 
voluntary isometric contraction, over a 48-hour period in marathon runners 
supplemented with tart cherries compared to the placebo group. The same 
authors also report significant reductions in inflammatory markers IL-6 and CRP 
and increased total antioxidant status in the cherry group. Similar findings 
regarding attenuation of muscle damage markers have been reported by others 
supplementing with MC (Dimitriou et al., 2015; Levers et al., 2015). Other benefits 
to tart cherry supplementation include reduced exercise-induced pain (Kuehl, 
Perrier, Elliot, & Chesnutt, 2010a) and potential attenuation of upper respiratory 
tract infections following prolonged exercise (Dimitriou et al., 2015), actions 
presumably also relating to their anti-inflammatory and antioxidant properties. 
Acceleration of recovery following tart cherry supplementation has also been 
reported in response to high-intensity and damaging eccentric exercise (Bell et 
al., 2015; Connolly, McHugh, Padilla-Zakour, Carlson, & Sayers, 2006; Levers et 
al., 2015), demonstrating a wide range of application for MC in exercise recovery.  
This section although a caveat is important because it demonstrates existing 
research that tart cherries could directly or indirectly benefit exercise 
performance. Direct effects could involve the reduction of muscle fatigue and 
function. Whereas the indirect effects could include enhancement of training due 
to reduction of physiological stressors that negatively impact on training (illness 
or pain) and the improved recovery from previous exercise bouts. 
2.2.5.2 Tart cherries in exercise capacity and performance 
As previously mentioned the capacity to exercise is progressively reduced with 
age, likely because of concomitant impairments in vascular function (Houghton 
et al., 2016). Moreover, reduced physical activity as a result of decreased 
tolerance/capacity might perpetuate vascular dysfunction and predispose those 
individuals to cardiovascular and neurodegenerative diseases (Pandey et al., 




because they might improve exercise capacity via several mechanisms. Firstly, 
through their previously described vasodilatory actions tart cherry 
supplementation might improve blood flow and tissue perfusion to the skeletal 
muscles (Morgan et al., 2019). Secondly, through their antioxidant capacity, 
because redox balance is imperative to muscle force production (Powers, Radak, 
& Ji, 2016), thus mitigating excess oxidative stress with MC supplementation 
might maintain muscle function during exercise. Lastly, some tart cherry 
anthocyanins have been shown to stimulate pathways associated with 
mitochondrial biogenesis (Matsukawa et al., 2017)  and improved mitochondrial 
efficiency (Skemiene, Liobikas, & Borutaite, 2015). However, only in the last 
decade has research determining the efficacy of fruit-derived (including MC) 
polyphenols to enhance exercise tolerance and performance become an area of 
interest (Gao & Chilibeck, 2020; Myburgh, 2014; Somerville, Bringans, & 
Braakhuis, 2017). 
Indeed, there is now accumulating evidence that polyphenols can improve 
exercise performance (Somerville et al., 2017). For example, Gao and colleagues 
(2020) conducted a meta-analysis on 10 studies that suggested that relatively 
short-term (1.5 hours – 7 days) tart cherry supplementation, in the concentrate or 
powdered form, improved endurance exercise performance (SMD: 0.36; 95% CI: 
0.07 to 0.64; p = 0.01; I2 = 0%). This meta-analysis highlights several limitations 
with the existing literature in MC and exercise performance, for example of the 
studies included only 2 found significant improvements in half marathon time 
(Levers et al., 2016) and 15km cycling time (Morgan et al., 2019) but the others 
failed to show effects on overall performance, likely due to the small sample sizes 
of existing studies. Moreover, included studies adopt short-term dosing strategies 
in trained individuals which leaves the question of the longer-term effects of MC, 
and the potential for sustained consumption to benefit exercise capacity in an 
unconditioned cohort, entirely open. This important question to address for 
several reasons. Firstly, although an acute intake of tart cherries may influence 
vascular function, such as vasodilation (Keane et al., 2016b) and increased 
peripheral blood flow (Keane et al., 2016c) it has been speculated longer intake 
durations may be required to result in changes in cellular signalling including, but 
not limited to, those described above (Cook & Willems, 2019). Secondly, 




compared to their trained counterparts and therefore MC which could have a 
potential role in reducing the prevalence of age-related diseases by (i) improving 
these risk factors and (ii) increasing the exercise capacity and the ability to 
perform physical activity. 
2.3 Summary of evidence  
This overview summarises the recent additions to the literature regarding MC and 
other phytochemical-rich supplements on vascular function, cognitive and 
physical performance in the context of human health. Firstly, a number of studies 
have established that tart cherries and foods containing similar phytochemicals 
can increase circulating bioactive compounds (with much research directed 
towards anthocyanins and their downstream metabolites). Moreover, 
consumption of foods rich in these compounds have been shown to improve a 
number of risk factors associated with CVD, type II diabetes, and 
neurodegenerative disease. Particularly, here evidence for the vascular effects 
of tart cherries is the main focus. As highlighted, there is some evidence that MC 
may improve vascular function in vivo (Table 3). This has several implications in 
human health as; firstly, and foremost vascular dysfunction is implicated in the 
pathophysiology several age-related diseases, such as CVD. Secondly through 
improved vascular function this may in turn positively influence cognition and 
exercise capacity, which are important aspects of healthy aging, but there is a 
clear lack of studies examining the longer-term effects of MC on these indices. 
Despite some promising evidence of the influence of MC on vascular and 
metabolic function there is a paucity of original research in humans relating to 
their longer-term influence on cardiovascular and health in general. Moreover, 
existing clinical studies are small in size, of short duration, paradoxical and 
inconsistent. This is likely a result of the different populations and dosing 
strategies used as exampled in Table 3. While the exact physiological dose of 
MC have yet to be established based on previous work from our research 
institution 60 ml of MC concentrate has beneficial effects on vascular function 
and exercise performance/recovery (Brown, Stevenson, & Howatson, 2019; 
Keane et al., 2018; Keane et al., 2016b; Keane et al., 2016c). While other 
analogues and doses have recently been adopted 30ml given bi-daily appears to 
have the most consistent evidence (Bell et al., 2014b; Chai et al., 2018). In light 




provide novel insight into potential role of dietary anthocyanins in cardiovascular 
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The average lifespan of humans is increasing, and with this there is an increase 
in mortality and morbidity from non-communicable diseases. Amongst mortality 
rates CVD remains the most predominant cause worldwide (Townsend et al., 
2016). However, strong epidemiological evidence suggest that dietary factors, 
such as increased intake of F&V can reduce risk of CVD and premature death 
(Forouzanfar et al., 2016), which might in part be attributable to plant polyphenols. 
For example, higher intake of major classes of dietary polyphenols, e.g. 
anthocyanins, have been linked to reduced risk of type II diabetes (Guo, Yang, 
Tan, Jiang, & Li, 2016; Rienks et al., 2018), CVD and all-cause mortality (Grosso 
et al., 2017; Wang, Ouyang, Liu, & Zhao, 2014b). Anthocyanins (from the Greek 
anthos, a flower, and kyanos, dark blue) are important secondary plant 
metabolites that occur primarily as glycosides of their aglycone anthocyanidins. 
They are water-soluble pigments often responsible for the orange, red, and blue 
colours in fruits, vegetables, flowers, and other tissues in plants (Delgado-Vargas 
et al., 2000). Nonetheless, these compounds are not evenly distributed between 
fruits and vegetables, cherries in particular can account for almost a third of 
overall dietary intake of anthocyanins (Adriouch et al., 2018a; Tresserra-Rimbau 
et al., 2014a), but they are also abundant in other colourful berry fruits. As 
discussed in Chapter 2 there is accumulating evidence substantiates that 
anthocyanin-rich foods such as berries and cherries can favourably improve 
major risk factors of CVD (Fairlie-Jones, Davison, Fromentin, & Hill, 2017; Huang, 
Chen, Liao, Zhu, & Xue, 2016; Luís, Domingues, & Pereira, 2018). 
Mechanistically, anthocyanins and their metabolites have been demonstrated to 
elicit cardiovascular-protective properties such as antioxidant, anti-inflammatory, 
anti-atherogenic and vasodilatory actions and there is now a growing body of 
evidence also supports that intake of dietary anthocyanins can improve functional 
vascular health in vivo (section 2.2.2). The potential underlying mechanisms for 
the aforementioned might involve the augmentation of endothelial-derived nitric 
oxide NO bioavailability. Anthocyanins can directly increase NO through 
upregulation of the endothelial nitric oxide synthase and L-arginine pathways, but 
also indirectly by potentiating the nitrate-nitrite-NO pathway, and minimising 
degradation of NO via their antioxidant actions (Edwards et al., 2015; Rocha, 




in regulating endothelial homeostasis and anthocyanin-rich foods, including tart 
cherries, have previously been demonstrated to improve endothelial function 
(Aboo-Bakkar et al., 2018; Rodriguez-Mateos et al., 2013), which has been 
replicated in studies utilising purified anthocyanin compounds (Rodriguez-Mateos 
et al., 2019a; Zhu et al., 2011). However, despite promising evidence that these 
compounds might improve major risk factors of CVD, the relationship specifically 
between dietary intake of anthocyanins and actual risk of CVD has yet to be 
systematically evaluated. Therefore, this chapter addresses the specific aim; to 
synthesize and evaluate the relationship between dietary intake of anthocyanins 
and the risk of CVD and related mortality from prospective cohort studies. 
3.2 Methods 
3.2.1 Search strategy 
This review followed the preferred reporting items for systematic reviews and 
meta-analysis (PRISMA) guidelines (Stroup et al., 2000). The protocol of this 
systematic review was pre-registered with PROSPERO, the International 
Prospective Register of Systematic Reviews [registration number: 
CRD42018089121].  A systematic literature search was performed using 
SCOPUS, MEDLINE (ProQuest), CINAHL (EBSCO) and Cochrane Library from 
inception until January 2018 (Appendix A). The search strategy was conducted 
using Boolean operations and formed from existing reviews of anthocyanin-rich 
foods (Fairlie-Jones et al., 2017), collated in three key concepts; (i) anthocyanins, 
(ii) cardiovascular disease and (iii) prospective study design. Furthermore, the 
reference list of retrieved systematic reviews and included studies were hand 
searched to find potential articles that could be included in the current meta-
analysis. A follow-up search was conducted in December 2019 to identify any 
additional studies that had been published. 
3.2.2 Study selection 
Studies were included for analysis if they met the following inclusion criteria: 1) 
were a prospective study in adults (≥ 18 years) including; prospective cohort, 
nested case-control and case-cohort studies; 2) included population distribution 
of ≥ 2 intakes of anthocyanins or anthocyanin-rich foods as exposure; 3) reported 
fatal or non-fatal CVD events as outcome of interest [i.e. coronary heart disease, 
ischemic heart disease, coronary artery disease, angina, myocardial infarction, 




stroke), peripheral artery disease, CVD mortality]; 4) reported relative risk (RR) 
or hazard ratio (HR) and their corresponding 95% confidence intervals (or 
sufficient data to compute them). Titles and abstracts were independently 
reviewed using Covidence systematic review software (Veritas Health Innovation, 
Melbourne, Australia) by two researchers (RK and GH). Only full texts that were 
published in English or had an existing translation were retrieved and examined.  
3.2.3 Data extraction and quality assessment 
Data was independently extracted into piloted forms by two investigators (RK and 
KMK) in accordance with the Meta-analysis of Observational Studies in 
Epidemiology (MOOSE) guidelines (Stroup et al., 2000). Any discrepancies were 
resolved by reviewing the original article. The following data was extracted from 
each study: the first author’s last name(s), publication date, location, the cohort 
name, participant’s age (at baseline) and sex, the follow up period, the method of 
dietary assessment and anthocyanin exposure range, type of outcome, number 
of cases, HR or RR and their corresponding 95% CI and any covariate 
adjustments. Quality of each study was evaluated using the nine-star Newcastle-
Ottawa scale (Stang, 2010), which assesses three major domains; selection of 
the study group (0–4 stars), comparability (0–2 stars) and outcome in the cohorts 
(0–3 stars). A maximum of 9-stars could be awarded, where 0-3, 4-6 and 7-9 
stars were regarded as low, moderate and high quality, respectively. 
3.2.4 Statistical Analysis 
A random-effects meta-analysis was conducted because of unexplained 
heterogeneity between studies, where the common measure was RR. All 
included studies used COX’s models, therefore HR were directly considered as 
RRs. The multivariate-adjusted RR and standard errors (SEs; derived from their 
corresponding 95% CIs) were logarithm transformed. If individual studies 
reported RR for multiple outcomes of CVD, or were stratified by sex, the risk 
estimates were pooled by fixed-effects model and the summary estimate was 
used in the main meta-analysis (Aune et al., 2017).  
Sensitivity analysis was performed by omitting one study at a time to evaluate the 
potential bias and robustness of the overall risk estimate. Heterogeneity between 
studies was determined by χ2 by Cochran’s Q test (significance level at Ph < 0.10) 
(DerSimonian & Laird, 1986) and the I2 statistic. For the I2 statistic, I2 values 




heterogeneity, respectively. Subgroup analysis was conducted to determine 
possible sources of heterogeneity. Subsequently, the effect of exposure, type of 
outcome, sex, location, sample size and follow-up length of the included studies 
evaluated. Potential publication bias was evaluated by Egger’s test (P < 0.10) 
and visual inspection of funnel plots (Begg & Mazumdar, 1994). All statistical 
analysis was conducted using STATA v.16.0 (StataCorp, College Station, Texas, 
USA), P < 0.05 was considered significant unless otherwise stated. 
3.3 Results 
3.3.1 Literature search 
The original literature search and study selection results are presented in Figure 
6. There were 1689 studies initially identified by the search strategy. After 
exclusion of duplicates 1277 titles and abstracts were reviewed. Seventy-six full 
texts were retrieved and after irrelevant articles were excluded for; wrong 
exposure (29), wrong study design (22), wrong outcomes (5), not complete (1), 
not English (2); 17 articles remained. Two additional study was identified by hand 
searching reference lists. After re-running the search strategy an additional 12 













Figure 6. PRISMA flow chart for literature search and study selection. 
 
3.3.2 Study characteristics 
The characteristics of the included studies are presented in Table 4. Twenty-
three studies involving 741,053 participants (aged between 25-81 years) with 
more than 37,054 incidences of non-fatal or fatal CVD were included in the 
current meta-analysis. All studies were published between 1996-2019, with 
seven studies conducted in USA, fourteen in Europe and two in Australia. Eight 
studies reported anthocyanin intake, eight studies reported anthocyanidin intake 
and seven studies reported berry intake. The follow-up length of the included 
studies ranged from 4.3 to 41 years. All studies provided covariate-adjusted risk 
models (e.g. age, sex, BMI, smoking). Quality scores were ≥ 6 stars (Table 4), 
two studies were moderate quality (6 stars) (Hirvonen et al., 2000; Ivey, Lewis, 







Table 4. Characteristics of prospective cohort studies on dietary anthocyanin intake and risk of cardiovascular disease 
Reference Country Study cohort 
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Males/Females 44.1 4.9 Anthocyanins 
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Males/Females 64.7 14 Anthocyanidins 
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and social economic 
status. 
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Cassidy et al. 
(2012) 
USA Nurses’ Health 
Study  
69622 











Age, BMI, physical 
activity, alcohol 
consumption, energy 
intake, use of multivitamin 
supplements, use of 
aspirin, menopausal 
status, smoking and 
history of Type 2 






Cassidy et al. 
(2013) 
USA Nurses’ Health 
Study II 
93600 





Age, BMI, physical 
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menopausal status, 
postmenopausal 
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contraceptive use, 
smoking, and family 
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history of hypertension, 
history of 
hypercholesterolemia, 
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baseline. Sensitivity 
analysis was performed 
by repeating logistic 
regression analysis in 
participants without 
previous atherosclerotic 
vascular disease and 
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Knekt et al., 
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Lai et al., 
(2015) 
UK UK Women’s 
Cohort Study 
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Age, BMI, physical 
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Swedish Men  
74961 














Age, sex, BMI, smoking 
status and pack-years of 
smoking, education, total 
physical activity, aspirin 
use, history of 
hypertension, diabetes, 
family history of 
myocardial infarction, and 
intakes of total energy, 
alcohol, coffee, fresh red 
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Males/Females 69.5 7 Anthocyanidins 




Age, smoking, beer and 
liquor intake, history of 
hypertension, history of 
cholesterol, family history 
of myocardial infarction, 
BMI, physical activity, 
energy intake, aspirin 
use, hormone 
replacement therapy (in 
women only), and sex (in 
combined model only). 
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Mink et al.,  
(2007) 
USA Iowa Women’s 
Health Study  
34489 
Females 55-69 16 Anthocyanidins 
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physical activity, serum 
cholesterol level, blood 
pressure and energy 
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Males 42-60 15.2 Anthocyanidins 
mean 6.2 mg/d 
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Age, randomized aspirin 
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myocardial infarction 60 
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hypercholesterolemia, 








components related to 
strawberry intake: fruit 
and vegetables, fibre, 
folate, vitamin C, 
potassium, saturated fat, 
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and Nutrition  
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CVD mortality  
416 
Age, sex, BMI, education 
level, physical activity, 
tobacco smoking, alcohol 
lifetime, total energy, 
vitamin C and fibre 
intakes. 
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Abbreviations: BMI, body mass index; CAD, coronary artery disease; CHD, coronary heart disease; CVD, cardiovascular disease; HDL, high-density lipoproteins; 





3.3.3 Intake of anthocyanins and cardiovascular disease risk  
The random-effects pooled results for fully adjusted risk estimates by type of CVD 
(Figure 7) showed an inverse association for intake of dietary anthocyanins and 
reduced risk of CVD mortality (RR = 0.91, 95% CI: 0.87, 0.95; I2 = 0.0, Ph = 0.772) 
and CHD mortality (RR = 0.88, 95% CI: 0.78, 0.99) with no between-study 
heterogeneity (I2 = 0.0, Ph = 0.928).  However, there was no relationship between 
the intake of these compounds and reduced risk of MI, CHD, stroke or total CVD. 
Subgroup analyses can be found in Table 5. Dietary intake of anthocyanidins 
was associated with reduced risk of CVD mortality (n = 7), CHD mortality (n = 2), 
total CVD (n = 1) and CHD (n = 1). Anthocyanin intake was associated with 
reduced risk of CVD mortality (n = 1) only, whereas dietary intake of berries was 
not associated with reduced risk of any CVDs. Studies in female cohorts showed 
an inverse relationship between intake of these compounds and CVD mortality 
(n = 4), CHD mortality (n = 1) and CHD (n = 2) and those with combined sexes 
associated with reduced risk of CVD mortality (n = 5) and total CVD (n = 5). Total 
CVD was also reduced (RR = 0.84; 95% CI: 0.72, 0.98) in those studies located 
in Europe (n = 6). Studies conducted in Europe were associated with reduced 
risk of CVD mortality (RR = 0.93; 95% CI: 0.88, 0.99; n = 4) but was lower in 
those in the USA (RR = 0.89; 95% CI: 0.83, 0.96; n = 3). Risk of MI remained 
non-significant when stratified by exposure, sex, location, follow up and sample 
size. Stroke was further stratified by type (Figure 8), but no association was found 
between the intake of these compounds and reduced risk of cerebral infarction, 







Figure 7. Random-effects analysis of fully-adjusted risk estimates of 
cardiovascular diseases (CVD) by highest versus lowest dietary anthocyanin 
intake. Summary relative risk for CVD mortality, coronary heart disease (CHD) 







Table 5. Subgroup analysis of different cardiovascular diseases 
Subgroup 
Outcome 


















Exposure            
Anthocyanins 0.90 (0.82, 0.99) - 1      0.84 (0.60, 1.18) 74.5 2 
Anthocyanidins 0.92 (0.87, 0.97) 0.0 7  0.88 (0.78, 0.99) 0.0 2     
Berries 0.76 (0.38, 1.53) - 1      1.84 (1.04, 3.25) - 1 
Sex            
Males 0.92 (0.79, 1.07) 0.0 2      0.97 (0.87, 1.08) - 1 
Females 0.89 (0.82, 0.96) 0.0 4  0.88 (0.78, 0.99) - 1  1.09 (0.41, 2.88) 88.5 2 
Males/Females 0.91 (0.86, 0.97) 3.3 5  0.90 (0.56, 1.45) - 1     
Location            
Europe 0.93 (0.88, 0.99) 0.0 4         
USA 0.89 (0.83, 0.96) 0.0 3  0.88 (0.78, 0.99) - 1  1.00 (0.68, 1.46) 78.1 3 
Australia 0.77 (0.54, 1.08) 0.0 2  0.90 (0.56, 1.45) - 1     
Follow up            
≥10 years 0.91 (0.87, 0.96) 0.0 8  0.88 (0.78, 0.99) 0.0 2  1.00 (0.68, 1.46) 78.1 3 
<10 years 0.67 (0.33, 1.35) - 1         
Samples size            
≥10,000 0.78 (0.55, 1.10) 0.0 2  0.88 (0.78, 0.99) 0.0 2  1.00 (0.68, 1.46) 78.1 3 







Table 4 continued 


















Exposure            
Anthocyanins 0.88 (0.75, 1.03) 78.5 4  0.84 (0.62, 1.14) 91.0 3  0.88 (0.64, 1.18) 68.9 2 
Anthocyanidins 0.56 (0.36, 0.88) - 1  1.01 (0.83, 1.23) - 1  0.73 (0.55, 0.96) - 1 
Berries 1.12 (0.80, 1.56) 33.5 2  1.00 (0.88, 1.14) 49.9% 6  0.95 (0.75, 1.21)  0.0 2 
Sex            
Males     0.98 (0.87, 1.11) 0.0 2  1.21 (0.89, 1.64) - 1 
Females 1.12 (0.80, 1.56) 33.5 2  1.00 (0.89, 1.13) 0.0 4  0.64 (0.43, 0.95) 0.0 2 
Males/Females 0.83 (0.70, 0.98) 79.5 5  0.86 (0.58, 1.29) 94.5 3  0.83 (0.65, 1.04) 65.5 3 
Location            
Europe 0.84 (0.72, 0.98) 74.5 6  0.89 (0.71, 1.11) 86.8 6  0.92 (0.80, 1.06) 19.8 4 
USA 1.27 (0.94, 1.72) - 1  1.00 (0.91, 1.10) 0.0 4  0.73 (0.55, 0.96) - 1 
Follow up            
≥10 years 0.97 (0.86, 1.10) 59.6 5  1.03 (0.96, 1.10) 0.0 8  0.97 (0.87, 1.09) 0.0 3 
<10 years 0.68 (0.53, 0.82) 0.0 2  0.71 (0.52, 0.98) 84.2 2  0.72 (0.58, 0.89) 0.0 2 
Samples size            
≥10,000 0.93 (0.72, 1.21) 79.6 4  0.95 (0.82, 1.10) 80.9 9  0.72 (0.59, 0.89) 38.1 3 





Figure 8. Random-effects analysis of fully-adjusted risk estimates of stroke by 
highest versus lowest dietary anthocyanin intake. Grey shaded area represents 
proportional weighting and the diamond represent summary relative risk for 
stroke subgroups. 
 
3.3.4 Publication bias and sensitivity analysis  
Egger’s test suggested the absence of significant publication bias for CHD, MI, 
stroke and total CVD (P ≥ 0.178). This was confirmed by visual inspection of the 
funnel plots (Appendix B) which showed no substantial asymmetry. There was 
weak evidence of potential publication bias for CVD mortality (P = 0.057). The 
sensitivity analysis determined no materially different risk estimates indicating 
stable results for CVD mortality or MI (Appendix B). However, there was some 





The current meta-analysis of twenty-three prospective cohort studies is the 
largest, most comprehensive and contemporary to evaluate the association 
between dietary anthocyanin intake and risk of CVD. The findings indicate that 
dietary intake of anthocyanins is inversely associated with both CHD and CVD 
mortality (Figure 7), which is consistent with the findings of others (Grosso et al., 
2017; Wang et al., 2014b). In the current meta-analysis, we found that those with 
the highest anthocyanin intake were associated with a 12% and 9% reduced risk 
of CHD and CVD mortality, respectively. This is of great interest because CVD 
remains the most common cause of death worldwide, accounting for 45% of all 
deaths in Europe (Townsend et al., 2016) and is estimated to cost healthcare 
services £15.7 billion in the UK alone (Luengo-Fernandez, Leal, Gray, Petersen, 
& Rayner, 2006). Our findings are of a similar magnitude to a recent meta-
analysis that found that berry intake was associated with a significant reduction 
(RR = 0.92, 95% CI: 0.88, 0.97; I2 = 8.0, Ph =0.34) in all-cause mortality (Aune et 
al., 2017). Moreover, Guo and colleagues (2016) previously reported that risk of 
type II diabetes was reduced (5%) by increasing anthocyanin intake (7.5 mg/day; 
RR = 0.95; 95% CI: 0.93, 0.98) and berry intake (17 g/day; RR = 0.95; 95% CI: 
0.91, 0.99), suggesting these compounds have a number of health benefits.  
Conversely, we found no relationship between the intake of these compounds 
and the risk of stroke, MI or total CVD. This is surprising given that there is 
commonality in the aetiology of CVDs and a recent meta-analysis of randomised 
controlled trial showed and berry supplementation improved risk factors of CVD; 
specifically lipid profiles, systolic and diastolic blood pressure, which the authors 
speculate might be, at least partly, attributable to the anthocyanin content (Luís 
et al., 2018). A number of studies in the current meta-analysis reported berry 
intake as the exposure. Berries are a major source of anthocyanins, but these 
compounds are not uniformly distributed between these and other sources 
(Clifford, 2000; Horbowicz, Kosson, Grzesiuk, & Dębski, 2008). Importantly, 
because the included studies reported sources other than berries to be major 
sources of overall anthocyanin intake (Adriouch et al., 2018a; Ponzo et al., 2015; 
Tresserra-Rimbau et al., 2014b), perhaps the specific foods need more careful 




(Table 5) and foods such as red wine and cherries have been reported to be 
significant contributions of anthocyanindins in these cohorts (Ponzo et al., 2015). 
Higher anthocyanin intake was not associated with reduced risk of strokes, even 
when further stratified by types of stroke (because of possible differences in 
underlying mechanisms; Figure 8). The reasons for the different risk estimates 
between anthocyanin intake and CVD mortality versus stroke remains unknown, 
but might be because 1) anthocyanins do not circulate the brain in large enough 
doses to elicit neurovascular protection, or 2) the cerebrovasculature is more 
susceptible to atherosclerosis because of the smaller vessel diameters (Mursu et 
al., 2008). Our findings are consistent with a recent meta-analysis that reported 
highest berry intake was not associated (RR = 0.98, 95% CI: 0.86, 1.12) with 
reduced risk of stroke (Aune et al., 2017). Previous meta-analytic evidence has 
suggested that increased polyphenol intake is associated with reduced risk of 
stroke (Tang, Li, Zhang, & Hou, 2016a). However, most of the prior epidemiologic 
evidence on flavonoids and CVD risk, specifically stroke, has focused on 
flavanones, flavones, flavonols, and flavan-3-ols (Tang et al., 2016a) that might 
have different bioactivities compared to anthocyanins. Interestingly, a number of 
these compounds are also found in tart cherries (Figure 1) and they have 
previously been shown to have synergistic and additive actions in combination 
with MC anthocyanins (Keane et al., 2016a; Kirakosyan et al., 2010) and 
protective properties against stroke related phenotypes (Seymour et al., 2013) 
against the findings of this review. 
A strength of this meta-analysis was the inclusion of multivariate-adjusted risk 
models that adjusted for important confounding variables. However, a limitation 
of the included studies is that intake of anthocyanins is positively correlated to 
fruit and vegetable intake and the beneficial nutrients associated with these, such 
as other flavonoids, vitamins, carotenoids and fibre (Zamora-Ros et al., 2013). 
Thus, because of multicollinearity, and because only some studies adjusted for 
some of these as covariates (Table 4), it is not possible to isolate whether the 
observed reduction in risk estimates is solely in response to intake of dietary 
anthocyanins and not other bioactive compounds. Nonetheless, recent in vitro 
and human studies of anthocyanins and their relevant metabolites suggests that 
these compounds are responsible for some degree of cardiovascular protection 




There are also a number of weaknesses in the available data that warrant 
discussion. Firstly, the majority of included studies in the current meta-analysis 
used FFQs to assess dietary intake of anthocyanin-rich foods and these may not 
always be comprehensive or reliable indicators of anthocyanin intake due to 
measurement error and misclassification. Secondly, there is inherent difficulty in 
determining the intake of these compounds because the databases have missing 
foods and limited information on retention of these compounds following cooking 
(Zamora-Ros et al., 2011), and there were major variations between the highest 
categories (Table 4). Moreover, studies were pooled which reported 
anthocyanidin, anthocyanin and berry intake indiscriminately (although they were 
later sub-grouped). This is thought to be appropriate because studies likely report 
anthocyanidin or anthocyanin based on database used (e.g. Phenol-explorer 
report anthocyanin content whereas USDA database reports just the aglycones 
(Haytowitz, Wu, & Bhagwat, 2018; Rothwell et al., 2013)) moreover C3G (a major 
anthocyanin) is a biomarker of berry intake in a dose-dependent manner 
(Sandoval-Ramírez et al., 2019). Nevertheless, the different associations 
between CVDs might be confounded by suboptimal quantification of dietary 
intake of anthocyanins (and because it was not possible to distinguish different 
types of these compounds), but could also be because of the limited number of 
studies that examined these variables (Jackson & Turner, 2017) or that the meta-
analysis was less robust (as per the sensitivity analysis; Appendix B).  
In summary, this systematic review and meta-analysis addressed the first specific 
aim of this thesis by synthesising and evaluating the relationship between dietary 
intake of anthocyanins and the risk of CVD and related mortality from prospective 
studies. Importantly this chapter has established empirical evidence that a higher 
dietary intake of anthocyanins is associated with reduced risk of both CHD and 
CVD mortality in cohorts of mostly middle-aged and older adults. Results from 
meta-analyses have to be interpreted with some caution given the limitations 
summarised above, however, the meta-analytical technique is currently the best 
method to systematically review previous work (Haidich, 2010) and hence adds 
to the body of knowledge through data synthesis. This data  taken together with 
the findings of recent randomised controlled trials (Chai et al., 2018; Desai et al., 
2019; Keane et al., 2016b) provides further support, that anthocyanin-rich foods 




Moreover, there is existing evidence that these compounds might also reduce 
risk factors of other non-communicable (Guo et al., 2016) and neurodegenerative 
diseases (Devore, Kang, Breteler, & Grodstein, 2012) which from a public health 
perspective might help lessen the socioeconomic burdens associated with aging. 
This chapter provides additional rationale for longer-term randomised controlled 
trials determining the effect of anthocyanin intake on cardiovascular risk factors, 
to try and establish a causal link. Resultantly, this will be investigated in the future 
chapters of this thesis. Future work should try and establish the optimal dose-
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Chapter 4: 
The test-retest repeatability of a battery of 







Cardiovascular diseases (CVD) remains the leading cause of morbidity and 
mortality in men and women in the United Kingdom and other developed societies 
(Townsend et al., 2016). Thus, effective interventions and prevention strategies 
are needed to reduce CVD risk in these populations. Hypertension is amongst 
the top five most robust modifiable risk factors for CVD (Yusuf et al., 2004) and 
BP has been widely targeted by nutritional (including MC) interventions (e.g. 
Section 2.2.2.1). However, in recent years the prognostic and clinical utility of 
measurements of endothelial function and arterial stiffness, particularly in the 
context of vascular aging, have become increasingly more apparent  (Anderson 
& Phillips, 2015). Moreover, because endothelial dysfunction and stiffening of the 
arteries precede hypertension, these measures collectively represent valuable 
nutritional targets in the prevention and management of CVD (Houston, 2018). 
Currently, there are now a number of non-invasive methods, that when used in 
combination, can determine both morphological and functional changes in the 
micro- and macro-vascular system that occur with age and these are being widely 
adopted in nutritional research (Desai et al., 2019; Keane et al., 2016b; 
Rodriguez-Mateos et al., 2013).  
Importantly, endothelial function has been demonstrated to be responsive to both 
acute and chronic nutritional interventions, e.g. polyphenols (Fairlie-Jones et al., 
2017; Kay, Hooper, Kroon, Rimm, & Cassidy, 2012). However, the effects of such 
interventions on arterial stiffness is less clear. For example, in a recent meta-
analysis anthocyanin supplementation has been reported to improve arterial 
stiffness acutely, measured by pulse wave velocity (PWV), but not following 
chronic supplementation (Fairlie-Jones et al., 2017). Per contra, epidemiological 
evidence suggests that higher intake of these compounds is associated with 
reduced PWV (Jennings et al., 2012). Moreover, other indices of arterial stiffness, 
such as AIx have produced inconsistent findings following MC and indeed other 
anthocyanin-rich food consumption (Desai et al., 2019; Fairlie-Jones et al., 2017; 
Keane et al., 2016b). 
In addition, despite the purported inter-relationship between endothelial function 
and arterial stiffness (Nigam, Mitchell, Lambert, & Tardif, 2003), these measures 
are not always measured concurrently. In studies where the aforementioned are 




observed, suggesting some might be more sensitive to interventions (Collier et 
al., 2008; Hobbs et al., 2013). These discrepancies demonstrate a clear benefit 
of being able to measure both endothelial function and arterial stiffness in a single 
testing session, i.e. as a ‘test battery’. However, to be clinically useful, multimodal 
vascular function assessment needs to be sensitive (as highlighted in section 
2.2.2.1) and repeatable, yet there is a paucity of data with regards to the reliability 
of multiple indices of vascular function taken in a single session (Ibrahimi et al., 
2018; Woodman et al., 2005). 
Woodman et al. (2005) reported the repeatability of a combination of common 
techniques used to assess peripheral and central arterial stiffness taken one 
week apart; however, some methods exhibited increased variability when taken 
in combination rather than when taken independently. For instance, the 
coefficient of variations (CVs) for the stiffness index (SI) derived from digital 
volume pulse (DVP) are typically less than 10% in healthy individuals (Millasseau, 
Kelly, Ritter, & Chowienczyk, 2002; Millasseau, Kelly, Ritter, & Chowienczyk, 
2003), but were higher (20.7%) when taken together with other measures 
(Woodman et al., 2005). This study highlights the importance of assessing the 
repeatability of multiple measurements taken in a single testing session. In this 
instance, the assessment of arterial stiffness measures are calibrated by 
peripheral BP and are influenced by heart rate that would likely change 
depending on the testing duration (Mahe et al., 2017). In addition, commonly used 
methods to assess endothelial function such as laser Doppler imaging with 
iontophoresis (LDI) and flow mediated dilation (FMD) are reliant on NO release 
(Green, Dawson, Groenewoud, Jones, & Thijssen, 2014; Turner, Belch, & Khan, 
2008) and NO might alter arterial stiffness (Sugawara et al., 2007). Therefore, 
measurements of endothelial function and arterial stiffness taken in a single 
testing session, which is becoming increasingly common, might exhibit different 
levels of repeatability than those taken independently. In this context, the aim to 
of this chapter addresses the second specific aim of determining the reliability of 
a battery of commonly used non-invasive measures of vascular function in vivo. 
4.2 Methods 
4.2.1 Participants and study design 
A convenience sample of twenty-one healthy, normotensive, non-smoking males 




24.7 ± 4.0 kg/m2) took part in this study. The study was ratified by the Northumbria 
University Research Ethics Committee and participants gave written informed 
consent prior to taking part. Participants were required to visit the laboratory on 
two separate occasions. For all testing visits they were required to arrive fasted 
(≥ 10h), avoid alcohol, strenuous exercise, any medication or nutritional 
supplements, 24 h before and caffeine 12h prior to each testing day. Vascular 
function was measured by a battery of tests, as described below, which were 
taken twice in the same session (intra‐session; repeatability [n = 20], n =1 missing 
due to time commitments) and again a week later (inter‐session; reproducibility 
[n = 21]) to determine the short-term reliability of these measures. The order of 
measurement was; automated BP, LDI, DVP, PWV, AIx measured by pulse wave 
analysis (PWA) and FMD, which took approximately 1.5 h to measure. To reduce 
the potential for variation, participants were required to wear loose fitting 
garments; whilst testing was performed in the same sequence on each 
participant, by the same researcher on each occasion. As LDI and FMD are both 
reliant on the release of NO, these measures were done at the beginning and 
end of the sequence, in contralateral arms. All vascular measures were taken at 
the same time of day (8 am ± 1 h) in ambient temperature (22 ± 2°C) with the 
participants in the supine position following a minimum of 5-minute acclimation 
period at the beginning of each test battery. 
4.2.2 Vascular function assessment 
4.2.3 Blood pressure  
Blood pressure (BP) and heart rate (Hr) were measured using a validated 
(Reinders, Reggiori, & Shennan, 2006), non-invasive, automated vital signs 
monitor (Carescape V100; Dinamap) closely adhering to the guidelines specified 
by the European Society of Hypertension (O’Brien et al., 2003). Supine brachial 
BP measurements were taken with the arm supported at the level of the heart in 
triplicate. Three  BP measurements were taken, each separated by 1 min , and 
the mean of the last  2 readings of SBP, DBP and Hr used for analysis (Pickering 
et al., 2005).  
4.2.3 Laser Doppler imaging with iontophoresis (LDI) 
All subjects had an acclimation period of at least 15 min before the measurements 
were taken. Two Perspex chambers (ION6, Moor Instruments Limited, UK) with 




(MIC-1AD; Moor Instruments Limited, UK) on the ventral aspect of the left forearm 
and connected to the iontophoresis controller (MIC2, Moor Instruments Limited, 
UK). A 2.5 ml volume of 1% acetylcholine chloride (ACh) dissolved in 0.5% NaCl 
solution was placed in the anodal chamber and the same volume of 1% sodium 
nitroprusside (SNP) in 0.5% NaCl solution was placed in the cathodal chamber 
(all reagents acquired from Sigma-Aldrich, UK). Circular glass coverslips (MIC-
ION6-CAP; Moor Instruments Limited, UK) were placed over each chamber to 
prevent loss of solutions. Current delivery was controlled by a laser Doppler 
imager Windows software v.6.1 (Moor Instruments Limited, UK). Measurement 
of skin perfusion was carried out using a moor LDI2-IR laser Doppler imager 
(Moor Instruments Limited, UK). The scanner head was positioned 30 cm above 
the chambers. The laser beam was directed by a moving mirror in a raster fashion 
over both chambers. A total of twenty repeat scans were taken; the first set with 
no current to act as a control, then four scans at 5 µA, four at 10 µA, four at 15 
µA and two at 20 µA, the final five scans were measured with no current.  The 
back scattered light (flux) is measured in arbitrary perfusion units (PU) and area 
under the median flux PU vs. time curve over the twenty scans was calculated 
(using the trapezoidal rule) as a measure of microvascular response to ACh 
(endothelium-dependent vasodilation) and SNP (endothelium-independent 
vasodilation), respectively (Figure 9). 
4.2.4 Digital volume pulse  
A PulseTrace PCA 2 with a photoplethysmograph transducer transmitting 
infrared light at a wavelength of 940 nm (MicroMedical, Kent, UK) was placed on 
the index finger of the right hand and used to calculate the DVP stiffness index 
(DVP-SI) and DVP reflection index (DVP-RI). The DVP records the systolic and 
diastolic waveforms of the pulse by measuring infrared-light transmission through 
the finger. The DVP-SI (in m/s) is defined as the height of the subject divided by 
the time between the peaks of the first and the second wave, and it is correlated 
with the stiffness of large arteries (Millasseau, Ritter, Takazawa, & Chowienczyk, 
2006; Woodman et al., 2005). The DVP-RI is the relative height of the second 
peak compared with the first and is associated vascular tone of small arteries 







Figure 9. Analysis of LDI was determined by backscattered light intensity (flux) 
of specified regions of interest for SNP (Left circle) and ACh (right circle) over 20 
scans. Flux is colour-coded with lowest perfusion in dark blue (0 perfusion units; 
PU) and highest in dark red (1000 PU). 
 
4.2.5 Pulse wave velocity  
The PWV was determined between carotid and femoral sites. A pencil-like 
pressure tonometer (SphygmoCor CPV system, ScanMed Medical, UK) was held 
at the base of the neck over the carotid artery and at the inguinal crease over the 
femoral artery on the right side of the body. The distance between carotid and 
femoral sites was measured and electrocardiogram gating permitted the time 
lapse between pulse waves at the carotid and femoral sites to be calculated. The 
PWV (in m/s) was calculated as the ratio of the distance between the two sites 
and the pulse transit time (PTT). Recordings were taken when a consistent signal 
was obtained with a high amplitude excursion. The SphygmoCor software 
(version 9.0, ScanMed Medical, UK) provides indices of quality control, if the 




by a new measurement. A minimum of two acceptable readings were obtained 
for PWV and the average used for analysis.  
4.2.6 Pulse wave analysis 
The PWA was recorded at the radial artery using the same pencil-like pressure 
tonometer and software (SphygmoCor CPV system, version 9.0, ScanMed 
Medical, UK). Peripheral pulse waveforms were recorded for a minimum 11 s and 
the aortic artery waveform determined using a generalised transfer function 
(Pauca, O’rourke, & Kon, 2001). The AIx was calculated by the software as the: 
𝑎𝑢𝑔𝑚𝑒𝑛𝑡𝑎𝑖𝑜𝑛 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒
𝑝𝑢𝑙𝑠𝑒 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒
 × 100; where augmentation pressure is the difference 
between the “shoulder” of the wave and “peak” systolic pressure.  Since AIx is 
influenced by heart rate (Wilkinson et al., 2000), AIx normalised for a standard 
heart rate of 75 bpm (AIx@75) is also reported. The AIx@75 is only calculated 
when a participants heart rate is between 40 and 110 bpm, outside this range it 
is not computed by the software (Stoner, Young, & Fryer, 2012).   A minimum of 
two acceptable readings were obtained for PWA (Quality Index ≥ 80%; pulse 
height ≥ 80 units; pulse height variation ≤ 5%; and diastolic variation ≤ 5%) and 
the average used for analysis. 
4.2.7 Flow mediated dilation 
Flow mediated dilation of the brachial artery was determined according to 
previously established guidelines (Corretti et al., 2002; Thijssen et al., 2010) 
using an ultrasound (HDI‐5000 SONO CT ultrasound machine; Philips Medical 
System) and semi-automated computer software (Brachial Analyzer; Medical 
Imaging Applications; Figure 10). Briefly, a blood pressure cuff placed around 
the forearm (approximately 55 mm below the antecubital fossa), using a 7.5 MHz 
linear-array transducer, baseline images of the brachial artery were recorded for 
60 s while the cuff remained deflated. The cuff was then inflated to 50 mmHg 
above systolic BP and following 5 min of occlusion, the pressure was rapidly 
released to allow reactive hyperaemia. Images were recorded for the last minute 
of occlusion and continuously for 3 min after release. Peak diameter was defined 
as the maximum diameter obtained post-occlusion. Average baseline diameter 
(60 s pre-occlusion) and the peak diameter were used to calculate the absolute 









Figure 10. Analysis of brachial artery, regions of interest were defined (purple) 
and edge detection of the brachial artery diameter (top) and rate of flow (bottom) 
are shown in yellow. 
4.2.8 Statistical analysis 
All measures are expressed as mean ± standard deviation (SD) unless otherwise 
stated. Variables were tested for normality (Shapiro-Wilks test) and Log 
transformed where appropriate. For intra-session repeatability and inter-session 
reproducibility; relative consistency of all vascular measures was assessed using 
intra-class correlation coefficient (ICC3,1(Hopkins, 2000)), where an ICC >90, 
0.75-90, 0.50–0.75 and <0.50 indicate excellent, good, moderate and poor 
reliability, respectively (Koo & Li, 2016). Typical error (TE) was calculated as the 
between-subject SD of the measurement pairs divided by √2 to represent 
absolute index of repeatability that encapsulates both the random and systematic 
error associated with each measurement (Batterham & George, 2000). For non-
negative values (Bedeian & Mossholder, 2000), the within-subject variability was 
also assessed using coefficients of variation (CV) for each pair of measurements, 
determined by using the following equation: (
𝑆𝐷
𝑚𝑒𝑎𝑛
) × 100. A CV ≤ 10% was 
considered good, 10–25% moderate and ≥ 25% poor reproducibility (Tew et al., 




systematic error (Atkinson & Nevill, 1998). All data were analysed using IBM 
SPSS statistics (v 24.0 for Windows; SPSS, Chicago, IL).   
4.3 Results 
4.3.1 Intra-session repeatability 
Results for repeatability of all measures are presented in Table 6. Intra-session 
SBP, DBP and Hr showed a moderate-good level of repeatability (ICCs ≥ 0.73; 
CV ≤ 8.9%).  Repeatability of LDI perfusion response to SNP taken within-session 
was poor (ICC: 0.34; CV = 28.4%). The AUC for ACh displayed a good level of 
consistency (ICC: 0.84) however CV was high. There was also evidence of 
systematic error for intra-session LDI-ACh. Repeatability of DVP-SI, DVP-RI, 
PWV, AIx and AIx@75 were moderate-excellent within-sessions (ICC ≥ 0.64; CV 
≤ 9.5%). However, a consistent pattern of pulse waveforms could not be 
established in one participant, therefore all AIx data presented is for 19 
participants. Additionally, three participants heart rates fell below 40 bpm and AIx 
normalised to 75 bpm was not calculated. Pulse wave velocity was highly 
repeatable within-session (ICC ≥ 0.89).  For FMD two participants data was 
excluded from analysis, one due to substantial movement of the arm during 
deflation and the other because clear images of the artery could not be obtained 
(n = 18). Baseline diameter had excellent repeatability (ICC: 0.90; CV = 3.1%) 
and both FMD absolute and percentage FMD had a moderate level of 
repeatability (ICC ≥ 0.53).  
4.3.2 Inter-session reproducibility 
Inter-session reproducibility data is presented in Table 6. The SBP, DBP and Hr 
displayed a similar level of reproducibility between-sessions (ICC ≥ 0.73; CV ≤ 
5.8%). Both LDI measures (ACh and SNP) displayed poor reproducibility inter-
session (ICC ≤ 0.40; CV ≥ 32.7%).  The DVP-SI was highly reproducible, whereas 
DVP-RI had poor consistency between measures (ICC: 0.17) despite only a 
moderate level of within-subject variability (CV = 15.1%).  The PWV and AIx was 
highly reproducible (ICC ≥ 0.83), however paired samples t-test suggested 
systematic bias between inter-session AIx measures (P = 0.030). No systematic 
error was found for AIx@75, which remained highly reproducible between-
sessions (ICC = 0.93). Absolute FMD and percentage FMD displayed a 
moderate-good level of reproducibility (ICC ≥ 0.71) and the reproducibility of the 







Table 6. Intra-session repeatability and inter-session reproducibility of vascular function assessment 
 
Measure 1 
(mean ± SD) 
Intra-session   Inter-session  
 Measure 2 








 Measure 3 





ICC P value 
 
SBP (mmHg) 117 ± 6 116 ± 7 3.3 2.2 0.733 0.741  117 ± 6 3.0 1.9 0.753 0.385  
DBP (mmHg) 65 ± 7 66 ± 7 2.9 3.5 0.812 0.113  64 ± 5 3.0 3.4 0.734 0.256  
Hr (BPM) 56 ± 11 52 ± 11 4.8 8.9 0.815 0.006  58 ± 10 4.2 5.8 0.846 0.318  
LDI-ACh (AUC; PU) 2125 ± 1494 1664 ± 1147 542 29.4 0.837 0.007  2459 ± 1543 1265 36.7 0.306 0.566  
LDI-SNP (AUC; PU)  2262 ± 1271 1985 ± 1026 946 28.4 0.339 0.433  2488 ± 1150 943 32.7 0.395 0.274  
DVP-SI (m/s) 5.5 ± 0.6 5.6 ± 0.5 0.2 2.7 0.876 1.000  5.5 ± 0.5 0.3 3.3 0.763 0.927  
DVP-RI (%) 
 
59.6 ± 13.3 61.0 ± 14.9 8.6 9.5 0.635 0.839  63.3 ± 13.1 11.9 15.1 0.173 0.337  
PWV (m/s) 
 
6.0 ± 0.9 6.0 ± 0.7 0.3 3.1 0.894 0.319  5.8 ± 1.1 0.4 6.2 0.825 0.149  
AIx† (%) -0.4 ± 11.3 -1.2 ± 12.0 3.2 ̶ 0.926 0.156  -2.2 ± 11.3 2.5 ̶ 0.955 0.030  
AIx @75† (%) -13.0 ± 11.9 -12.9 ± 12.5 3.4 ̶ 0.920 0.483  -13.7 ± 11.6 3.1 ̶ 0.932 0.541  
FMD (%) 8.2 ± 2.2 8.8 ± 2.9 1.8 16.6 0.528 0.391  8.6 ± 2.8 1.3 14.2 0.714 0.408  
†CV is not reported for AIx or AIx@75 as these produce both negative and positive values. 
Systolic and diastolic blood pressure (SBP and DBP); heart rate (Hr) laser Doppler imaging with iontophoresis (LDI); acetylcholine chloride (ACh); sodium nitroprusside (SNP); perfusion units 
(PU); area under the curve (AUC); digital volume pulse (DVP); stiffness index (SI); reflection index (RI); pulse wave velocity (PWV); augmentation index (AIx); flow mediated dilation (FMD); 
absolute (Abs); typical error (TE); coefficient of varation (CV); intraclass correlaction (ICC) 
For intra-session SBP, DBP, HR, LDI-ACh and LDI-SNP (n = 20), DVP- SI, DVP-RI and AIx (n = 19); PWV, percentage FMD (n = 18); and AIx@75 (n = 16)  
For inter-session SBP, DBP, HR, LDI-ACh, LDI-SNP, DVP-SI and DVP-RI (n = 21); PWV and AIx (n = 20); percentage FMD (n = 19); and AIx@75 (n = 17) 
Reasons for excluding data from analyses include: technical problems with equipment (DVP), no consistent pattern of waveforms (PWV and AIx), substantial arm 





The aim of the current study was to determine the repeatability and reproducibility 
of a battery of vascular function tests. The main finding of this study was that 
taken together, there is a considerable range of variability regarding the 
repeatability and reproducibility (poor-excellent; Table 6) of non-invasive 
measures of endothelial function and arterial stiffness, which holds important 
information for the future experimental chapter in this thesis. Before comparing 
the reliability of a vascular function test battery to measures taken independently, 
there is a number of important factors relating to the technical and biological 
variability that need to be considered. Firstly, there are extensive differences 
between the degree of skill needed to perform the measures reported in the 
current study (Anderson & Phillips, 2015), and therefore to reduce the amount of 
variability several trained researchers might be needed to carry out each 
measurement, but this is an unlikely scenario in a single site research study. 
Secondly, the testing duration to do multiple methods can be much longer than a 
single measurement, which increases participant burden and the potential for 
additional stress that might influence vascular function variables (Poitras & Pyke, 
2013). Lastly, the close interplay between the BP, endothelial function and arterial 
stiffness could also contribute to sources of variability. With this in mind, the 
automated BP and Hr was found to be measured with an adequate level of 
repeatability and reproducibility (Table 6). The between-day reproducibility 
appears to be consistent with previous reports of resting SBP and DBP (Stanforth 
et al., 2000). However, in this scenario non-invasive measurements of arterial 
stiffness were more reliable (within- and between-sessions) than methods used 
to assess endothelial function in the test battery.  
Endothelial dysfunction is a hallmark of the early development of atherosclerosis 
and CVD (Bonetti et al., 2003; Grover-Páez & Zavalza-Gómez, 2009). Moreover, 
because of the systemic nature of endothelial function, dysregulation of 
microvascular endothelial function is thought to be a surrogate marker of coronary 
endothelial function (Hansell, Henareh, Agewall, & Norman, 2004). As such, the 
micro-vascular endothelial function, as measured by LDI and DVP-RI, and macro-
vascular endothelial function measured by FMD, are important therapeutic 
targets (Anderson, 2006). With regards to micro-vascular endothelial function, 




to perform and do not require extensive operator experience (Roustit & 
Cracowski, 2013). That said, there are a number of extraneous factors that 
introduce variability into these measures, especially when used in conjunction 
with iontophoresis (Loader et al., 2017). Moreover, despite the putative clinical 
utility of these methods, there is currently no standardisation of methods and/or 
data analysis (Roustit & Cracowski, 2013; Turner et al., 2008). In the current 
study an iontophoresis protocol that had previously been reported to be reliable 
was adopted (Jadhav, Sattar, Petrie, Cobbe, & Ferrell, 2007) and is presented as 
AUC (Table 6) as this is commonly used in randomised controlled trials (Jin, 
Alimbetov, George, Gordon, & Lovegrove, 2011; Keane et al., 2016b; Macready 
et al., 2014). In contrast to our findings, Jadhav et al. (2007) reported good 
reproducibility of the AUC for both ACh and SNP taken 8 weeks apart in females 
with cardiac syndromes, which might be attributable to the longer rest period 
before the measure, correction for skin resistance and the different populations 
between studies. Nonetheless, the findings in the current study are in line with 
others, in that, laser Doppler methods in conjunction with iontophoresis have 
been reported to produce high day-to-day CVs (Kubli, Waeber, Dalle-Ave, & 
Feihl, 2000; Morris & Shore, 1996), low ICCs (Tibiriçá, Matheus, Nunes, 
Sperandei, & Gomes, 2011) and SNP perfusion response can be less 
reproducible compared to ACh (Jadhav et al., 2007; Kubli et al., 2000; Tibiriçá et 
al., 2011).  Moreover, it is particularly noteworthy that a second measurement 
taken within the same testing session produced a lower endothelial-dependent 
(ACh) perfusion response; despite identical placement of the Perspex chambers, 
limiting variations and spatial differences in capillary density. Although the reason 
for this remains unknown, it might relate to the lower heart rate (Maio et al., 2013) 
and warrants careful consideration in research designs. 
The DVP method is quick-to-perform, operator-independent and the DVP-RI is 
strongly related to the vascular tone of small arteries  (Millasseau et al., 2003) but 
there are limited published data concerning the reproducibility of DVP-RI.  
Notwithstanding, in  agreement with others, the current study found that RI had 
higher intra-individual variability and poorer reliability within and between-
sessions than SI (Millasseau et al., 2003). The current study also found better 
intra-session reliability for DVP-RI than inter-session, which has been reported 




variability (15.1%) is also similar to those reported by Millasseau and colleagues 
(2003) who found inter-session CVs of 13.8% in a very small cohort of 8 healthy 
males.  However, in the current study the low ICC demonstrated poor 
reproducibility between-sessions. On the other hand, macro-vascular endothelial 
function was assessed using FMD which showed moderate repeatability and 
reproducibility, despite requiring more operator skill than LDI and DVP-RI. 
Moreover, FMD produced a comparable level of technical and biological variation 
as previous studies (median CV of 17.5% (van Mil et al., 2016) and TE ranges 
from 0.4-4.8 in healthy individuals (Greyling et al., 2016)). 
Arterial stiffness, which is an independent predictor of CVD (Mattace-Raso et al., 
2006), was measured in the current test battery by several different methods due 
to an absence of a true ‘gold standard’ (Woodman et al., 2005). Firstly, we 
measured DVP-SI, which has been associated with stiffness of the large arteries 
(Millasseau et al., 2002), vascular aging (Millasseau et al., 2003) and risk of CVD 
(Gunarathne, Patel, Hughes, & Lip, 2008; Vakalis et al., 2015). The current study 
demonstrated that the intra- and inter-session DVP-SI can be measured 
consistently with very little variability (ICC ≥ 0.76; CV ≤ 3.3%), which is supported 
by the literature (Millasseau et al., 2002; Millasseau et al., 2003). In the current 
study, arterial stiffness was also measured by PWV and PWA, which were both 
highly reproducible (ICC ≥ 0.83) within- and between-sessions, and compare 
favourably with previous research (Tripkovic, Hart, Frost, & Lodge, 2014; 
Woodman et al., 2005). Notably, there was also evidence of systematic bias 
between-days for AIx, although all other statistical tests supported excellent 
repeatability and reproducibility. Conversely, AIx normalised for heart rate (75 
bpm) was not different between-session, suggesting Hr might have contributed 
to the observed systematic bias, however it should be acknowledged that fewer 
individuals contributed to AIx@75 analysis (n = 17). This is because some 
participants Hr fell below 40 in the supine position, which might pose a problem 
and minimises the utility of this measure in athletic or bradycardic populations. 
This study has various strengths such as the use of well-established, commonly 
used methodologies, but it is conceivable that other methods used to assess 
endothelial function might have been more reproducible.  There are several other 
limitations that warrant discussion, firstly, the population in the current study were 




nonetheless was importantly not confounded by the influence of menstrual cycle 
or medications and hence represent a relatively stable population to examine 
vascular function. Secondly, as recommended, a minimum of 5 minutes 
acclimation period was utilised (O'brien et al., 2003; Pickering et al., 2005); 
however it should be acknowledged that a longer acclimation period might have 
provided a more stabilised BP reading (Sala, Santin, Rescaldani, & Magrini, 
2006) and perhaps more reproducible results. Nonetheless, this would have 
increased the testing period and participant burden, so has to be weighed up with 
pragmatically.  
The study has addressed the specific thesis aim of determining the reliability of a 
battery of commonly used non-invasive measures of vascular function in vivo. 
The current research demonstrates considerable inconsistencies in the 
repeatability and reproducibility of non-invasive measures of structural and 
functional vascular health. This study found that BP, Hr, indices of arterial 
stiffness and macro-vascular endothelial function can be taken in a battery with 
adequate reliability in a test battery. However, measurements of microvascular 
endothelial function, LDI and to a lesser extent DVP-RI, demonstrates poor 
reproducibility between-sessions. Particularly LDI responses were highly 
variable, as has been reported elsewhere (Kubli et al., 2000; Morris & Shore, 
1996; Tibiriçá et al., 2011). This chapter was a prelude to investigating the 
influence of anthocyanins on cardiovascular risk factors given the role of these 
human health discussed in section 2.2. This data has been used to inform the 
final experimental chapter of this thesis, as a result LDI measurements will be 
excluded from the randomised controlled trial. Moreover, this study has added to 
the literature as it highlights the importance of testing the reliability of multiple 
measures of vascular function taken in a single session and methodological 






















The influence of tart cherry (Prunus Cerasus, cv 
Montmorency) concentrate on physiological and 
cognitive function: a randomised, placebo-





Recent advances in technology and medicine have resulted in increased life 
expectancy. Subsequently due to an aging population, it is now estimated that 
non-communicable diseases account for 71% of all deaths globally (WHO, 2019). 
In particular, CVD and type II diabetes combined are the primary cause of global 
mortality, increasing in prevalence with age (Danaei et al., 2014). Midlife risk 
factors have been proposed to underlie the development of these diseases, which 
evolve over years or decades before the emergence of clinical manifestations 
(Samieri et al., 2013). Thus, midlife has consistently been highlighted as a pivotal 
period for lifestyle interventions to improve health and reduce disease trajectory 
to promote healthy aging (King, Mainous III, & Geesey, 2007; Samieri et al., 
2014). For example, middle-aged individuals who decrease their BP to normal 
ranges (<120/<80 mm Hg) have a significantly lower risk of remaining lifetime 
CVD compared to those with hypertension (Allen et al., 2012). As reviewed in 
detail in Section 2.2 of this thesis MC are currently being investigated for their 
positive impact on cardiovascular risk factors, including potential antihypertensive 
properties. Moreover, Chapter 3 demonstrated that higher intake of 
anthocyanins, a major class of tart cherry polyphenols, was inversely associated 
with the risk of CHD and CVD death − and cherries can account for a 
considerable dietary intake of these compounds (Adriouch et al., 2018a; Igwe, 
Charlton, & Probst, 2019; Tresserra-Rimbau et al., 2014a). Nonetheless, 
despites some promising epidemiological and in vitro studies suggesting a 
putative role for MC in cardiovascular and overall health (Keane et al., 2016a; 
van de Klashorst et al., 2020), clinical trials so far have provided paradoxical and 
equivocal findings for any benefits associated with their intake. Thus, well 
designed clinical trials are needed to clarify any causal link. 
In addition to reducing morbidity and mortality in aging populations, another 
important aspect of healthy aging is maintaining good physical and cognitive 
function (Rowe & Kahn, 1997). Importantly, as highlighted in section 2.2.4 and 
2.2.5, by improving vascular function and other cardiovascular risk factors, MC 
could also improve cognition and exercise capacity, as both are heavily reliant on 
vascular function, delivery and redistribution of metabolic substrates to the brain 
and muscle, respectively (Ainslie et al., 2008). In addition, tart cherry 




mitochondrial biosynthesis function (Matsukawa et al., 2017), cell survival and 
regeneration (Williams et al., 2008) conferring potential nootropic and ergogenic 
activities. However, research surrounding the influence of tart cherries on 
physical and cognitive function in humans has been less consistent.  For 
example, previous work from this laboratory demonstrated that acute 
supplementation with 60 ml of MC concentrate enhanced cerebral oxygenation 
in middle-aged adults without any influence on measures of cognitive function 
(Keane et al., 2016c). However, longer-term cherry supplementation has been 
shown to improve some areas of cognitive performance, specifically those 
associated with attention and memory, in older adults with or without cognitive 
impairment (Chai et al., 2019b; Kent et al., 2017a). Hence, the question remains 
whether longer-term exposure to dietary anthocyanins could be beneficial to 
cognitive function in other populations. In addition, while C3G, a major tart cherry 
anthocyanin, has been shown to increase exercise capacity in rats (Matsukawa 
et al., 2017), the effect of MC on physical performance in humans has yielded 
conflicting results (Keane et al., 2018; Morgan et al., 2019). In a recent meta-
analysis short-term tart cherry supplementation was demonstrated to improve 
endurance exercise (Gao & Chilibeck, 2020), but the effects of longer-term MC 
supplementation on exercise capacity remain unknown. Subsequently it was 
hypothesised is that MC would improve vascular function and in turn cognitive 
function and exercise capacity. Therefore, the aim of the current study was three-
fold; to determine the influence of longer-term (3 month) MC supplementation on 
1) vascular function; 2) cognitive function; 3) exercise capacity; in free-living 
middle-aged adults and thus addresses the final specific aim of this thesis.  
5.2 Methods 
5.2.1 Participants 
Power calculations were performed for the primary end point: change in SBP after 
3 month consumption. The power was based on the inter-individual variability for 
SBP measurement (SD = 6) from Chapter 4. Assuming an 80% power, and a 
0.05 significance level, the total number of subjects required to provide sufficient 
power to detect a 5 mmHg, a clinically meaningful amount (Makai, IntHout, 
Deinum, Jenniskens, & van der Wilt, 2017), in a 2-arm, parallel study was 





Non-smoking males and females between the ages of 40 to 60 years were 
recruited from Newcastle and the surrounding areas by the use of posters, email 
distributions, social media and word of mouth. To be included in the study, 
participants must have reported to consume (on average) less than 5 servings of 
fruits and vegetables per day, did ≤4 hours of moderate-vigorous physical activity 
per week and additionally had ≥1 risk factor for type II diabetes. These risk factors 
included body mass index (BMI) >25 kg/m2; waist circumference >102 cm for 
males and >88 cm for females; family history of type 1 or type 2 diabetes; were a 
member of a type 2 diabetes high risk population (Aboriginal, Hispanic, Asian, 
South Asian, or African decent) or were hypertensive;  >140/90 mmHG (Ekoé et 
al., 2013; Lindström & Tuomilehto, 2003). All participants were otherwise in 
apparent good health as assessed by a health-screening questionnaire, not 
regularly taking medication (or stabilised ≥ 3 months, with no adverse symptoms) 
or antioxidant supplements and willing to report any changes in health status or 
medication during the study period.  
Exclusion criteria was defined as a history of cardiometabolic disease, 
uncontrolled hypertension (SBP >159 mmHg or DBP >99 mmHg), 
gastrointestinal disease or malabsorption syndromes, reported changes in 
dietary or physical activity patterns within 3 months prior or intention to change 
during the study period, had unusual dietary habits (vegetarians, vegans or 
known eating disorders), alcohol intake of more than 21 units per week for males 
or 14 units per week for females, or a BMI ≥40 kg/m2. Additionally, participants 
who were pregnant or planning to become pregnant during the study, lactating, 
or initiating or changing a hormone replacement therapy regimen within 3 months 
of the start of the study were also excluded. The study was conducted in 
accordance with the Declaration of Helsinki and ratified by the University’s 
Research Ethics Committee prior to participants providing written, informed 
consent.  This study was registered as a clinical trial with clinicaltrials.gov 
[NCT04021342]. 
5.2.2 Study design 
This study employed a randomised, double-blind, placebo-controlled, parallel 
design. After screening and recruitment, participants were familiarised with the 
testing equipment and procedures. Following this they were randomly assigned 




placebo for 3 months using a computer-generated plan (randomization.com), 
stratified by sex. The study comprised of two experimental visits, following a 
minimum of a 7-day low anthocyanin run-in. Outcome variables were assessed 
at baseline (visit 2; pre-supplementation) and at 3 months (visit 3; post-
supplementation) as shown in Table 7. All experimental visits took place between 
8:00 and 10:00 am and were preceded by an overnight fast (≥ 10h). Participants 
were also asked to arrive hydrated and to avoid strenuous exercise, alcohol, 
nutritional supplements 24 hours and caffeine 12 hours prior. 
Table 7. Overview of study design 
 
5.2.3 Dietary intervention 
A concentrated MC juice stored at 4ºC was used in this study.  The concentrate 
was supplied by CherryActive (Active Nutrition Ltd., Sunbury, UK) and King 
Orchards (USA). Once randomised participants received the same type of juice 
throughout the trial. Participants were instructed to consume either 30 ml of MC 
concentrate diluted in 240 ml of water (as recommended by the supplier) or the 









Informed consent X   
International Physical Activity 
Questionnaire 
X  X 
General health and lifestyle questionnaire X   
Anthropometrics X X X 
Resting blood pressure X X X 
Diet and exercise diary (3 day) X  X 
Urine collection  X X 
Pittsburgh Sleep Quality Index  X X 
SF-36 Health Survey  X X 
Body Composition (DXA)  X X 
Vascular Function*  X X 
Near infra-red spectroscopy  X X 
Cognitive test battery§ [Practice] X X 
Plasma Samples†  X X 
Astrand-Rhyming exercise capacity [Practice] X X 
* Arterial stiffness (pulse wave analysis/velocity) and endothelial function (flow mediated dilation) 
§ Bond-Lader mood scales, digital vigilance, rapid visual information processing and 3-back task 
† Lipid profiles, insulin, glucose, and high-sensitivity C reactive protein 




evening. According to the supplier each 30 ml dose of MC is estimated to be 
equivalent to approximately 90 whole cherries (equating to ~180 cherries per 
day). The placebo was prepared by mixing unsweetened black cherry flavoured 
Kool-Aid (Kraft Foods, United States), dextrose (MyProtein Ltd., Northwich, UK), 
fructose (Sports Supplements Ltd., Essex, UK) with bottled water to best match 
the calorie content of the MC concentrate (Energy = 102 kcal, volume = 30 ml, 
carbohydrates = 25.5 g, protein = 0 g and fat = 0 g). Additional lemon juice, for 
tartness, and artificial food colouring was added (Chai et al., 2018; Losso et al., 
2017) so the final product had identical visual properties (Figure 11). The placebo 
was packed in clear polyethylene terephthalate containers (provided by 
ActiveEdge Nutrition® Ltd). The assigned treatment and a 30 ml measuring cup 
were supplied to the participants by a researcher (independent to the project) to 
ensure the study remained double-blinded. Compliance was measured by daily 
tick sheets and return of any unconsumed juice. On the second experimental 
visit, following the supplementation period, participants were asked to guess 
which treatment they thought they had been taking for the duration of the study. 
Throughout the study participants were encouraged to maintain their habitual diet 
and exercise routines, however they were asked to refrain from consuming 
cherries, cherry products, or any antioxidant supplements. Additionally, they were 
given verbal and written instructions to limit berry fruits, red grapes (including 
extracts/ juices) and red wine [which are the top contributors of dietary 
anthocyanins (Adriouch et al., 2018a; Tresserra-Rimbau et al., 2014a)] to ≤1 
portion per day throughout the study period. Participants recorded their pre-
evening meal before experimental visit one and were asked to replicate this 
before the second experimental visit. To monitor dietary intake, participants 
recorded a 3-day food and exercise diary (two consecutive weekdays and one 
weekend day), which was analysed retrospectively (Nutritics software, v5.09, 
Dublin, Ireland). Participants also completed the International Physical Activity 
Questionnaire (IPAQ) and a short form quality-of-life survey (SF-36 (Ware & 
Kosinski, 2001)) at the beginning and end of the study to determine physical 





Figure 11. Montmorency tart cherry concentrate (left) and isocaloric placebo 
(right). Labels were removed by an independent researcher before assigning 
treatments to the participants. 
5.2.4 Total Anthocyanin Content  
The monomeric anthocyanin pigment content of the cherry juice was determined 
using the pH-differential method (Giusti and Wrolstad, 2001). The cherry juices 
were diluted 1:20 in 0.025 M potassium chloride buffer at pH 1.0 and 0.4 M 
sodium acetate buffer at pH 4.5, respectively.  The absorbance was measured 
spectrophotometrically at 510 and 700 nm with a Jenway 7135 UV/Visible 
spectrophotometer (Cole-Parmer Ltd., United Kingdom). The absorbance 
difference A was calculated as A=(A510-A700)pH1.0 - (A510-A700)pH4.5. The 
total anthocyanin concentration C (mg/L) was expressed as mg cyanidin-3-
glucoside equivalents according to the following equation: 
C=A.MW.DF.1000/(ε.l), where MW = molar mass for cyanidin-3-glucoside (449.2 
g/mol); DF the dilution factor, 1000 the conversion from g to mg; ε the molar 
extinction coefficient for C3G (26900 L/mol.cm); l the path-length (1 cm).                                                                                                                                                                                                             
5.2.5 Total Phenolic Content  
Total phenolic content (TPC) was measured using a modified Folin-Ciocalteu 
colorimetric method as previously described (Keane et al., 2016b). Briefly, the 
cherry juice and placebo was diluted in deionised water (1:10) and 50 µL of the 




µL of 6% (w/v) sodium carbonate were added into corresponding sample wells of 
a 96 well plate.  Absorbance readings were taken at 725 nm, at 5 minute intervals, 
over a 30 minute period at 25°C using a BioTek Synergy HT Multi-Mode 
Microplate Reader (BioTek, Winooski, USA). The quantification was performed 
on the basis of a standard curve (R2=0.99) in the range 0-500 mg/L (Waterhouse, 
2009). The analysed samples were measured versus a blank and are expressed 
as mean mg/L of gallic acid equivalents (corrected for the dilution factor) ± SD for 
6 replications. The CV for this method was <3%.                                                                                                                                                                                                                                                                                                                      
5.2.6 Anthropometry and body composition 
Stature was measured to the nearest 0.1 cm using a stadiometer and body mass 
measured to the nearest 0.1 kg using the same digital scale (Seca Scales 703, 
Seca Ltd. Birmingham, UK). Waist circumference was measured in accordance 
with the International Society for the Advancement of Kinanthropometry 
guidelines. Body composition (fat mass, fat percentage, android/gynoid ratio and 
lean body mass) was measured by dual-energy X-ray absorptiometry (DXA; 
Hologic, Horizon, Manchester, UK). The scanner was calibrated before each 
scan in accordance with manufacturer’s guidelines and participants were 
instructed to wear the same clothing for each visit. All measurements were 
performed at baseline and on the return visit, 3 months later.  
5.2.7 Vascular function 
Measurements of BP, Hr, arterial stiffness (PWV and PWA) and endothelial 
function (FMD) were taken as described in Chapter 4.2. 
5.2.8 Cerebral blood flow, cognitive function, sleep and mood 
5.2.8.1 Near infra-red spectroscopy (NIRS) 
The NIRS is a non-invasive imaging technique in which two nominal wavelengths 
of light, which are differentially absorbed by oxygenated and deoxygenated 
haemoglobin, respectively, are introduced through the body tissues via a laser 
emitter. The wavelengths are then measured, following transit through the upper 
surface of the tissue of interest, by an optode placed at a pre-set distance from 
the light source. Recently NIRS has been applied to demonstrate changes in 
cerebral haemodynamics following acute (Keane et al., 2016c; Wightman et al., 
2015) and chronic nutritional interventions (Jackson, Reay, Scholey, & Kennedy, 
2012). Accordingly, NIRS has been deemed sensitive enough to assess changes 




activity following supplementation with nutritional interventions (Jackson & 
Kennedy, 2013).  
In the current study, relative change in CBF was assessed using continuous wave 
NIRS (NIRO-200NX, Hamamatsu Photonics K.K., Japan). Two near-infrared 
sensors were placed over the left and right frontal lobe region of the forehead 
corresponding to the International 10–20 system Fp1 and Fp2 EEG positions; 
these signals were averaged to determine cerebral oxygenation. The sensors 
were secured to the skin using double-sided adhesive tape and shielded from 
ambient light using an elastic head band. The sensors alternately emit two 
wavelengths of near-infrared light (~765 and 855 nm) with an emitter/optode 
separation distance of 4 cm. A 5-minute rest (which acted as the NIRS baseline 
for CBF calculations) was taken at each testing session and data were acquired 
continuously throughout a cognitive task battery. Output was time stamped at the 
start of each task segment to assure that data corresponded to the relevant 
period of task performance. Baseline adjusted data with respect to the 5 min of 
NIRS data collected immediately prior to completing the tasks  (Jackson et al., 
2016; Wightman et al., 2015), was then calculated for each task offline. NIRS 
data is reported as changes in cerebral oxy- (HbO2), deoxy- (hHb) and total-(tHb) 
haemoglobin concentrations.  
5.2.8.2 Cognitive function, sleep and mood assessment 
Participants completed the Pittsburgh Sleep Quality Inventory, PSQI (Buysse, 
Reynolds III, Monk, Berman, & Kupfer, 1989), to assess sleep quality. Cognitive 
function and mood measures were assessed using a test battery and 
administered via the Computerised Mental Performance Assessment System 
(COMPASS, Northumbria University, Newcastle upon Tyne, UK), a purpose-
designed software application for the flexible delivery of randomly generated 
parallel versions of standard and novel cognitive assessment tasks. The test 
battery included three tasks; digital vigilance (DV; 3 min), rapid visual information 
processing (RVIP; 5 min) and N-back task (~3 min). These tests were chosen 
because firstly they have previously been shown to activate the prefrontal cortex 
where cerebral haemodynamics were being assessed (Coull, Frith, Frackowiak, 
& Grasby, 1996; Jansma, Ramsey, Coppola, & Kahn, 2000). Secondly they have 
been frequently applied to evaluate the efficacy of polyphenol supplementation 




2015) and lastly they asses the domains attention and memory which have 
previously been shown to be influenced by dietary anthocyanin and cherry 
supplementation (Chai et al., 2019b; Kent et al., 2017a; Kent, Charlton, Netzel, & 
Fanning, 2017b). The cognitive tests (described below) were repeated twice in 
order to induce some level of cognitive fatigue, which was assessed immediately 
after each battery by a visual analogue scale (VAS). Participants also completed 
Bond-Lader VAS (Bond & Lader, 1974) before and after the test-battery to assess 
subjective mood.  
5.2.8.3 Bond-Lader VAS  
The VAS required participants to indicate how they currently feel “at this moment 
in time” by clicking, using the mouse, at the appropriate point along a 100 mm 
scale on screen. Sixteen scales are presented with antonyms at either end, e.g. 
‘alert’ vs. ‘drowsy’, ‘lethargic’ vs. ‘energetic’ and ‘troubled’ vs. ‘tranquil’, with these 
16 scores (% along the line towards the right end) combining to create three 
overall measures of mood factors: ‘alert’, ‘content’ and ‘calm’.  
5.2.8.4 Digit Vigilance (DV) 
The DV task is a measure of sustained attention and psychomotor speed. A 
single target digit was randomly selected and constantly displayed on the right 
hand side of the screen.  A series of single digits appeared on the left hand side 
of the screen, one at a time, at the rate of 150 per minute. The participant was 
required to press the spacebar on the keyboard as quickly as possible every time 
the digit in the series matched the target digit. Task outcomes included accuracy 
(%) and reaction time for correct responses (ms). This task has been shown to 
identify age-related declines in attention and the test-retest correlation coefficient 
for reaction time is 0.81 (Wesnes et al., 2017). 
5.2.8.5 Rapid Visual Information Processing (RVIP) 
The RVIP task is a measure of sustained attention and working memory. The 
task requires the participant to monitor a continuous series of single digits for 
targets of three consecutive odd or three consecutive even digits. The digits are 
presented on the computer screen one at a time at the rate of 100 per minute in 
pseudo-random order, and the participant responds to the detection of a target 
string by pressing the spacebar on the keyboard as quickly as possible. Task 
outcomes included number of target strings correctly detected (%) and average 




(>0.70) in older adults and has been reported as reliable in the detection and 
monitoring of cognitive deficits (Goncalves, Pinho, & Simoes, 2016). 
5.2.8.6 N-Back 
The 3-back task measures working memory and memory capacity. The task 
requires participants to indicate whether the letter presented on screen was also 
presented 3 letters previously in the letter sequence. Participants are required to 
respond by pressing buttons corresponding to ‘yes’ or ‘no’ on the keyboard, to 
each letter, as quickly as they can. Participants were presented with 45 stimuli 
(letters), however the task is dependent on speed (i.e. slower reaction times will 
result in a lengthier task). The task outcomes included accuracy of correct yes 
responses (%) and reaction time for correct yes responses (ms). The test-retest 
correlation coefficient for this task has been reported to be 0.73 for accuracy and 
0.81 for reaction time, respectively (Hockey & Geffen, 2004). 
5.2.10 Exercise capacity 
Aerobic exercise capacity (V̇O2max) was estimated using a frequently applied sub-
maximal cycle test; the Astrand-Rhyming single-stage, 6-min test (Noonan & 
Dean, 2000) on an electronically braked cycle ergometer (Lode Excalibur Sport, 
Groningen, The Netherlands). A submaximal protocol was chosen as this method 
is less strenuous and safer for individuals who are relatively inactive and/or at 
increased cardiovascular risk. The Astrand-Rhyming test has been shown to be 
a valid (r = 0.85) and reliable (r = 0.83) estimate of V̇O2max  (Cink & Thomas, 1981) 
and has been utilised in other lifestyle interventions assess the influence on 
exercise capacity (Fibbins et al., 2020; Vadstrup, Frolich, Perrild, Borg, & Roder, 
2012). Following a 3 minute warm up, participants were instructed to maintain a 
pedalling rate of 50 revolutions per minute (rpm) for the six minutes, which was 
started with a constant workload 100 W for males and 75 W for females (ACSM, 
2017). During cycling, Hr was continuously recorded (T31, Polar, Finland) and 
workload was adjusted where necessary to reach a target Hr of 125-170 bpm. 
The average HR, which differed by no more than 5 bpm during the last two 
minutes of the test was used to estimate V̇O2max, adjusted for age (Astrand, 1960).   
5.2.11 Biological samples 
5.2.11.1 Collection 
All samples were collected following an overnight fast on the morning of each 




the first morning void, were collected into 30 ml sterile tubes (Sterillin, Thermo 
Scientific, UK). Aliquots of urine were immediately stored at −80 °C for later 
analysis. Venous blood samples (~12 ml) were collected in lithium-heparin 
vacutainers (Becton, Dickinson and Company, USA). Due to blood sampling error 
samples were only available for 40 participants. These were centrifuged at 
3000×g (4°C) for 10 min and the plasma aliquotted and stored at −80 °C to be 
analysed later.  
5.2.9.2 Preparation and Analysis 
Plasma samples were analysed by the Department of Blood Sciences in the 
Royal Victoria Infirmary Hospital, Newcastle. Cholesterol, HDL cholesterol, non-
HDL Cholesterol, triglycerides and total/HDL cholesterol ratio, as well as high 
sensitivity CRP (hs-CRP), glucose and insulin levels were analysed for the 
available samples (Cherry n = 19; Placebo n = 21). The LDL cholesterol was 
calculated using the Friedewald equation (Friedewald, Levy, & Fredrickson, 
1972). The homeostatic model assessment of insulin resistance (HOMA-IR) was 
calculated according to Matthews et al. (1985) using the following formula: 
HOMA − IR =




Urine samples were defrosted on ice and normalised to the same reflective index 
(Edmands, Ferrari, & Scalbert, 2014). Then 100 μl of normalised urine was mixed 
with 100 μl of chilled methanol (-20°C), vortex mixed and kept on ice for 30 
minutes. Samples were then centrifuged for 2 minutes at 10,000 rpm.  The top 
100 μl of the sample was aliquotted, filtered, and transferred to an LCMS vial for 
analysis. 
Analysis of the urinary metabolome was intended to take place, but because of 
the issues raised by COVID-19, this has been indefinitely postponed. 
Consequently, this thesis does not contain these data, but the intention is to 
analyse non-targeted metabolomic profiles of the spot urine samples. 
5.2.12 Data and Statistical Analysis 
All data were analysed using IBM SPSS statistics (v 26.0 for Windows; SPSS, 
Chicago, IL), measures are reported as means ± standard deviation (SD) in 




distribution for outcome measures was tested using the Shapiro Wilks test and 
assumptions were tested prior to analysis. Baseline characteristics where 
analysed by Wilcoxon signed-rank test where data were continuous, and Chi 
squared where data were categorical. Dietary, physical activity and SF-36 data 
were analysed using a two-way (treatment × time) analysis of variance (ANOVA). 
Treatment guess data was analysed by Chi squared. The effect of the 
intervention on vascular function variables was evaluated using a one-way 
analysis of covariance (ANCOVA) adjusted for baseline (Vickers & Altman, 2001) 
and also sex and use of medication. 
The PSQI data was analysed using a Friedman non-parametric test. Despite 
familiarisation with the cognitive function tasks some participants did not perform 
the tasks correctly. Therefore, cognitive function and mood data was cleaned by 
generating box plots for each outcome variable to identify potential outliers. 
Values that were more than one and a half and three deviations from the 
interquartile range were identified as outliers, and extreme outliers, respectively 
(Tukey, 1977). Outliers were removed, meaning a number of data points were 
missing for each participant. Therefore, to accommodate missing data points 
cognitive function variables were analysed using a linear mixed model with; 
treatment (cherry juice/placebo) and repetition (1,2) as fixed factors and baseline 
(pre-treatment) values, sex and use of medication as covariates. 
For NIRS data, task length was fixed for the DV (180 s) and RVIP (300 s), but 
NIRS data from the N-Back test was truncated so that the same amount of data 
was analysed for all participants during each task period. The data was adjusted 
for resting baseline data (5 mins prior) and the 2 channels were averaged across 
hemispheres. If the participant’s data had been omitted from the cognitive 
function task (both accuracy and time) they were excluded for that task. The 
analysis of resting baseline adjusted data was performed using a linear mixed 
model with as described above.  
For blood samples where values fell below the limits of detection the sensitivity 
threshold of the assay were used to maintain participant numbers. The hs-CRP, 
HOMA-IR and insulin values were non-normally distributed so were log 
transformed before analysis. The variables were analysed using a linear mixed 
model with; treatment (cherry juice/placebo) as a fixed factor and baseline (pre-








A total of 56 individuals were enrolled in the study and randomised to the 
intervention. There was no difference between the group characteristics at 
baseline (Table 8). Three participants from each group did not complete the study 
as shown in Figure 12. 
Table 8. Baseline Characteristics  





(n = 56) 
Cherry 
(n = 28) 
Placebo 
(n = 28) 
 
P-Value 
Age (y) 48 ± 6 49 ± 6 47 ± 6  0.160 
Sex (m/f) 37/19 19/9 18/10  0.778 
Stature (cm) 173.1 ± 8.8 173.7 ± 8.9 172.4 ± 9.0  0.494 
Body Mass (kg) 81.8 ± 12.9 81.7 ± 14.0 82.0 ± 11.9  0.793 
BMI (kg/m2) 27.3 ± 3.7 27.0 ± 3.8 27.4 ± 3.7  0.569 
Ethnicity (n; %)     0.368 
White  54 (96.4) 27 (96.4) 27 (96.4)   
Education (n; %)     0.798 
Less than high school - - -   
High school or equivalent 24 (43) 11 (39) 13 (46)   
Bachelor’s degree 19 (34) 9 (32) 10 (36)   
Postgraduate degree 13 (23) 8 (29) 5 (18)   
Left handed (n; %) 5 (9) 3 (11) 2 (7)  0.639 





Figure 12. Consort flow diagram of participants 
 
5.3.1 Polyphenol content, safety and tolerance of the interventions 
The total anthocyanin and polyphenol content of the intervention beverages are 
shown in Table 9, below. The mean (± SD) self-reported compliance (as 
assessed by tick sheets) was 94 ± 9% and 98 ± 4% in the cherry and placebo 
group, respectively. Five participants (20%) correctly guessed they were in the 
placebo group, but Chi squared (Table 1; Appendix D) suggested successful 
blinding (P = 0.386). One participant in the cherry group discontinued the juice 




treatments were otherwise well tolerated as suggested by the SF-36 (Appendix 
E) which showed no treatment, time or interaction differences between groups. 






Abbreviations: TACN; total anthocyanin content (cyanidin 3 glucoside 
equivalents); TPC; total polyphenol content (gallic acid equivalents). Placebo was 
not analysed because it contained artificial colourant (E129) which causes 
interference with the assay (Giusti & Wrolstad, 2001). 
 
5.3.2 Physical activity, diet and body composition 
There was no treatment, time or treatment × time interaction effects observed for 
physical activity, sitting time or exercise capacity (Table 10). Analysis of 3-day 
diet records showed that there were no significant differences between the two 
groups for mean intake of total energy, fat or saturated fat intake. Protein intake 
showed a treatment × time interaction (F= 7.8, P = 0.011). Planned Post hoc tests 
revealed protein intake at baseline was on average 12g higher in the placebo 
group compared to the cherry group (F = 6.7, P = 0.016). There was also an 
increase in carbohydrate (36g) intake at 3 months in both groups, main effect of 
time (F= 17.3, P < 0.001). Body mass (F = 8.5, P = 0.007), BMI (F = 12.6, P = 
0.002) and fat mass (F = 4.8, P = 0.040) increased relative to baseline in the 
placebo group, main effect of time. Fat mass (F= 7.7, P = 0.011) and fat 
percentage (F= 4.38, P = 0.047) also increased after 3 months in the cherry group 
There was no treatment effect observed at baseline or 3 months for body mass. 
There was no treatment, time or treatment × time interaction effects between lean 
mass or android/gynoid ratio (Table 10).  
Beverage TACN (mg/L) TPC (mg/L) 
Placebo - 358.3 ± 37.6 
Cherry Active 258.0 3089.9 ± 155.7 




Table 9. Physical activity, diet and body composition 
Mean ± SD 
Body mass index (BMI)  
b Significantly different from baseline (P <0.05): * significantly different between 
groups (P <0.05) 
 
 Cherry Placebo 
ANOVA 
 Treatment Time Interaction 
METs (min/week)       
Baseline 2462 ± 2038 1953 ± 1527   0.267 0.959 0.961 
3 months 2464 ± 2336 1978 ± 1217     
Sitting time (h)       
Baseline 6.6 ± 3.1 6.7 ± 3.0  0.856 0.852 0.486 
3 months 6.7 ± 2.8   6.3 ± 3.0     
V̇O2max (ml·kg-1·min-1)       
Baseline 35.9 ± 11.1 37.3 ± 7.5  0.319 0.187 0.386 
3 months 33.7 ± 9.6 37.1 ± 6.2     
Energy (Kcal)       
Baseline 1921 ± 340 1896 ± 439  0.997 0.212 0.673 
3 months 1977 ± 439 2001 ± 423     
Carbohydrates (g)       
Baseline 208.8 ± 38.6 196.1 ± 47.3  0.671 <0.001 0.350 
3 months 237.3 ± 70.0b 239.6 ± 66.7b     
Fat (g)       
Baseline 76.5 ± 18.5 78.4 ± 24.2  0.681 0.231 0.999 
3 months 72.1 ± 18.1 74.1 ± 21.2     
Saturated fat (g)       
Baseline 28.2 ± 8.6 27.5 ± 8.0  0.849 0.224 0.836 
3 months 25.8 ± 8.3 25.7 ± 10.6     
Protein (g)       
Baseline 80.2 ± 21.9 92.3 ± 16.9*  0.193 0.051 0.006 
3 months 80.3 ± 15.7 78.5 ± 19.3b     
Body mass (kg)       
Baseline 82.8 ± 13.9 82.4 ± 12.3  0.968 0.007 0.048 
3 months 83.4 ± 14.2 84.1 ± 13.2b     
BMI (kg/m2)       
Baseline 27.3 ± 3.8 27.5 ± 3.8  0.757 0.001 0.057 
3 months 27.5 ± 3.8 28.1 ± 4.0b     
Body fat (%)       
Baseline 37.1 ± 7.9 36.1 ± 6.8  0.642 0.031 0.862 
3 months 37.7 ± 6.8b 36.7 ± 6.8     
Fat mass (kg)       
Baseline 30.2 ± 9.1 29.6 ± 7.1  0.856 0.007 0.691 
3 months 31.1 ± 9.5b 30.7 ± 7.5b     
Lean mass (kg)       
Baseline 48.1 ± 9.4 49.8 ± 8.5  0.360 0.248 0.199 
3 months 48.1 ± 8.5 50.4 ± 9.2     
Android/gynoid ratio       
Baseline 1.09 ± 0.17 1.13 ± 0.18  0.394 0.403 0.529 




5.3.3 Vascular function  
After adjusting for baseline (pre-treatment) values, sex and medication there 
were no group differences between cherry juice and placebo for SBP (Figure 13), 
DBP,  Hr, arterial stiffness (PWV, AIx and AIx@75) or endothelial function (FMD) 
after three months (Table 11). 
 
Figure 13. SBP before and after 3-month supplementation with cherry juice (A) 













Table 10. Effect of cherry juice compared to a placebo on vascular function 
Mean ± SD; Abbreviations; augmentation index (AIx); AIx normalised for a heart rate of 75 bpm (AIx@75); diastolic blood pressure (DBP); 
flow-mediated dilation (FMD); heart rate (Hr); pulse wave velocity (PWV).
 Cherry Juice Placebo 




 Difference (95%CI) 
F P-Value 
SBP (mmHg)          
Baseline 120 ± 15 119 ± 11 -0.5 (-4.9, 3.8) 0.056 0.814  -0.6 (-5.1, 3.9) 0.079 0.780 
3 months 117 ± 14 118 ± 11        
DBP (mmHg)          
Baseline 73 ± 10 73 ± 8 -0.4 (-3.0, 2.3) 0.086 0.770  -0.5 (-3.1, 2.2) 0.127 0.723 
3 months 73 ± 9 73 ± 8        
Hr (BPM)          
Baseline 59 ± 11 59 ± 10 -0.3 (-3.7, 3.1) 0.033 0.858  -0.2 (-3.6, 3.2) 0.014 0.908 
3 months 59 ± 12 59 ± 10        
PWV (m/s)          
Baseline 6.7 ± 1.0 6.4 ± 0.8 0.3 (-0.3, 0.8) 1.051 0.312  0.2 (-0.2, 0.7)  0.967 0.332 
3 months 6.8 ± 1.3 6.2 ± 0.8        
AIx (%)          
Baseline 22.1 ± 8.9 17.8 ± 11.4 0.3 (-3.6, 4.2) 0.021 0.886  0.3 (-3.6, 4.2) 0.022 0.884 
3 months 20.4 ± 9.6 17.0 ± 10.0        
AIx@75 (%)          
Baseline 13.4 ± 8.1 9.6 ± 12.9 0.02 (-3.6, 3.6) <0.001 0.991  -0.06 (-3.6, 3.5) 0.001 0.937 
3 months 12.3 ± 9.2 9.3 ± 11.0        
FMD (%)          
Baseline 8.3 ± 3.5 9.3 ± 3.5 1.1 (-1.1, 3.3) 0.972 0.330  1.2 (-1.0, 3.3)  1.256 0.269 




5.3.4 Cerebral blood flow 
There was no treatment or treatment × repetition interaction effects for HbO2, hHb 
or tHb concentrations during any of the tasks (Figure 14).  
Figure 14. The baseline-adjusted oxygenated (HbO2; top panel), deoxygenated 
(hHb; middle panel) and total- haemoglobin (THb; bottom panel) concentrations 
for each task repetition pre-supplementation (left) and post-supplementation 




5.3.5 Cognitive function, sleep and mood 
There was no difference between treatments for the sleep measures as assessed 
by the PSQI (Table 12). There was also no treatment or treatment × repetition 
interaction effects between cherry juice or the placebo between any of the 
cognitive function variables (Table 13Table 13). There was a treatment × 
repetition interaction for alertness, post-hoc revealed a difference between 
treatments after the second repetition (P = 0.041). The post-supplementation 
mental fatigue VAS was significantly lower in the cherry group (F = 4.38, P = 
0.042), main effect of treatment.  
 
Table 11. The composite Pittsburgh Sleep Quality Inventory (PSQI) scores  
Data is presented as median (interquartile range) 
  
 Cherry Placebo 
Friedman 
 Χ2 P-Value 
Subjective Sleep Quality      
Baseline 1.0 (1.0) 1.0 (1.3)  1.43 0.699 
3 months 1.0 (1.0) 1.0 (0.3)    
Sleep Latency      
Baseline 1.0 (1.0) 1.0 (1.0)  1.75 0.626 
3 months 1.0 (1.3) 1.0 (1.3)    
Sleep Duration      
Baseline 1.0 (1.0) 1.0 (0.0)  7.25 0.064 
3 months 1.0 (1.0) 1.0 (1.0)    
Habitual Sleep Efficiency (%)      
Baseline 91 (8) 87 (9)  5.50 0.138 
3 months 84 (10) 88 (21)    
Sleep Disturbances      
Baseline 1.0 (0.0) 1.0 (1.0)  2.70 0.440 
3 months 1.0 (0.0) 1.0 (0.0)    
Use of Sleeping Medication      
Baseline 0.0 (0.0) 0.0 (0.0)  3.00 0.392 
3 months 0.0 (0.0) 0.0 (0.0)    
Daytime Dysfunction      
Baseline 1.0 (1.0) 1.0 (2.0)  3.01 0.378 
3 months 1.0 (1.0) 1.0 (1.0)    
Global PSQI score      
Baseline 4.0 (2.3) 5.0 (2.0)  3.58 0.310 




Table 12. Cognitive function tasks (data are presented as Mean ± SD)  
 
Abbreviations; Digital vigilance (DV); rapid visual image processing (RVIP); reaction time (RT); repetition (Rep). Effects are treatment (T) 
and treatment by repetition interaction (T*R). 
Measure Treatment n 
Baseline  3 months  Mixed Model 
Rep 1  Rep 2  Rep 1  Rep 2  Effect P-Value 
DV accuracy (%) Cherry 
45 
94.1 ± 5.9  88.2 ± 13.1  95.7 ± 3.5  88.6 ± 11.6  T 0.091 
Placebo 93.0 ± 6.0  84.7 ± 14.7  89.0 ± 9.8  85.9 ± 10.3  T*R 0.407 
DV RT (ms) Cherry 
46 
477.8 ± 37.8  492.5 ± 39.5  477.4 ± 33.9  495.3 ± 38.8  T 0.357 
Placebo 473.5 ± 31.4  500.1 ± 37.2  484.7 ± 37.5  511.4 ± 34.2  T*R 0.149 
RVIP accuracy (%) Cherry 
42 
57.2 ± 17.3  63.0 ± 18.3  63.0 ± 20.9  71.5 ± 15.3  T 0.116 
Placebo 50.4 ± 18.7  53.8 ± 17.2  56.3 ± 21.8  56.7 ± 20.5  T*R 0.240 
RVIP RT (ms) Cherry 
41 
555.6 ± 62.1  568.1 ± 50.6  555.5 ± 53.5  549.6 ± 35.0  T 0.448 
Placebo 557.9 ± 63.9  540.1 ± 47.3  536.4 ± 51.7  545.1 ± 37.1  T*R 0.339 
3-Back accuracy (%) Cherry 
40 
80.2 ± 5.4  85.3 ± 8.4  79.7 ± 9.1  85.4 ± 9.0  T 0.398 
Placebo 76.9 ± 9.3  81.8 ± 8.8  77.5 ± 9.4  83.3 ± 7.9  T*R 0.823 
3-Back RT (ms) Cherry 
40 
1110 ± 231  980 ± 234  1111 ± 248  942 ± 195  T 0.562 




Table 13. Mood and visual analogue scale measures (data are presented as Mean ± SD) 
 
Abbreviations; repetition (rep). Effects are treatment (T) and treatment by repetition interaction (T*R). * Significant difference between 
treatments (P < 0.05). 
Measure Treatment n 
Baseline  3 months  Mixed Model 
Rep 1  Rep 2  Rep 1  Rep 2  Effect P-Value 
Alert Cherry 
48 
71.8 ± 9.5  52.6 ± 14.8  69.3 ± 11.3  59.7 ± 18.5*  T 0.134 
Placebo 71.8 ± 11.1  47.8 ± 14.2  65.6 ± 15.3  43.2 ± 14.8  T*R 0.025 
Content Cherry 
48 
77.5 ± 9.2  68.1 ± 12.6  80.9 ± 7.9  74.4 ± 12.2  T 0.095 
Placebo 76.7 ± 10.6  60.7 ± 18.5  75.8 ± 13.8  66.1 ± 17.8  T*R 0.142 
Calm Cherry 
49 
74.2 ± 9.6  57.3 ± 13.5  76.0 ± 13.1  64.7 ± 15.3  T 0.573 
Placebo 65.1 ± 18.0  54.4 ± 13.1  74.8 ± 13.7  61.8 ± 18.4  T*R 0.748 
Mental fatigue Cherry 
46 
53.5 ± 18.1  72.3 ± 10.5  48.8 ± 21.9  56.0 ± 22.9  T 0.042 




5.3.6 Blood markers 
Table 14. Plasma markers  
 
Cherry 
(n = 19) 
Placebo 





Insulin¶ (pmol/L)      
Baseline 20.3 ± 15.4 19.6 ± 10.2 -0.02 (-0.2, 0.2) 0.050 0.824 
3 months 17.8 ± 10.0 19.0 ± 13.0    
Glucose (mmol/L)      
Baseline 5.4 ± 0.5 5.5 ± 0.5 -0.03 (-0.3, 0.2) 0.049 0.826 
3 months 5.4 ± 0.5 5.4 ± 0.3    
HOMA-IR¶      
Baseline 0.7 ± 0.6 0.7 ± 0.4 0.03 (-0.1, 0.2) 0.089 0.767 
3 months 0.7 ± 0.4 0.7 ± 0.5    
hs-CRP¶ (mg/L)      
Baseline 1.6 ± 2.3 1.2 ± 1.2 0.1 (-0.2, 0.3) 0.488 0.489 
3 months 1.4 ± 1.7 1.2 ± 1.0    
Triglycerides (mmol/L)      
Baseline 1.2 ± 0.6 1.2 ± 0.7 -0.08 (-0.5, 0.4) 0.115 0.736 
3 months 1.2 ± 0.7 1.3 ± 0.7    
Cholesterol (mmol/L)      
Baseline 5.3 ± 1.2 5.0 ± 1.0 0.1 (-0.6, 0.8) 0.084 0.773 
3 months 5.2 ± 1.1 5.1 ± 0.9    
LDL cholesterol 
(mmol/L) 
     
Baseline 3.2 ± 1.0 3.0 ± 1.0 0.08 (-0.6, 0.7) 0.060 0.808 
3 months 3.1 ± 1.0 3.1 ± 1.0    
HDL cholesterol 
(mmol/L) 
     
Baseline 1.6 ± 0.3 1.5 ± 0.4 0.1 (-0.2, 0.3) 0.191 0.665 
3 months 1.5 ± 0.4 1.5 ± 0.4    
Non-HDL cholesterol 
(mmol/L) 
     
Baseline 3.7 ± 1.2 3.5 ± 1.2 0.04 (-0.7, 0.8) 0.010 0.919 
3 months 3.7 ± 1.1 3.6 ± 1.1    
Total/HDL cholesterol 
ratio 
     
Baseline 3.5 ± 1.0 3.7 ± 1.3 -0.2 (-1.7, 0.7) 0.224 0.693 
3 months 3.6 ± 1.2 3.8 ± 1.4    
Mean ± SD. Abbreviations: high-density lipoproteins (HDL); homeostatic model assessment of 
insulin resistance (HOMA-IR); high-sensitivity C-reactive protein (hs-CRP) ¶ log transformed before 






After adjusting for baseline (pre-treatment) values, sex and medication there 
were no group differences between cherry juice and placebo for lipid profiles, 
insulin, glucose, HOMA-IR or hs-CRP (Table 15). 
 
5.4 Discussion 
The aim of the current study was to determine whether long term (3 month) 
supplementation with Montmorency tart cherry juice (MC) could positively impact 
risk factors of CVD in middle-aged adults. The primary outcome of interest was a 
change in vascular function, specifically SBP based on previous studies. 
However, on the basis of the vascular function variables measured in the current 
study, contrary to the hypothesis, there was no effect on BP, endothelial function 
or arterial stiffness (Table 11).  
Our research group has previously shown that an acute bolus of 60 ml MC 
concentrate, presumably because of its anthocyanin content, can reduce SBP by 
approximately 6 mmHg in middle-aged individuals (Keane et al., 2016c). More 
recently, Chai and colleagues (2018) reported that twice daily supplementation 
with 30 ml MC concentrate for 12 weeks reduced SBP by 4.1 mmHg in older 
adults. These data are of interest because hypertension is one of the leading risk 
factors for CVD and is responsible for 10.7 million deaths globally (Forouzanfar 
et al., 2016). Moreover, observational studies involving persons without CVD 
have shown there is a continuous relationship with risk throughout the normal 
range of usual SBP down to at least 115 mmHg, particularly in those aged 40-69 
years (Lewington, 2003). Similarly, lower SBP in middle-aged and older adults 
has been associated with reduced risk of CVD and all-cause mortality 
(Antikainen, Jousilahti, & Tuomilehto, 1998; Bundy et al., 2017). Thus, 
determining if a natural anthocyanin-rich food such as concentrated MC juice, 
which could be incorporated to the diet to reduce SBP is of great importance.   
In the current study we did not observe any difference in BP following 3-month 
MC consumption when compared to an isocaloric placebo. The reason for these 
discrepancies could be several-fold, for example MC concentrate has been 
shown to increase circulating phenolic acids, which modulate VSMC. In addition, 
peak plasma phenolic acids (PCA and VA) have been shown to coincide with the 
greatest post-prandial reductions in SBP (Keane et al., 2016a; Keane et al., 




vasomodulation of SBP returns to basal levels within 3-4 hours (Desai et al., 
2019; Keane et al., 2016b).  If  the vaso-relaxatory properties of MC are solely 
related PCA and VA (Keane et al., 2016a; Keane et al., 2016b), there is no 
information regarding to the long-term accumulation of these simple phenolic 
acids from tart cherries. However, results from other anthocyanin-rich foods (e.g. 
chokeberry) suggest that plasma concentrations of these are increased following 
acute intake (2 hours), but not chronic (12 weeks) intake (Istas et al., 2019a). 
Moreover, blueberry intake has shown no change in plasma PCA (Feliciano, 
Istas, Heiss, & Rodriguez-Mateos, 2016) and a decline in urinary anthocyanins 
(Kalt, McDonald, Vinqvist-Tymchuk, Liu, & Fillmore, 2017) after longer-term 
supplementation. These data suggest a reduction in exposure to anthocyanins 
metabolites following long-term ingestion, perhaps due to systemic saturation 
over time. In the current study vascular function was measured after an overnight 
fast, therefore peak vasodilation might have been missed because of the rapid 
metabolism and/or excretion of PCA and VA (Keane et al., 2016a); 
notwithstanding, this investigation was ultimately interested in the cumulative 
influence of MC consumption.  
Both tart (Chai et al., 2018) and sweet cherry juice (Kent et al., 2017a) have been 
reported to reduce SBP in older adults following longer-term (12 week) 
supplementation. The reason for sustained changes in vascular function following 
chronic anthocyanin and other polyphenol supplementation are currently not 
known but are thought to be mediated via host-microbiome co-metabolism of 
these compounds and complex gene expression alterations (Istas et al., 2019a; 
Krga et al., 2016; Rodriguez-Mateos et al., 2019a). Therefore, the genetic 
changes and reductions in microbial diversity that occur with age (Barrera-Reyes, 
de Lara, González-Soto, & Tejero, 2020; Filosa, Di Meo, & Crispi, 2018), could 
partially explain the observed differences during periods across the lifespan or 
why some individuals benefit more than others. Indeed, in a recent study with a 
similar population to the current study, MC supplementation was not shown to 
have any influence on microbial diversity or richness (Lear et al., 2019), but these 
individuals were likely to have higher numbers and diversity of many protective 
species, compared to older adults (de la Cuesta-Zuluaga et al., 2019; Mariat et 
al., 2009). Although, another important distinction is the aforementioned studies 




SBP (>130 mmHg). In a recent review of the factors that influence the efficacy of 
anthocyanins on BP regulation, the authors highlight that baseline BP was an 
important factor with changes only evident in those with elevated initial BP 
(Vendrame & Klimis-Zacas, 2019). This is consistent with antihypertensive drugs 
in which the magnitude of change in BP is directly proportional to baseline values 
(Hu et al., 2017; Motaweih et al., 2015). Despite recruiting middle-aged 
individuals with additional risk-factors for CVD, the participants in the current 
study were either pre-symptomatic or had controlled hypertension, thus had BP 
readings within the normal range, therefore any changes might have been too 
small to detect. In fact, their vascular function on a whole was similar to the 
healthy younger cohort in Chapter 4, and well within normal expected ranges, 
thus the most likely reason for a lack of response. The finding that  longer-term 
tart cherry supplementation does not influence SBP in normotensive individuals, 
even those with increased CVD risk (Johnson et al., 2020; Martin et al., 2018), is 
in line with others (Desai et al., 2018; Lynn et al., 2014).  
Endothelial dysfunction is the earliest indicator of subclinical atherosclerosis and 
precedes hypertension, thus is a major risk factor for CVD, but also modifiable by 
diet (Houston, 2018). There is a growing interest in the influence of fruit 
polyphenols on non-invasive measures of functional vascular health. For 
instance, in a recent meta-analysis, chronic supplementation (≥1 week) with 
anthocyanin-rich foods was shown to improve endothelial function (SMD: 0.84%, 
95% CI: 0.55, 1.12), measured by FMD (Fairlie-Jones et al., 2017). It was 
therefore anticipated that an anthocyanin-rich food, such as MC concentrate, 
could improve endothelial function in middle-aged adults. Cherry juice did appear 
to improve FMD above the TE expected, but given the high variability (Chapter 
4) this study might have been underpowered to detect the small changes that are 
reported in healthy populations following anthocyanin-rich foods (Istas et al., 
2019a; Rodriguez-Mateos et al., 2019a). Nonetheless, the finding in the current 
study is consistent with Aboo-Bakkar et al. (2018)  who found 4 week 
supplementation of MC powder (256 mg/day anthocyanins split into two doses, 
morning and evening) did not improve FMD response in overweight, 
hypertensive, yet healthy, middle-aged men following an overnight fast. 
Polyphenols, including anthocyanins, are purported to improve endothelial 




However, unlike some anthocyanin-rich foods which have been shown to 
increase systemic markers of NO under resting conditions (Johnson et al., 2015; 
Stote et al., 2017), tart cherries have not (Aboo-Bakkar et al., 2018; Keane et al., 
2018; Keane et al., 2016b; Keane et al., 2016c). Albeit, MC powder has been 
reported to restore FMD and enhance recovery of plasma nitrite following 
occlusion induced ischemia reperfusion (Aboo-Bakkar et al., 2018), which could 
suggest that tart cherries might protect vascular cells in response to additional 
stress (i.e. pathological conditions).  
In the present study arterial compliance was measured by PWV and PWA (AIx 
and AIx@75). Previous research has reported no effect of MC on these indices, 
at least acutely (Keane et al., 2016b). However, a recent addition to the literature 
suggested MC might influence AIx  at 2 hours after a bolus MC concentrate in 
individuals with metabolic syndrome, which also coincided with peak reductions 
in SBP (Desai et al., 2019). In contrast, Lynn and colleagues (2014) reported no 
effect on brachial-knee PWV in healthy middle-aged adults, following 6 week 
supplementation with 30 ml MC concentrate in an open-labelled randomised 
controlled trial. More recently, Johnson and colleagues (2020) reported no effect 
of 12-week bi-daily MC consumption on AIx, AIx when corrected for a Hr of 75 
beats/min or PWV in individuals with metabolic syndrome. Here we also found no 
noteworthy changes in PWV or PWA. These findings are in line with a recent 
meta-analysis which reported no change in PWV or AIx following longer-term (1 
week – 4 month) supplementation with anthocyanin-rich foods (Fairlie-Jones et 
al., 2017). However, tart cherries have been shown to improve cholesterol (Chai 
et al., 2018), oxidised LDL (Johnson et al., 2020) and antioxidant status following 
a high fat meal (Polley et al., 2019). Moreover, epidemiological evidence 
suggests higher intake of anthocyanins is associated with lower arterial stiffness 
(Jennings et al., 2012) and a reduced risk of CHD and CVD mortality (Chapter 
3). This suggests some anti-artherogenic properties and the ability to reduce 
stiffening of the arteries; however, it might be that the relatively short duration of 
existing studies is not sufficient to distinguish these changes. Furthermore, the 
acute influence on AIx is likely to represent a functional change in compliance 
(De Bruyne et al., 2019), whereas the time span needed to determine any 
preservation or even reversal of structural stiffening of blood vessels would likely 




Apart from vascular function we also measured the effects of MC concentrate on 
CBF, cognition, sleep and mood. It was found that MC improved alertness and 
mental fatigue (Table 14), consistent with the anti-fatigue effects in response to 
cognitive demand batteries reported with other polyphenols (Massee et al., 2015; 
Wightman et al., 2015). As this was not associated with any change in sleep or 
CBF measures it is unlikely that these were involved. However, tart cherry 
polyphenols have been shown to elicit anti-neuro-inflammatory properties and to 
suppress neuronal apoptosis and stimulate pro-survival signalling cascades (Kim 
et al., 2005; Shukitt-Hale et al., 2016; Thangthaeng et al., 2016) − mechanisms 
that might protect against depression pathophysiology (Ogle et al., 2013). In 
addition, anthocyanin-rich blackcurrant juice has been shown to inhibit 
Monoamine Oxidase (MAO)-B activity (Watson et al., 2015). As MAO is involved 
in the oxidation of neurotransmitters, including the regulation of serotonin, 
inhibiting MAO has been suggested as a viable method to reduce anxiety, 
depression and fatigue (Fiedorowicz & Swartz, 2004). Moreover, specific tart 
cherry polyphenols, e.g. quercetin, similarly to caffeine, has been shown to act 
as an adenosine receptor antagonist (Alexander, 2006). Thus, the ability of 
anthocyanins to influence neurotransmitters offers a potential avenue in which 
they may promote positive mood states following longer-term supplementation 
This data is of interest and warrants further attention, since the anti-fatiguing 
effect of polyphenols might improve physical and cognitive performance 
(Matsukawa et al., 2017; Wightman et al., 2015). Nonetheless, although these 
data seem promising, due to the subjective nature of the VAS used and that these 
effects were not mirrored in cognitive or physical performance in the current 
study, it should be interpreted cautiously. 
With regards to CBF we did not find any differences following 3-month 
supplementation. CBF and velocity is an important factor in optimal brain 
functioning and subsequently cognition, because it regulates the supply of 
oxygen and glucose to the neurons, as well as the removal of CO2 and 
metabolites (Ajmani et al., 2000). Previous work from our research team has 
shown that MC concentrate can modulate CBF variables, specifically HbO2 and 
tHb during cognitive function tasks (Keane et al., 2016c). In the current study we 
did not identify any changes in these parameters in response to the MC 




represents the first study to determine the longer-term effects of MC on NIRS in 
response to cognitive performance. However, Wightman and colleagues 
demonstrated that both resveratrol (Wightman et al., 2015) and Sideritis scardica 
(Wightman et al., 2018) supplementation induced acute but not chronic changes 
in CBF parameters measured by NIRS. In fact, in a recent review CBF changes 
following longer-term polyphenol supplementation was only apparent using MRI, 
highlighting the difficulty in the methodology surrounding measurements of CBF 
(Joris, Mensink, Adam, & Liu, 2018). For instance, Bowtell et al. (2017) reported 
regional changes in brain perfusion measured by MRI following 12-week 
supplementation with blueberry concentrate. In the current study, we used 
continuous wave NIRS and the limitations surrounding this are well documented, 
namely it only measure relative changes in cerebral activation and CBF as 
opposed to the measurement of absolute, quantifiable, amounts of haemoglobin 
present within the cortex (Jackson & Kennedy, 2013; Murkin & Arango, 2009). 
Moreover, NIRS was only used on the prefrontal cortex and it is therefore possible 
some changes occurring elsewhere in the cerebral cortex were not detected.  
With regards to cognitive function, both tart and sweet cherries have failed to 
show an acute improvement in cognitive performance (Caldwell et al., 2016; 
Keane et al., 2016c). Contrastingly, in a chronic study by the same group (Kent 
et al., 2015) it was reported that the daily consumption of sweet cherry juice for 
12 weeks improved cognitive performance across almost all tasks in older adults 
with mild-to-moderate dementia; this group showed improvements for category 
verbal fluency and tasks relating to verbal learning and memory and concluded 
the positive changes have clinical relevance for these cognitive improvements.  
More recently, Chai et al. (2019b) reported improvements in visual sustained 
attention and spatial working memory in healthy older adults after 12 week 
supplementation with MC concentrate. It would therefore appear that longer-term 
cherry interventions might have the potential to induce sustained modifications to 
cognition. Despite this hypothesis we did not observe any differences in cognitive 
performance compared to a placebo (Table 13). A probable reason for this 
disparity is that in both aforementioned studies, improvements in cognition were 
predicated by lower SBP post-supplementation with cherry juice. High BP, due to 
its role in hypoperfusion, is a risk factor for late-life cognitive decline and risk of 




Therefore, the previously observed changes in cognitive performance in older 
adults might be in direct response to improvements in cerebral perfusion, as 
supported by changes in peripheral blood flow, i.e. SBP (Chai et al., 2019b; Kent 
et al., 2017a). In the present study we did not observe any changes in SBP or 
CBF and therefore it is perhaps unsurprising there was no difference in cognitive 
performance. Alternatively, the differences between our findings and previous 
work might be because of the different tasks used, despite measuring similar 
domains (i.e. memory and sustained attention), some tasks may have been more 
sensitive in detecting changes. Also it may be related to the population, for 
instance, older individuals are could more amenable to changes in cognitive 
performance despite using a similar task as there is a rapid decline in the ability 
to organize incoming and outgoing information that happens with the progression 
of age (Kirchner, 1958). It should also be acknowledged that despite 
familiarisation, due to incorrect performance of the tasks, a number of participants 
were excluded from analysis in this study which reduced statistical power and 
might have confounded the results.  
We also collected sleep measures in the current study. There was no difference 
found in sleep measures, as assessed by the PSQI (Table 12). This contradicts 
previous research which showed that tart cherries, due to their melatonin content, 
improved sleep quality (Howatson et al., 2012; Losso et al., 2017; Pigeon et al., 
2010). However, this is likely because of the use of a questionnaire rather than 
any objective measures of sleep quality. For example, previous research from 
this institution reported improved sleep efficiency and total sleep time measured 
by actigraphy, following 7 day consumption of MC, but the same measures 
collected by subjective questionnaires did not differ (Howatson et al., 2012). 
Therefore, there might have been some subtle differences in sleep quality in 
response to the intervention that were not observed, but importantly there were 
no substantial changes in the sleep patterns of participants, which might affect 
outcome measures.  
This study also identified no changes in markers of metabolic health or 
inflammation following the intervention (Table 15). This is somewhat surprising 
given that MC have previously been shown to reduce LDL cholesterol (Chai et 
al., 2018), insulin levels (Desai et al., 2019) and hs-CRP (Martin et al., 2018). 




influence cholesterol (Lynn et al., 2014), insulin concentrations/ resistance 
(Martin & Coles, 2019) and markers of systemic inflammation (Lear et al., 2019) 
in similar populations in this study. In the current study the levels of these markers 
before the intervention were all within normal ranges and thus, similar to BP, less 
likely to benefit from an intervention, relative to those with elevated baseline 
values, i.e. older individuals, those with metabolic or inflammatory conditions 
(Chai et al., 2018; Desai et al., 2019; Martin et al., 2018; Schumacher et al., 
2013). Therefore, the discrepancies between studies might once again be due to 
the population in question. Importantly, early intervention in at-risk individuals 
(such as those in the current study) may be particularly opportunistic in reversing 
or reducing the disease risk trajectory preventing CVD and type II diabetes and 
thus remains a research priority. Certainly, there is longitudinal population studies 
(Jennings, Welch, Spector, Macgregor, & Cassidy, 2014; Wedick et al., 2012) 
that demonstrate higher intake of dietary anthocyanins is associated with reduced 
inflammation, insulin resistance and risk of type II diabetes (which are all also 
cardiovascular risk factors). Therefore, future studies should try to establish the 
optimum dosing, delivery and duration of anthocyanin intake in healthy cohorts, 
but also whether they are beneficial in clinical populations. However, there was a 
marked effect of the intervention on body composition in both groups. After 3 
months both body mass and BMI was higher in the placebo group, whereas fat 
percentage was higher in the cherry group and fat mass had increased in both 
groups (Table 10). While changes in fat mass following longer-term cherry juice 
consumption have not been reported elsewhere (Johnson et al., 2020; Martin et 
al., 2018), changes in body composition are not in isolation. For example, Chai 
and colleagues (2018) reported a higher BMI (1.06 Kg/m2; P = 0.02) in those 
consuming MC concentrate for 12 weeks. Moreover, Lynn and colleagues (2014) 
reported a trend for higher body mass in the placebo group (P = 0.073) following 
6 week MC intervention in middle-aged adults. A limitation of the present study is 
that dietary records and IPAQ were only collected at the beginning and end of 
the study as opposed to throughout, although total energy intake, physical activity 
or exercise capacity did not appear to change, we cannot rule out that changes 
may be seasonal and un-related to the intervention (Ma et al., 2006). However, 
given the increase in calorie intake due to the concentrate future studies should 




Finally, there were no change in exercise capacity from MC in middle-aged 
adults. A finding that contradicts a recent meta-analysis, which suggested MC 
can improve endurance exercise performance (Gao & Chilibeck, 2020). However, 
based on pre-existing literature, performance aspects appear to be most 
beneficial in all-out or pro-longed exercise (Keane et al., 2018; Levers et al., 2016; 
Morgan et al., 2019), whereas here a short sub-maximal test was applied 
Moreover, this represents the first longer-term study, where previous MC dosing 
strategies have been relatively short term (≤ 7 days). Therefore previous 
enhancements might be due to acute influences of the bioactive compounds, 
whereas it has been speculated longer intake durations may be required to result 
in beneficial changes in cellular signalling (Cook & Willems, 2019). To date, there 
have been few studies determining the effect of polyphenols on exercise capacity 
but our findings are in agreement that 7-day New Zealand blackcurrant (Cook et 
al., 2020) and 4-week resveratrol supplementation (Voduc, La Porte, Tessier, 
Mallick, & Cameron, 2014) had no effect on exercise capacity.  
Due to the low number of adverse events, good compliance levels reported and 
no effect on quality of life indices, it is reasonable to suggest that cherry juice is 
a safe and tolerable intervention. This study has several strengths such that it 
was successfully blinded, relatively large sample size, longer-term 
supplementation period and well controlled compared to other studies of a similar 
nature (Ataie-Jafari et al., 2008; Chai et al., 2018; Desai et al., 2019; Johnson et 
al., 2015; Lynn et al., 2014).  However, there are other limitations that warrant 
discussion. Firstly, compliance to the intervention was self-reported; as these 
were free living adults, there was no control over whether they adhered to the 
intervention, how they stored the concentrate or when they consumed the MC. 
Secondly, two different juices were used in the current study due to a change in 
supplier, however both were confirmed to contain anthocyanins and high levels 
of polyphenols, but in varying amounts (Table 9). Moreover, subgroup analysis 
of the two different juices was done on vascular function which did not change 
the findings, thus suggesting the use of two different juices did not influence the 
outcomes or conclusion of this study.  Whilst the variation between the juices is 
a potential limitation of the current work, it equally represents the batch-to-batch 
variation that can naturally occur due to growing conditions (e.g. soil, use of 




done at the end of the study after storage, it adds confidence that the bioactive 
compounds were in good availability over the study duration. Moreover, given 
that these compounds will likely be extensively metabolised (Section 2.1.3), 
determining the compounds in the urine as a means of compliance and 
bioefficacy might add more clarity to these limitations. Lastly, BP was measured 
in the laboratory which was shown to be reliable (Chapter 4) but 24-hour 
ambulatory BP could be more advantageous in establishing small changes in BP 
following MC supplementation (Desai et al., 2020) due to the large number of 
readings and avoidance of white-coat hypertension. 
In conclusion, the current study investigated whether longer-term 
supplementation with MC concentrate was capable of improving vascular 
function and, in turn, cognitive performance or exercise capacity. The results of 
this study revealed that a 3-month intervention was unable to improve these 
indices in this cohort. This study addresses the final specific aim of the thesis to 
which was to determine the longer-term effects of MC on physiological and 
cognitive function in in free-living middle-aged adults. These data have not found 
a causal relationship for the reduced risk of CVD mortality in Chapter 3, but this 
should be taken in light of the limitations described throughout. The findings are 
in line with previous literature that suggests tart cherry polyphenols might only be 
effective in modulating vascular and metabolic function in select populations. 
Moreover, this study has for the first time investigated the effects of long-term 
supplementation on indices of CBF, cognitive function and exercise capacity in a 
middle-aged population. Although there was some evidence that MC could 
improve alertness and mental fatigue during cognitive demand task we did not 
find any effect of the intervention on CBF, cognitive or physical performance, 
which is an important addition to the body of knowledge. Ultimately, MC 
concentrate was shown to be safe and well tolerated and importantly did not have 
any deleterious effects on these outcomes, further investigation might be better 
suited in populations with greater impairments in vascular, metabolic or cognitive 
function at baseline. Nonetheless, given the current interest in the facilitation of 
healthy aging, investigation in to the intake of anthocyanin-rich foods in pre-
symptomatic and at-risk individuals are important as a means to preserve 






























6.1 Experimental chapter synopsis 
The research presented in this thesis has systematically examined evidence for 
the cardiovascular health benefits of dietary anthocyanins, specifically through 
knowledge synthesis and knowledge generation. This is in response to a number 
of studies that have recently established that tart cherries and berries, purportedly 
due to their high anthocyanin content, can reduce a number of risk factors 
associated with CVD (Section 2.2). Nevertheless, the relationship specifically 
between dietary intake of anthocyanins and actual risk of CVD has yet to be 
systematically addressed. Therefore, in Chapter 3 the association between 
dietary intake of anthocyanins and the risk of CVD and related mortality was 
systematically evaluated and synthesized from existing prospective cohort 
studies. This is an important addition to the literature as to date this is the largest 
and most contemporary and comprehensive meta-analysis of dietary 
anthocyanins and CVD risk. This was a necessary step as although randomised 
control trials suggest that supplementation with these compounds may improve 
factors of CVD, whether this could translate to reduced risk (in light of the ‘CVD 
detection gap’) was unknown. The results of this Chapter suggest there is an 
inverse association between anthocyanin intake and reduced risk of both CHD 
and CVD mortality, which is an important addition to the body of knowledge. This 
perhaps represents an important steppingstone in informing policy makers into 
recommending incorporating foods rich anthocyanins as an adjunct to the diet, 
but dose-response data is still needed. 
In Chapter 4 the test-retest reliability of a battery of non-invasive multimodal 
measures of vascular function in vivo was assessed. The use of these methods 
in clinical trials, including nutritional research is becoming more common. Despite 
the influence that these variables can have on each other, the variability or typical 
error of doing them together in a single testing session (i.e. as a test battery) had 
not been reported. Therefore, as a prelude to Chapter 5 the variability in vascular 
function measures which were investigated and considered when designing an 
intervention. For example, measures of microvascular endothelial function, 
measured by LDI and DVP-RI, where found to have low reproducibility when 
taken in a test battery. On the other hand, it was found that BP, arterial stiffness 
(PWV/A) and macrovascular endothelial function (FMD) could be measured with 




Moreover, the results were used to form the power calculation for the intervention. 
In addition, these data have been added to the literature to highlight the 
importance of testing the reliability of multiple measures taken in a single session 
and methodological considerations for future research designs. 
Lastly, in an attempt to provide a causal relationship to support the findings of 
Chapter 3, Chapter 5 consists of the main experimental randomised controlled 
trial which investigated the influence of MC on cardiovascular risk factors, as well 
as cognitive function and exercise capacity in middle-aged adults. This study has 
several strengths such that it was successfully blinded, relatively large sample 
size, of longer duration and well controlled compared to other studies of a similar 
nature. However, despite this the results of Chapter 5 showed no significant effect 
of MC on modulation of vascular or metabolic function, cognitive performance or 
exercise capacity. There was some evidence that tart cherries could improve 
alertness and metal fatigue, but also might influence body composition.  
These data extend previous findings which suggest that the influence of MC 
concentrate is directly related to the characteristics of the cohort. In the current 
thesis despite being at elevated risk of CVD the middle-aged adults had no 
identifiable issues with their vascular, metabolic and/or cognitive function at 
baseline and thus less responsive to the intervention. Importantly, midlife has 
been consistently highlighted as a critical turning point in prevention of CVD and 
neurodegenerative diseases, due to the progression of morphological and 
functional alterations to the vasculature (MacIntosh et al., 2020; Pandey et al., 
2016). Although this study did not establish any difference in the risk factors or 
cognitive function measures in this study compared to a placebo it cannot be 
ruled out that the MC elicited some vasoprotective properties that were not 
observed, which may translate to the reduced risk established in Chapter 3. For 
example, Johnson and colleagues (2020) recently reported that MC juice had no 
influence on vascular function but did influence oxidized LDL and soluble vascular 
cell adhesion molecule-1 compared to a placebo, suggesting some anti-
artherogenic properties that might have been apparent but missed. The final 
study of this thesis did however show that MC was a relatively safe and well 
tolerable intervention, but more longitudinal studies across different populations 




6.1.1 Limitations of the current findings 
A number of limitations exist in the interpretation of the findings from this thesis, 
which have been discussed in each chapter. The following over-arching 
limitations are potential issues and criticisms of the work. 
A limitation is the generalisation of dietary anthocyanins. In chapter 3 dietary 
intake of these compounds were shown to reduce risk of CHD and CVD mortality, 
but the pharmacodynamics of specific anthocyanins is not well understood. In the 
final intervention MC concentrate was used which has previously been shown to 
be a relatively rich source of cyanidin and to a lesser extent peonidin glucosides 
(Kirakosyan et al., 2009). However, other anthocyanin-rich foods such as 
blackcurrant and blueberries have shown promising health benefits and the main 
anthocyanins in these are delphinidin and malvidin, respectively (Cook & 
Willems, 2019; Stevenson & Scalzo, 2012), where the position of the hydroxyl 
group, and thus type of anthocyanin might be responsible for their biological 
effects (Rechner & Kroner, 2005).   
Another important limitation of the current thesis is that emphasis has been 
placed on dietary anthocyanins in general. This was based on emerging evidence 
that these compounds might elicit some degree of cardioprotection (Keane et al., 
2016b; Rodriguez-Mateos et al., 2019a). However, it should be acknowledged 
that these compounds were not studied in isolation. In fact, foods that are rich in 
anthocyanins (such as those in Chapter 3 and 5) are likely to be sources of 
additional health-promoting nutrients such as other phytochemicals, vitamins, 
minerals and fibre. The different pharmacokinetics, metabolites and thus 
cardiovascular health benefits of specific dietary anthocyanins and the synergistic 
activities of the other nutrients in these foods should be taken into consideration 
when interpreting the results of the present thesis. It was intended to analyse the 
urinary metabolome in order to shed some light on this limitation, unfortunately 
due to unprecedented circumstances this was not possible. But this would have 
for the first time shown potential metabolic pathways and excreted polyphenol 
metabolites following longer-term intake of MC. 
6.2 Future research directions 
There are several important factors that might impact the influence of dietary 
anthocyanins on cardiovascular health, which should be reflected in future 




existing evidence for the health benefits of MC is so varied these factors need to 
be addressed to improve our understanding of the application of these to human 
health. 
First of all, extrinsic factors (e.g. the dose, duration, timing, and food matrix) need 
to be considered. There is inherent difficulty in quantifying the dietary intake of 
anthocyanins, i.e. due to the method of quantification, different databases, limited 
information on retention of these compounds following cooking and seasonal 
variability. Moreover existing studies, see Table 4 (Section 2.2)  and Table 4 
(Section 3.3), are inconsistent in doses and the highest intake of these 
compounds, thus establishing an optimal dose was not possible. Therefore in the 
current thesis, MC was given as a concentrate, bi-daily in a dose that had 
previously been found to be physiologically relevant as described in Section 2.3. 
However, this is a rather reductionist approach. Future studies should try to 
elucidate the appropriate dosing strategy, duration and source of anthocyanin 
interventions, how and when they should be taken. Given that this area of 
research is expanding rapidly uniformity in the quantification and reporting of 
anthocyanin content of certain foods might afford the opportunity to address these 
areas and give specific recommendations based on the intake of these 
compounds. With regards to the matrix, while the majority of studies have utilised 
MC concentrate (Chai et al., 2018; Johnson et al., 2020; Keane et al., 2016b; 
Lynn et al., 2014; Martin et al., 2018), there is emerging evidence for the 
physiological effects of MC powder and extracts (Aboo-Bakkar et al., 2018; Desai 
et al., 2019; Levers et al., 2016; Morgan et al., 2019). Given the potential impact 
of the juice on body composition (seen in Table 10. Chapter 5) these might be 
more beneficial given the limited calorie content. Moreover, co-ingestion should 
be investigated given that there is some evidence that the bioavailability of 
anthocyanins can be reduced, delayed and/or inhibited by other commonly 
consumed foods such as oats (Walton, Hendriks, Broomfield, & McGhie, 2009), 
dairy (Xiao et al., 2017) and soy milk (Oksuz, Tacer-Caba, Nilufer-Erdil, & 
Boyacioglu, 2019). It therefore may be necessary to recommend with what and 
when to take the tart cherries but there is limited information available. 
The second important point relates to intrinsic factors (e.g. age, health status, 
microbiome and genetic polymorphisms). As highlighted in the Section 2.2.2.1 




in the efficacy of anthocyanin supplementation. Anthocyanin-rich foods such as 
tart cherries have been shown to elicit antioxidant and anti-inflammatory 
properties (section 2.1), therefore it is plausible these interventions would likely 
benefit those with underlying pathologies due to the systemic pro-inflammatory 
and pro-oxidative state associated with these. Future studies should determine 
the influence of MC concentrate on clinical populations. However, it should be 
noted this is not to say that dietary anthocyanins might only beneficial in 
‘unhealthy’ or symptomatic cohorts, but if continuing to research in healthy or at-
risk population studies should examine the longitudinal effects as any 
physiological changes will likely be smaller and harder to detect. Moreover, it is 
likely that dependant on the population of interest there could be differences in 
dose-responses. For instance, in a recent dose-response study of purified 
anthocyanins serum IL-6 was lower after 12 week supplementation with higher 
doses of anthocyanins (80 and 320 mg) in individuals with dyslipidemia  (Zhang 
et al., 2020). Whereas the same authors found that in healthy individuals the 
dose-response curve suggested 40 mg of anthocyanins reduced IL-6 more than 
higher doses in healthy young adults (Guo et al., 2020). It remains to be 
established whether clinical populations need higher doses of MC due to 
underlying inflammation associated with these. Finally, another important factor 
is the interplay between the microbiome and genetic variations and the 
consideration of how these might contribute to responders vs non-responders. 
Even in this relatively small study in Chapter 5 there were differing effects of the 
intervention on SBP (Figure 13). Large clinical trials investigating the effects of 
these interventions on microbial enterotypes (Mayta-Apaza et al., 2018) and 
nutrient-gene interactions (Krga et al., 2016) might shed some light on the intra- 
and inter-individual responses to anthocyanin interventions. Before we have a 
better understanding of the factors highlighted above, it is difficult to draw any 
conclusions on the benefits of these compounds in the diet since the existing 
evidence base and the results of this thesis are inconclusive and equivocal. 
6.3 Concluding remarks 
The research summarised above has addressed the over-arching aim of this 
thesis provide novel insight into potential role of dietary anthocyanins in 
cardiovascular health. Firstly, Chapter 3 established an association between 




Secondly, Chapter 4 highlighted important methodological considerations when 
investigating cardiovascular risk factors which was used to inform a final 
intervention. Lastly, Chapter 5 reports the influence of anthocyanin-rich MC on 
vascular function, cognitive and physical performance. Collectively, these studies 
progress scientific evidence and importantly have contributed to knowledge 
around how dietary anthocyanins can impact health outcomes in humans and 
influence chronic diseases. Moreover, the future directions outlined above can 
provide further clarity and understanding to the findings presented within this 
thesis. Although this thesis addresses knowledge gaps in relation to the longer-
term health effects of dietary anthocyanins and corroborates previous literature, 
several important areas relating to the dietary sources and intra- and inter-
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Appendix A: Systematic review search strategy 
 
Table 1. Search Methods (originally run 25/01/2017)   
 
Item  
Search terms ((“flavonoid*” OR “anthocyani*” OR “berry” OR “berries” OR 
“chokeberry*” OR “aronia” OR “melanocarpa aubergine*” 
OR “brinjal*” OR “eggplant*” OR “solanum melongena*” OR 
“Guinea squash” OR “Solanum insanum” OR “black 
currant*” OR “Ribes nigrum” OR “blueberr*” OR “Vaccinium 
corymbosum” OR “Vaccinium cyanococcus” OR “blood 
orange*” OR “cherry” OR “cherries” OR “Cerasus vulgaris” 
OR “Prunus cerasus” OR “Prunus avium” OR “grape*” OR 
“rhubarb” OR “rheum rhabarbarum” OR “strawberr*” OR 
“fragaria vesca” OR “Fragaria ananassa” OR “blackberr*” 
OR “raspberr*” OR “rubus glaucus” OR “Rubus fruticosus” 
OR “plum” OR “plums” OR “red cabbage*” OR “purple 
cabbage*” OR “Brassica oleracea var capitata f rubra” OR 
“red wine” OR “cranberr*” OR “vaccinium macrocarpon*” 
OR “elderberr*” OR “sambucus Canadensis” OR “bilberr*” 
OR “vaccinium myrtillus” OR “whortleberr*” OR 
“pomegranate*” OR “Punica granatum”) 
AND  
("heart disease*" OR "chd" OR "cardiovascular diseases" 
OR "cvd" OR "myocardial infarction" OR "ischemic heart 
disease" OR "stroke" OR "death" OR "mortalit*" OR 
"surviv*") 
 AND  
("prospective" OR "cohort" OR “nested case-control” OR 













EndNote Total 1689 



























































































Signature of participant.......................................................    Date.....……………….. 
 
 





Signature of researcher.......................................................   Date.....……………….. 
 
 




INFORMED CONSENT FORM 
 
 
TITLE OF PROJECT: The effect of a fruit juice on 
physiological and cognitive function 
Participant ID 
Number:   
 
Researcher: Rachel Kimble   
 
Researcher contact details:  rachel.kimble@northumbria.ac.uk 
 
Principal Investigator: Glyn Howatson 
 
Please tick where appropriate 
 
I have read and understood the Participant Information Sheet.  
 




I understand I am free to withdraw from the study at any time, without having to give a 
reason for withdrawing, and without prejudice. 
 
 
I agree to take part in this study.  
 
I would like to receive feedback on the overall results of the study at the email address 












INFORMED CONSENT FORM: REMOVAL AND STORAGE OF TISSUE 
TITLE OF PROJECT: The effect of a juice on physiological and cognitive function 
Participant ID 
Number:   
 
Researcher: Rachel Kimble   
Researcher contact details:  rachel.kimble@northumbria.ac.uk 
Principal Investigator: Glyn Howatson 
 














To analyse markers of 
inflammation, metabolic health and 
metabolites 
 
To analyse for DNA genotypes 
 
 
To analyse for metabolomics 
profiles 
 











I understand that if the material is required for use in any other way than that explained to me, 
then my consent to this will be specifically sought. I understand that I will not receive specific 
feedback from any assessment conducted on my samples, but should any kind of abnormality be 
discovered then the investigator will contact me.  
 
I understand that the University may store this tissue in a Licensed Tissue Bank only for 
the duration of the study, it will then be destroyed. 
 
Method of disposal:    
Clinical Waste               
 
Other                             
If other please specify........................................................... 
 
I consent to the University distributing this tissue to partners in this research study, outside 
of the University, for further testing (please tick the box if you agree).                                                                     
 
                                                        














Appendix D: Treatment guess 











Cherry Placebo Not sure 
Cherry 16 5 4 25 


















 Cherry Placebo 
ANOVA 
 Treatment Time Interaction 
Physical functioning (%)       
Baseline 92 ± 2 89 ± 4  0.198 0.811 0.119 
3 months 90 ± 2 96 ± 1     
RF physical (%)       
Baseline 96 ± 3 81 ± 7  0.724 0.825 0.150 
3 months 90 ± 5 94 ± 5     
RF emotional (%)       
Baseline 87 ± 5 80 ± 6  0.802 0.147 0.652 
3 months 93 ± 4 89 ± 5     
Energy/fatigue (%)       
Baseline 65 ± 3 56 ± 4  0.458 0.183 0.443 
3 months 64 ± 4 60 ± 4     
Emotional well-being (%)       
Baseline 79 ± 3 71 ± 4  0.496 0.268 0.609 
3 months 78 ± 3 74 ± 4     
Social functioning (%)       
Baseline 90 ± 4 85 ± 4  0.381 0.866 0.079 
3 months 86 ± 6 93 ± 3     
Pain (%)       
Baseline 86 ± 3 84 ± 5  0.195 0.340 0.467 
3 months 86 ± 6 88 ± 4     
General health (%)       
Baseline 68 ± 3 72 ± 3  0.722 0.391 0.652 
3 months 68 ± 3 68 ± 3     
Health change (%)       
Baseline 54 ± 3 58 ± 3  0.871 0.149 0.452 
3 months 53 ± 4 51 ± 3     
Mean ± SEM.   Abbreviations; Role functioning (RF). 
 
 
 
 
 
